**Title:** Annual Research Progress Report (U)

**Author:** JOHN K. PODGORE, Colonel, MC

**Performing Organization Name and Address:**
Department of Clinical Investigation
Fitzsimons Army Medical Center
Aurora, Colorado 80045-5001

**Controlling Office Name and Address:**
Office of Deputy Commander (HSHG-ZB)

**Monitoring Agency Name and Address:**
U.S. Army Health Services Command
ATTN: HSHN-I
Fort Sam Houston, Texas 78234-6060

**DISTRIBUTION STATEMENT (of this Report):**
Approved for public release, distribution unlimited

**DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report):**
N/A

**Supplementary Notes:**
The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

**Key Words:**
Unit summary; research protocols (objective, technical approach, progress); publications; presentations.

**Abstract:**
Subject report identifies those individuals who are conducting investigative protocols at Fitzsimons Army Medical Center. An abstract of each protocol giving abbreviated technical approach, objectives, and progress is presented.

**Keywords:**
Military Medicine; Clinical Medicine; Medical Research; Obstetrics; Gynecology; Pediatrics; Dentistry; Radiology; Medical Services; Nursing; Emergency Medicine.
FOREWORD

This report identifies the research activities conducted by Fitzsimons Army Medical Center investigators through protocols approved by the Institutional Review Committee and registered with the Department of Clinical Investigation during Fiscal Year 1988 along with other known presentations and publications by FAMC professional staff.

The research protocols described in this report were conducted under the provisions of AR 40-38, Clinical Investigation Program, AR 40-7, Use of Investigational Drugs in Humans, AR 42-23, as amended, Management of Clinical Investigation Protocols and Reports, to insure the medical safety, well being, preservation of rights and dignity of human subjects who participated in these investigations.

In conducting the research described in this report, the investigator(s) adhered to AR 70-18, Laboratory Animals, Procurement, Transportation, Use, Care, and Public Affairs and the "Guide for Laboratory Animal Facilities and Care", as promulgated by the Committee or the Guide for Laboratory Animal Resources, National Academy of Sciences, National Research Council.

The Department of Clinical Investigation is especially grateful to our former Commander, BG THOMAS M. GEER, MC, and BG THOMAS E. BOWEN, MC, Commanding General of Fitzsimons Army Medical Center, the professional and administrative staff, and to the Commanding Officers and staff of other supporting activities for the cooperation and assistance provided this Department of Clinical Investigation in our efforts to accomplish our mission. Finally, I would like to recognize the outstanding work, dedication, and wholehearted corroboration of my entire staff. I would especially like to thank my Research Protocol Specialist, Ms. Marcia Bilak and Ms. Chris Montoya, Secretary, without whose assistance and support this report would not have been possible.

JOHN K. PODGORF
Colonel, MC
Chief, Department of Clinical Investigation
# TABLE OF CONTENTS

**REPORT NO. 24**

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreword</td>
<td>i</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>ii–xv</td>
</tr>
<tr>
<td>Unit Summary</td>
<td>a–g</td>
</tr>
<tr>
<td>Publications FY 88</td>
<td>1–13</td>
</tr>
<tr>
<td>Presentations FY 88</td>
<td>14–27</td>
</tr>
<tr>
<td>Detail Summary Sheets</td>
<td>28</td>
</tr>
<tr>
<td>Investigator's Index</td>
<td>307</td>
</tr>
<tr>
<td>Key Word Index</td>
<td>313</td>
</tr>
<tr>
<td>Distribution</td>
<td>319</td>
</tr>
</tbody>
</table>

**DEPARTMENT OF MEDICINE**

<table>
<thead>
<tr>
<th>Report No.</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>74/110</td>
<td>Reactive Hypoglycemia: An Analysis of Glucose-Insulin-Glucagon Interrelationships and Counter Hormonal Regulatory Factors (C)(P)(PR)</td>
<td>29</td>
</tr>
<tr>
<td>79/105</td>
<td>Breathing Pattern Effects on Steady-State DLCO Measurement (O)(P)(PR)</td>
<td>32</td>
</tr>
<tr>
<td>80/120</td>
<td>Evaluation of Carbohydrate Metabolism in Thyrotoxicosis: Investigations into the Frequency, Type and Mechanisms of Carbohydrate Tolerance (O)</td>
<td>34</td>
</tr>
<tr>
<td>80/121</td>
<td>An Evaluation of Pituitary and Thyroid Hormonal Responses to a 4-Hour Continuous and a Bolus Intravenous Infusion of TRH as a Useful Test of Thyroidal Functional Reserve (C)(PR)(P)</td>
<td>35</td>
</tr>
<tr>
<td>81/117</td>
<td>The Role of Calcitonin in Osteoporosis (O)(PR)(P).</td>
<td>37</td>
</tr>
<tr>
<td>81/118</td>
<td>Hypothalamic Pituitary Gonadal Function in Hypothyroidism (O)</td>
<td>39</td>
</tr>
<tr>
<td>81/119</td>
<td>The Effect of Thyrotropin Releasing Hormone on Gonadotropin Releasing Hormone Stimulated Gonadotropin Secretion (O)(SP)</td>
<td>40</td>
</tr>
<tr>
<td>82/104</td>
<td>The Effect of Tamoxifen on Gynecomastia (O)(PR)(P)</td>
<td>41</td>
</tr>
<tr>
<td>82/114A</td>
<td>Growth of Basal Cell Carcinoma Cells in Defined Medium and Study of their Growth and Immunological Characteristics (O)</td>
<td>42</td>
</tr>
<tr>
<td>83/107</td>
<td>Use of Isotretinoin in Prevention of Basal Cell Carcinoma (O)(PR)(P)</td>
<td>43</td>
</tr>
<tr>
<td>83/113A</td>
<td>Growth of Human Keratinocyte in Defined Medium and Study of Thin Growth and Immunological Characteristics (O)(P)</td>
<td>44</td>
</tr>
<tr>
<td>83/122</td>
<td>The Role of Food Allergy in the Pathogenesis of Migraine Headaches (O)(PR)</td>
<td>45</td>
</tr>
<tr>
<td>83/126</td>
<td>The Role of Altered Prostaglandin Synthesis in the Impaired Water Excretion and Abnormal Renin-Aldosterone Axis of Hypothyroidism (O)</td>
<td>47</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>84/100</td>
<td>The Effect of Abnormal Thyroid States on the Metabolism of Theophylline and Methylprednisolone</td>
<td>(O)(PR)</td>
</tr>
<tr>
<td>84/115A</td>
<td>Heterotransplantation of Basal cell Carcinomas to Nude Mice</td>
<td>(O)(P)(PR)</td>
</tr>
<tr>
<td>84/119</td>
<td>Treatment of Graves' Ophthalmopathy with Cyclosporin</td>
<td>(O)</td>
</tr>
<tr>
<td>85/100</td>
<td>SWOG #7804 - Adjuvant Chemotherapy with 5-Fluorouracil, Adriamycin and Mitomycin-C (FAM) vs. Surgery Alone for Patients with Locally Advanced Gastric Adenocarcinoma, Phase III (O)</td>
<td></td>
</tr>
<tr>
<td>85/101</td>
<td>SWOG #7808 - Combined Modality Treatment for Stages III and IV Hodgkin's Disease - MOPP #6, Phase III (C)</td>
<td></td>
</tr>
<tr>
<td>85/102</td>
<td>SWOG 7827 - Combined Modality Therapy for Breast Carcinoma, Phase III (O)</td>
<td></td>
</tr>
<tr>
<td>85/114</td>
<td>SWOG #8107 - Management of Disseminated Melanoma, Master Protocol, Phase III (C)</td>
<td></td>
</tr>
<tr>
<td>85/122</td>
<td>SWOG 8221 - Treatment of Advanced Bladder Cancer with Preoperative Irradiation and Radical Cystectomy vs. Radical Cystectomy Alone, Phase III (O)</td>
<td></td>
</tr>
<tr>
<td>85/132</td>
<td>SWOG #8294 - Evaluation of Adjutant Therapy and Biological Parameters in Node Negative Operable Female Breast Cancer, Intergroup Study (O)</td>
<td></td>
</tr>
<tr>
<td>85/133</td>
<td>SWOG #8300 - Treatment of Limited Non-Small Cell Lung Cancer: Radiation Versus Radiation Plus Chemotherapy (FOMi/CAP), Phase III (O)</td>
<td></td>
</tr>
<tr>
<td>85/136</td>
<td>SWOG #8313 - Multiple Drug Adjutant Chemotherapy for Patients with ER Negative Stage II Carcinoma of the Breast, Phase III (O)</td>
<td></td>
</tr>
<tr>
<td>85/139</td>
<td>SWOG 8393 - National Intergroup Protocol for Intermediate Thickness Melanoma 1.0-4.0 mm. Evaluation of Optimal Surgical Martins (2 vs 4 cm) Around the Melanoma and Evaluation of Elective Regional Lymph Node Dissection (O)</td>
<td></td>
</tr>
<tr>
<td>85/141</td>
<td>SWOG 8411 - Evaluation of DTIC in Metastatic Carcinoid, Phase II (O)</td>
<td></td>
</tr>
<tr>
<td>85/142</td>
<td>SWOG 8415 - Evaluation of Tamoxifen in Unresectable and Refractory Meningiomas, Phase II (O)</td>
<td></td>
</tr>
<tr>
<td>85/147</td>
<td>HLA and Gm Genes in Sytemic Lupus Erythematosus Antibody Expression (O)</td>
<td></td>
</tr>
<tr>
<td>85/157</td>
<td>SWOG 8590 - Phase III Study to Determine the Effect of Combining Chemotherapy with Surgery and Radiotherapy for Resectable Squamous Cell Carcinoma of the Head and Neck (O)</td>
<td></td>
</tr>
<tr>
<td>85/158</td>
<td>SWOG #8591 - NCI Intergroup #0035, An Evaluation of Levamisole Alone or Levamisole Plus 5-Fluorouracil as Surgical Adjuvant Treatment for Resectable Adenocarcinoma of the Colon, Phase III-Intergroup (O)</td>
<td></td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated, (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Journal/Conference</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>67</td>
<td>The Effect of Theophylline and Nifedipine on Hormone Secretion</td>
<td>(O)(P)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>68</td>
<td>An Evaluation of Cross Allergenicity Among Pollen Extracts of Members of the Chenopodiaceae and Amaranthaceae Polens and Mold Spores of the Same or Related Botanical Families</td>
<td>(O)(PR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>69</td>
<td>Colon Inflammation in Reiter's Syndrome: Response to Sulfasalazine. Results in a Controlled Study</td>
<td>(O) (P) (PR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>70</td>
<td>The Effect of Age on Thyroid Function Studies: The Perchlorate Discharge Test</td>
<td>(O)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>71</td>
<td>The Effects of Gonadal Steroids on Arachidonic Acid Metabolites and Angiotensin Converting Enzyme Activity in Female Rats</td>
<td>(C)(PR)(P)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>73</td>
<td>SWOG #8326/27 - Evaluation of Combination Chemotherapy Using High Dose ARA-C in Adult Acute Leukemia and Chronic Granulocytic Leukemia in Blastic Crisis, Phase III</td>
<td>(O)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>74</td>
<td>- Feasibility Study to Determine if Estrogen and Progesterone Affect In-vitro Growth of Cultured Malignant Melanoma (MM) Cell Lines</td>
<td>(O)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>75</td>
<td>Assessment of Nonspecific Decrease in Skin Test Reactivity During Immunotherapy</td>
<td>(O)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>76</td>
<td>SWOG #8592 - Evaluation of Low Dose Ara-C versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes (ECOG EST 4483)</td>
<td>(O)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>77</td>
<td>Comparison of Quantitative Immunoelectrophoresis (QIE), Skin Prick Testing, RAST Inhibition, and ELISA Inhibition (EI) Methods for Determination of Allergen Extract Potency</td>
<td>(T)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>78</td>
<td>Immune Response in Dialysis Patients Receiving Desferrioxamine (C)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>79</td>
<td>In-Vitro Drug Sensitivity Utilizing the Guinea Pig Airway Smooth Muscle Model</td>
<td>(O) (PR) (P)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>80</td>
<td>Investigation of Alterations in Angiotensin Converting Enzyme Activities Resulting from Different Pro-lactinemic States in the Male Sprague-Dawley Rat</td>
<td>(O)(P)(PR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>82</td>
<td>The Effect of INH and Combination INH-Rifampin Therapy on Calcium and Vitamin D Metabolism</td>
<td>(O)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>83</td>
<td>The Use of Standardized Allergen Extracts in Prick Skin Testing</td>
<td>(C)(P)(SP)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>84</td>
<td>Natural History of HTLV-III Infection and Disease in a United States Military Community</td>
<td>(O)(PR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>85</td>
<td>A Prospective Evaluation of Neuropsychiatric Sequelae of HTLV-III Disease</td>
<td>(O)(PR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>86</td>
<td>Endocrine Function in the Acquired Immune Deficiency Syndrome</td>
<td>(O)(PR)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>87</td>
<td>SWOG #8507 - Maintenance vs. No Maintenance BCG Immunotherapy of Superficial Bladder Cancer</td>
<td>(O)(P,PR)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
86/119 SWOG #8514 - Randomized Comparison of Cisplatin + 5-Fluorouracil vs. CBDCA + 5+Fluorouracil vs. Methotrexate in Advance Squamous Cell Carcinoma of the Head and Neck, Phase III (O) ........................................ 88

86/120 SWOG #8516 - A Phase II Comparison of CHOP versus m-BACOD versus ProMACe-CytaBOM versus MACOP-B in Patients with Intermediate or High Grade Non-Hodgkins' Lymphoma (O) ................................. 89

86/122 Pulmonary Function Standards at FAMC: Correlation with Anthropomorphic Measurement (O) ............................. 90

86/123 SWOG #8519 - Phase II Evaluation of Methyl-Glyoxal Bis-Guanylylhydrazone (MGBG) in Patients with Advanced Bladder Cancer (O) ............................................. 91

86/124 SWOG #8573 - Treatment of Limited Small Cell Lung Cancer with Concurrent Chemotherapy, Radiotherapy and Intensification with High Dose Cyclophosphamide (O) ........................................ 92

86/125 LCSG #821 - A Randomized Comparative Trial of Lobectomy versus Limited Resection for Patients with Cancer of the Lung (O) ........................................... 93

86/126 LCSG #832 - A Prospective Randomized Trial to Determine the Benefit of Surgical Resection of Residual Disease Following Response of Small Cell Lung Cancer to Combination Chemotherapy (O) .................................. 94

86/127 LCSG #852 - Phase II Pilot Program of Concurrent Chemotherapy and Radiation Therapy Before Surgery in Patients with Stage III Non-Small Cell Lung Cancer (C) .................................................... 95

86/128 LCSG #853 - A Clinical Trial in Patients with Stage II and III Completely Resected Non-Small Cancer of the Lung Comparing Chemotherapy vs. no Therapy Following Surgery (O) .................................. 96

86/129 Evaluation of Ambulatory Recording Oximetry and Holter Monitoring in Screening for Sleep Apnea (O)(PR).............. 97

86/132A The Effect of Theophylline on Calcium and Vitamin D Metabolism (O)(P)(PR) ..................................................... 98

87/102 Anti-Histone Antibody Production in Procainamide Associated Drug-Induced Lupus Erythematosus: Association of Serologic Patterns and Lymphocyte Subsets (O) .................................................. 100

87/103 Identification of Those at Risk for Osteoporotic Hip Fractures, by an Noninvasive Measurement (O)(P)(PR).............. 101

87/104 SWOG 8600 - A Randomized Investigation of High-Dose Versus Standard Dose Cytosine Arabinoside with Daunorubicin in Patients with Acute Non-Lymphocytic Leukemia, Phase III (O) .................................................. 103

87/105 Pre-operative Cimetidine Therapy in Patients Undergoing Parathyroid Exploration: Efficacy and Mechanisms of Action (O) .................................................. 104

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>105</td>
<td>Effects of Concomitant Alcohol and Exercise on High Density Lipoprotein Subfractions and Lipolytic Enzymes in Sedentary, Healthy Men (O)</td>
</tr>
<tr>
<td>106</td>
<td>Weekly Low Dose of CCNU for Extensive Adenocarcinoma of the Colon and Rectum (C)</td>
</tr>
<tr>
<td>107</td>
<td>Prostaglandin Synthesis Inhibition and Glucose Counter-Regulatory Hormone Secretion in Diabetes Mellitus (T).</td>
</tr>
<tr>
<td>108</td>
<td>The Efficacy of Conjugated Estrogens in Reducing Blood Loss During and After Cardiac Surgery; Decreased Endothelial Prostacyclin Production as a Possible Mechanism (C)</td>
</tr>
<tr>
<td>109</td>
<td>The Role of Excess Prostaglandin Production in Causing the Abnormal Hemodynamic Status of Adrenalectomized Rats (O)(PR)</td>
</tr>
<tr>
<td>110</td>
<td>A Prospective Double Blind Study of Retrovir in Early HIV Infection (O)</td>
</tr>
<tr>
<td>111</td>
<td>SWOG 8598 - (RTGO-85-01) Prospective Trial for Localized Cancer of the Esophagus: Comparing Radiation as a Single Modality to the Combination of Radiation Therapy and Chemotherapy, Phase III Intergroup (O)</td>
</tr>
<tr>
<td>112</td>
<td>SWOG 8624 - A Phase II Randomized Trial of Combination Therapy for Multiple Myeloma: Comparison of (1) VMCP/VBAP to VAD or VMCPP/VBAPP for Induction, (2) Alpha-2b Interferon or No Therapy for Maintenance; and (3) Alpha -2b Interferon + Dexamethasone for Incomplete or Nonresponders (O)</td>
</tr>
<tr>
<td>113</td>
<td>Patient Evaluation of Physicians' Humanistic Qualities (O)</td>
</tr>
<tr>
<td>114</td>
<td>A Double-Blind, Multicenter, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of HA-1A Human Monoclonal Antibody in Patients with Gram-Negative Sepsis (O)</td>
</tr>
<tr>
<td>115</td>
<td>Effect of Iodine Containing Water Purification Tablets on Thyroid Function in Man (O)</td>
</tr>
<tr>
<td>116</td>
<td>Analysis of von Willebrand Factor Multimers Before and After Cardiopulmonary Bypass (O)</td>
</tr>
<tr>
<td>117</td>
<td>LCSG 861 Pilot Study to Evaluate the Efficacy of Intrapleural Chemotherapy in the Mangement of Malignant Pleural Effusions (C)</td>
</tr>
<tr>
<td>118</td>
<td>LCSG 871 Centralized Non-Small Cell Lung Cancer Specimen Repository and DNA/RNA Bank (O)</td>
</tr>
<tr>
<td>119</td>
<td>Effect of Chronic Coumadin Therapy on Cortical and Trabecular Bone Density in Man (O)</td>
</tr>
<tr>
<td>120</td>
<td>Clinical Efficacy of Phenindamine as Determined by Skin Test Suppression (O)</td>
</tr>
<tr>
<td>121</td>
<td>Descriptive Study of Pastoral Care Interventions Designed to Assist HIV+/AIDS Patients in Achieving Their Maximum Quality of Life (O)(P)(PR)</td>
</tr>
<tr>
<td>122</td>
<td>Detection of Unsuspected Disease by the Complete Admission Physical Exam (O)</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>88/106</strong> Use of Nifedipine (Gastrointestinal Therapeutic System) in the Treatment of Hypertension (O)</td>
</tr>
<tr>
<td><strong>88/108</strong> The Effect of Thyroid Hormone Administration in Acute Renal Failure (O)</td>
</tr>
<tr>
<td><strong>88/109</strong> Methotrexate in the Treatment of Steroid Dependent Asthmatics (O)</td>
</tr>
<tr>
<td><strong>88/110A</strong> Biological Investigation of Cutaneous Lupus Employing Athymic Mice as Skin Heterotransplant Recipients (O)</td>
</tr>
<tr>
<td><strong>88/111</strong> The Use of Fibrin Monomer and D-Dimer in the Evaluation of Patients with Chest Pain (O)</td>
</tr>
<tr>
<td><strong>88/112</strong> Long-Term 5-Fluorouracil Infusion for Recurrent Head and Neck Cancer. A Phase II Pilot Study (O)</td>
</tr>
<tr>
<td><strong>88/113</strong> Methotrexate vs D-Penicillamine in Rheumatoid Arthritis: A Randomized Comparative Study (O)</td>
</tr>
<tr>
<td><strong>88/114</strong> Crossover Comparison of Maximum Dose Glyburide and Glipizide (O)</td>
</tr>
<tr>
<td><strong>88/115</strong> The Impact of an Ambulatory Care Rotation on Interns' Psychosocial Attitudes (O)</td>
</tr>
<tr>
<td><strong>88/116A</strong> Mouse Anti-Chenopod/Amaranth Pollen Monoclonal Antibody Production (O)</td>
</tr>
<tr>
<td><strong>88/117</strong> A Comparison of Amitriptyline vs. Trazodone vs. Placebo as Adjuvants to Opiate Analgesics in the Management of Pain in Cancer Patients (O)</td>
</tr>
<tr>
<td><strong>88/118</strong> (CAP Study 12-21-87) Use of Nifedipine (Gastrointestinal Therapeutic System) in the Treatment of Angina Pectoris (O)(PR)</td>
</tr>
</tbody>
</table>

**DEPARTMENT OF SURGERY**

| 84/20X-001 | Repair of Femoral Artery by Microvascular Technique in Rabbits and Rats (O) | 143 |
| 84/20X-002 | Repair of Femoral Artery by Microvascular Technique in Rabbits and the Rat (O) | 144 |
| 84/20X-003 | Microsurgical Training in Free Flap Transfer and Vessel and Nerve Repair Utilizing the Rabbit and Rat (O) | 145 |
| 85/200 | Differential Fixation of Centrifuged and Non-Centrifuged Acrylic Bone Cement Specimens (C)(PR) | 147 |

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>85/202</td>
<td>NSABP Protocol C-02 - A Clinical Trial Evaluating the Postoperative Portal Vein Infusion of 5-Fluorouracil and Sodium Heparin in Patients with Resectable Adenocarcinoma of the Colon (C) ........ 148</td>
</tr>
<tr>
<td>86/200A</td>
<td>Treatment of Urinary Tract Trauma in the Porcine Animal Model (O) ................................................. 149</td>
</tr>
<tr>
<td>86/201A</td>
<td>Vasovasostomy in the Porcine Animal Model (O) .......................... 150</td>
</tr>
<tr>
<td>86/208A</td>
<td>Medical Readiness Support Program (T) .................................................. 151</td>
</tr>
<tr>
<td>86/209A</td>
<td>Effects of Nonsteroidal Anti-inflammatory Agents on Tendon Healing (O) ........................................ 152</td>
</tr>
<tr>
<td>87/200</td>
<td>Military Boxing Related Injuries (O) .............................. 153</td>
</tr>
<tr>
<td>87/201</td>
<td>Lipid Composition of Normal and Abnormal Foot Pads (T). 154</td>
</tr>
<tr>
<td>87/202</td>
<td>Improving Cancer Management Through the Tumor Conference (O) ...................... 155</td>
</tr>
<tr>
<td>87/203</td>
<td>Comparison of Thermography and Standard Techniques for Detection, Diagnosis and Tracing of Disorders Marked by Altered Patterns of Peripheral Blood Flow (O)(P) ... 156</td>
</tr>
<tr>
<td>88/200</td>
<td>Alcon Surgical Intraocular Lenses Study (O) .................... 157</td>
</tr>
<tr>
<td>88/201A</td>
<td>Use of Goats for Training in Advanced Trauma Life Support (O) .................................................. 158</td>
</tr>
<tr>
<td>88/202</td>
<td>A Comparison of Clinical Features of Ulnar Nerve Compression at the Elbow Before and After Medial Epicondylectomy (O) ............................................... 159</td>
</tr>
<tr>
<td>88/203</td>
<td>Evaluation of Current Nasal Surgical Techniques Used to Improve Nasal Obstruction (Subjective and Objective), Utilizing Anterior Rhinometric Techniques (O) ........ 160</td>
</tr>
<tr>
<td>88/204</td>
<td>Biomedical Analysis of Tibial Fractures Treated with Intramedullary Nails (C)((PR)(SP) .......................... 161</td>
</tr>
<tr>
<td>88/205A</td>
<td>The Use of Gore-Tex Soft Tissue Patches in Repair of Lid and Adnexal Defects in New Zealand White Rabbits (O)... 162</td>
</tr>
<tr>
<td>88/206A</td>
<td>An Analysis of the Effect of Nonsteroidal Anti-inflammatory Medications on Regeneration of Articular Cartilage in New Zealand White Rabbits Treated by Intermittent Active Motion and Continuous Passive Motion (O) .................................................. 163</td>
</tr>
<tr>
<td>88/207A</td>
<td>Biomechanical and Histological Analysis of Achilles Tendon Healing After Open and Percutaneous Repair in a Rabbit Model (O) .................................................. 164</td>
</tr>
<tr>
<td>88/208</td>
<td>A Retrospective Analysis of the Incidence of Pseudoarthrosis in Posterior Spine Fusion Done Between 1971 and 1986 at St. Anthony's Hospital and Denver Children's Hospital (O) .................................................. 165</td>
</tr>
<tr>
<td>88/209</td>
<td>A Comparison of Percutaneous Repair vs Open Repair of Achilles' Tendon Ruptures (O)(PR)(SP) ...................... 166</td>
</tr>
<tr>
<td>88/210A</td>
<td>Delayed Repair of Traumatic Intratemporal Facial Nerve Palsy in the Pig (O) ...................... 168</td>
</tr>
<tr>
<td>88/211</td>
<td>Double Blind Crossover Study of Cyclobenzaprine versus Placebo in Patients with Primary Fibrositis: Correlation of Symptomatic versus Thermographic Criteria of Improvement (O) .................................................. 169</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
88/212 Prevention of Nosocomial Pneumonia and Gastroduoderal Ulcer Prevention in Mechanically-Ventilated Patients (O) ............................................. 170

DEPARTMENT OF CLINICAL INVESTIGATION

72/302 Comparison of Metabolic and Functional Changes in Defects of Platelet Function (O)(P)(PR) ................. 172
77/300 Immunologic Disorders in Children and Adults. I. Correlation of Immune Function in the Immuno-deficiency State. II. Correlation of Immune Function of Leukemia and other Childhood Malignancies (O)(PR) ..................................... 175
82/302 The Evaluation of Recently Introduced, Commercially Available Clinical Microbiology Products for Possible Use in the FAMC Diagnostic Microbiology Laboratory (O)(P)(PR) ........................................ 177
86/300 Early Identification of Borrelia burgdorferi Antibody in Human Sera (O) .................................. 179
86/301 ELISA and Western Blot Detection of Pneumocystis carinii Antigen in Rat Lung and Human Tissue Culture Models (T) ............................................. 180
87/300 Etiology of Low Back Pain Due to Muscle Tension (O) ... 181
87/301 Determination of Mechanisms of Phantom Limb Pain: Phase 2 (O)(P)(PR) ........................................ 183
87/302 Psychophysiological Etiology and Self-help Treatment of Headache (T) ........................................ 185
87/303 Mechanism Based Treatment of Phantom Limb Pain (O)(P) 186
87/304 Use of Heat Patterns in Evaluation of Spinal Cord Injured Veterans (T)(P) ............................................. 188
87/305 Evaluation of Psychophysiological Ways to Assess Chronic Low Back Pain (O)(P) .............................. 189
88/300A Effect of Clonidine on Longitudinal Bone Growth in Juvenile Sprague-Dawley Rats (O) ....................... 191
88/301 Pilot Study For: Continuous Environmental Recording of Activity, Headache, and Muscle Contraction Level Among Subjects with Tension, Migraine or No Headache (O) ... 192
-------- Training Support Summary ......................................................... 193

DEPARTMENT OF OB-GYN

82/35X-001 - Repair of Femoral Artery and Fallopian Tube of Rabbit and Rat (O) ............................................. 196
80/351 GOG #26 - Section A: Master Protocol for Phase II Drug Studies in the Treatment of Advanced Recurrent Pelvic Malignancies (O) ................................. 197
80/352 GOG #26 - Section C: A Phase II Trial of Cis-Platinum (O) ............................................................. 198

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>80/353 GOG #26 - Section D: A Phase II Trial of VP 16 (C)</td>
</tr>
<tr>
<td>80/355 GOG #26 - Section N: A Phase II Trial of DHAD (C)</td>
</tr>
<tr>
<td>80/356 GOG #26 - Section O: A Phase II Trial of AZQ (C)</td>
</tr>
<tr>
<td>80/357 GOG #26 - Section Q: A Phase II Trial of Aminothiadiazole (C)</td>
</tr>
<tr>
<td>80/358 GOG #26 - Section R: A Phase II Trial of Progestin (C)</td>
</tr>
<tr>
<td>80/359 GOG #26 - Section S: A Phase II Trial of VM26 (O)</td>
</tr>
<tr>
<td>80/362 GOG #40 - A Clinical-Pathologic Study of Stages I and II Uterine Sarcomas (O)</td>
</tr>
<tr>
<td>80/369 GOG #54 - The Treatment of Women with Malignant Tumors of the Ovarian Stroma with Combination VCR, Dactinomycin and Cytoxan (Phase III) (O)</td>
</tr>
<tr>
<td>80/370 GOG #55 - Hormonal Contraception and Trophoblastic Sequelae After Hydatidiform Mole (Phase III) (C)</td>
</tr>
<tr>
<td>80/374 GOG #63 - A Clinical-Pathologic Study of Stages II-B, III and IV, A Carcinoma of the Cervix (C)</td>
</tr>
<tr>
<td>80/376 GOG #66 - Ultrastructural Staging and Therapeutic Consideration in Small Cell Carcinoma of the Cervix (Phase II) (O)</td>
</tr>
<tr>
<td>80/378 GOG #72 - Ovarian Tumors of Low Malignant Potential: A Study of the Natural History and a Phase II Trial of Melphalan and Secondary Treatment with Cisplatin in Patients with Progressive Disease (O)</td>
</tr>
<tr>
<td>80/379 GOG #74 - Early Stage I Vulvar Cancer Treated with Ipsilateral Superficial Inguinal Lymphadenectomy and Modified Radical Hemivulvectomy (Phase III) (O)</td>
</tr>
<tr>
<td>80/380 GOG #73 - A Clinical Pathologic Study of Primary Malignant Melanoma of the Vulva Treated by Modified Radical Hemivulvectomy (O)</td>
</tr>
<tr>
<td>80/381 GOG #75 - Postoperative Pelvic Radiation in Stages I and II Mixed Mesodermal Tumors of the Uterus (Phase III) (C)</td>
</tr>
<tr>
<td>80/384 GOG #78 - Evaluation of Adjuvant Vinblastine, Bleomycin and Cis-platinum Therapy in Total Resected Choriocarcinoma, Endodermal Sinus Tumor, or Embryonal Carcinoma of the Ovary Pure and Mixed with Other Elements (C)</td>
</tr>
<tr>
<td>83/351 Danazol in the Treatment of Premenstrual Syndrome (O,P)..</td>
</tr>
<tr>
<td>84/352 Characterization of Steroid Hormones Produced by Short-Term Incubation of Luteal Cells Obtained from Macaca Fascicularis with Induced Luteal Phase Defects (O)</td>
</tr>
<tr>
<td>87/351 GOG 85 - Comparison of Hydroxyurea versus Cis-platinum and 5FU as an Adjunct to Radiation Therapy in Patients with Advanced Carcinoma of the Cervix (O)</td>
</tr>
<tr>
<td>87/352 GOG 86D - A Phase II Trial of Methotrexate in Patients with Advanced or Recurrent Endometrial Carcinoma (C)</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>219</td>
<td>GOG 90 - Evaluation of Cisplatin, Etopuside, and Bleomycin Induction Followed by Vincristine, Dactinomycin and Cyclophosphamide Consolidation in Advanced Ovarian Germ Cell Tumors (O)</td>
</tr>
<tr>
<td>220</td>
<td>GOG 95 - Randomized Clinical Trial for the Treatment of Women with Selected Stage IAi &amp; IAii &amp; IBii Ovarian Cancer (Phase III) (O)</td>
</tr>
<tr>
<td>221</td>
<td>GOG 84 - Evaluation of a Shortened Course of Vincristine, Dactinomycin and Cyclophosphamide as Adjuvant Therapy for Immature Teratoma of the Ovary, State I, Grade 2, Completely Resected (C)</td>
</tr>
<tr>
<td>222</td>
<td>GOG 97 - A Phase III Randomized Study of Cyclophosphamide and Cisplatin in Patients with Suboptimal Stage III and Stage IV Epithelial Ovarian Carcinoma Comparing Intensive and Non-Intensive Schedules (O)</td>
</tr>
<tr>
<td>223</td>
<td>GOG 26W Echinoycin in Advanced Pelvic Malignancies (O)</td>
</tr>
<tr>
<td>224</td>
<td>GOG 93 Evaluation of Intraperitoneal Chromic Phosphate After Negative Second-Look Laparotomy in Ovarian Carcinoma (O)</td>
</tr>
<tr>
<td>225</td>
<td>GOG 99 Adjunctive Radiation Therapy in Intermediate Risk Endometrial Carcinoma (O)</td>
</tr>
<tr>
<td>226</td>
<td>GOG 92 Radiation Therapy vs No Further Therapy in Selected Patients with Stage IB Invasive Carcinoma of the Cervix (O)</td>
</tr>
<tr>
<td>227</td>
<td>GOG 94 A Phase II Study of the Treatment of Stage III and IV Disease of Advanced Endometrial Carcinoma and All Stages of Papillary Serous Carcinoma and Clear Cell Carcinoma of the Endometrium with Total Abdominal Radiation Therapy (O)</td>
</tr>
<tr>
<td>228</td>
<td>GOG 26V A Phase II Trial of N-Methylformamide in Patients with Advanced Pelvic Malignancies (O)</td>
</tr>
<tr>
<td>229</td>
<td>GOG 26Y A Phase II Trial of Vinblastine (NSC#049842) in Patients with Advanced Pelvic Malignancies (O)</td>
</tr>
<tr>
<td>230</td>
<td>GOG 76G A Phase II Trial of Cisplatin and 5-FU in Patients with Advanced Cancer of the Cervix (C)</td>
</tr>
<tr>
<td>231</td>
<td>GOG 104 Intraperitoneal (SWOG 8501) Intraperitoneal Cis-Platinum and Cyclophosphamide IV vs Intravenous Cis-Platinum and Cyclophosphamide IV in Patients with Optimal Stage III Ovarian Cancer (O)</td>
</tr>
<tr>
<td>232</td>
<td>GOG 76J A Phase II Trial of Mitomycin-C (NSC #26980) in Patients with Advanced Squamous Cell Carcinoma of the Cervix (O)</td>
</tr>
<tr>
<td>233</td>
<td>GOG 102B: Phase Two Study of the Intraperitoneal Administration of Cisplatin (NSC#119875) and 5-Fluorouracil (NSC#19893) in Residual Ovarian Carcma (O)</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>88/361</td>
<td>GOG 26Z - A Phase II Trial of Leuprolide Acetate in Advanced Ovarian Carcinoma (C)</td>
</tr>
<tr>
<td>235</td>
<td>DEPARTMENT OF PEDIATRICS</td>
</tr>
<tr>
<td>78/40X-001</td>
<td>Use of Laboratory Animals (Cats) to Teach Medical Skills (O)</td>
</tr>
<tr>
<td>237</td>
<td>82/403</td>
</tr>
<tr>
<td>238</td>
<td>82/407</td>
</tr>
<tr>
<td>239</td>
<td>82/414</td>
</tr>
<tr>
<td>240</td>
<td>82/420</td>
</tr>
<tr>
<td>241</td>
<td>83/401</td>
</tr>
<tr>
<td>242</td>
<td>83/402</td>
</tr>
<tr>
<td>243</td>
<td>85/401</td>
</tr>
<tr>
<td>245</td>
<td>85/406</td>
</tr>
<tr>
<td>247</td>
<td>86/401</td>
</tr>
<tr>
<td>248</td>
<td>86/403</td>
</tr>
<tr>
<td>249</td>
<td>86/404</td>
</tr>
<tr>
<td>250</td>
<td>86/406</td>
</tr>
<tr>
<td>251</td>
<td>86/407</td>
</tr>
<tr>
<td>252</td>
<td>86/408</td>
</tr>
<tr>
<td>253</td>
<td>86/409</td>
</tr>
<tr>
<td>254</td>
<td>86/410</td>
</tr>
<tr>
<td>255</td>
<td>86/411</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
Adolescent Oral Contraceptive Study: A Comparison of a Triphasic Formulation (Triphasil) with a Fixed-Combination Pill (Norinyl) (T) ........................................ 257

POG 8594 - Pilot Protocol for Marrow Relapse on Continuation Therapy in Childhood Acute Lymphoblastic Leukemia (T) .................................................. 258

POG 8625/8626 - Combined Therapy and Restaging in the Treatment of Stages I, IIA, and IIIAI Hodgkin's Disease in Pediatric Patients, A Pediatric Oncology Group Phase III Study (O) ........................................ 259

POG 8638 - Randomized Phase II Study of Carboplatin (CBCDA) VS CHIP in Treatment of Children with Progressive Brain Tumors (O) ........................................ 260

POG 8653/54 - A Study of Childhood Soft Tissue Sarcomas (STS) Other Than Rhabdomyosarcoma and Its Variants, A Pediatric Oncology Group Phase III Study (O) ........ 261

POG 8695 - Front Loading Chemotherapy in Children with Increased Medulloblastoma (O)(PR) ........................................ 262

POG 8704 T-Cell #3 Protocol: A Pediatric Oncology Group Phase III Study (O) ....................... 266

POG 8741/42 Stage D NBL#3 Treatment of Stage D Neuroblastoma in Children >365 Days at Diagnosis (O). 267

POG 8759 Effectiveness of Phase II Agents in Untreated Metastatic Osteosarcoma or Unresectable Primary Osteosarcoma vs Previously Treated Recurrent Osteosarcoma (O) ........................................ 268

POG 8763 Evaluation of Response and Toxicity of Ifosfamide and VP-16-213 in Children with Resistant Malignant Tumors (O) ........................................ 269

Ceftriaxone vs Amoxicillin/Clavulanate for Initial Empirical Therapy of Occult Bacteremia (O) .......... 270

Macromolecular Absorption in the Post-Asphyxiated Small Intestines of the Adult Rat (O) ............ 271

Efficacy of Methylenidate in Previously Undiagnosed Adolescents with Attention Deficit Disorders (O) .... 272

Comparison of Growth Response of Growth Hormone Deficient Children in Two Commercially Available Preparations of Growth Hormone (O) ............................... 273

Effect of Human/Animal Interaction on Stress (O) .... 274

DENTAL ACTIVITIES

Effect of Salivary Function on Oropharyngeal Bacterial Colonization (T) ........................................ 276
DEPARTMENT OF RADIOLOGY

80/602 I.V. Administration of 131-I-6-B Indomethyl-norcholesterol (NP-59) for Adrenal Evaluation and Imaging (O) .......................................................... 278
84/601 An Evaluation of Computed Tomography of the Chest in Changing the Stage or Treatment of Patients with Hodgkin's Disease (C) (PR) ........................................... 279
88/600 a. The Usefulness of Magnetic Resonance Imaging and Transrectal Ultrasound in the Staging of Prostatic Cancer: Comparison to 1mm Whole Gland Mounts.
   b. Artifacts and Variants of the Normal Prostate Seen by MRI and Transrectal Ultrasound: Comparison to 1mm Whole Gland Mounts (O) ............................................. 281
88/601 A Comparison of Body Fat Determinations by the Methods of Dual Photon Absorptiometry, Skin Fold Measurements, Specific Body Circumferences, and Hydrostatic Weighting (O) ............................................. 282

DEPARTMENT OF PRIMARY CARE AND COMMUNITY MEDICINE

74/651 Establishment of and Training in Methods for Special Studies of Abnormal Hemoglobins (C) (P) .......... 284
80/650A The Ontogenesis of Hemoglobin in the American Opossum (Didelphis Virginia) (O) (P) .................. 286
87/650 Clonal Fidelity of Erythroid Lineage in Dyserythropoiesis: An Inquiry Into Ultrastructure (O) ............ 288

DEPARTMENT OF NURSING

86/700A Introduction to Suturing Techniques Using Outbred Adult Rats (O) ........................................... 290
88/700 A Study of the Clinical Nurse Specialist in the AMEDD (O) ......................................................... 291

MEDDAC

83/902A Use of Goats for Training in Emergency Medical Procedures (O) ........................................... 293
87/900 Serological Assessment of Lyme Disease Among Soldiers Training at Fort McCoy, Sparta, Wisconsin (O) ................ 294
87/901 Effect of Patient's Position at the Time of Subarachnoid Puncture on the Incidence of Post Spinal Puncture Headache (T) .................................................. 295
88/900 IOLAB Investigational Plan for the Clinical Study of Intraocular Lenses (O) ................................. 296
88/901 COBURN IOL at GLWACH, Ft. Leonard Wood, MO (O) .......... 297

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
COMPASSIONATE EMERGENCY USE PROTOCOLS .................................... 298

POG 8495 - A Phase I Study of Hyperfractionation in Brain
Stem Glioma in Children .......................................................... 299

Ciprofoxacin Therapy, Protocol U87-007 ...................................... 300

SWOG 8710 ............................................................................. 301

Ofloxacin .................................................................................. 302

NCI protocol I-88-14 ................................................................. 303

Storz Ophthalmic Inc. Co. .......................................................... 304

POG 8696/97 ............................................................................. 305

IND #124001487 Carboplatin ..................................................... 306
UNIT SUMMARY

Clinical Investigation Program, FAMC

Clinical Investigation efforts by FAMC personnel in FY 88 culminated in the publication of 110 articles and 41 presentations and lectures at national, international, and regional scientific meetings. As of 30 September 1988, there were 238 research protocols on the DCI register. Of these, 183 projects were ongoing, 30 projects completed, 17 projects terminated, and for this FY there were 63 new registrations.

Objectives:

To encourage the performance of clinically-oriented investigation by personnel assigned to the Fitzsimons Army Medical Center (FAMC). To aid in the planning, development, support, and execution of experimental clinical studies, both in patients and by directly related laboratory work, into the clinical problems of significant concern in the health care of members of the military community. To provide physician experience in research and investigative procedures by furnishing a highly educated and trained staff of specialists, laboratory facilities, administrative services and funding for: supplies, equipment, consultants, publications and reprints. To achieve continuous improvement in the quality of patient care by providing an atmosphere of inquiry, maintaining high professional standing and accreditation of advanced health programs.

The Clinical Investigation Program differs from Medical Research and Development in that the emphasis is on the health care problems existing in our patient populations, i.e., active duty, retired, and dependents and not solely on medical problems affecting combat readiness and the fighting strength. It is, by its nature, an integral part of the triad of patient care and medicine. It promotes and supports the finest ideals and traditions of Military Medicine and enhances the vitality of the teaching programs which in turn elevates the standard of medical care. The research program operates on the premise that all approved protocols will be supported to the fullest extent allowed by current funding. This concept allows for a larger number of physicians and ancillary personnel to participate in research rather than as in the grant system used elsewhere. This means that virtually every investigator is given a chance to pursue his research without having to compete for funds with "established" names in the field.

Technical Approach:

This support is carried out under the aegis of AR 40-38, Clinical Investigation Program; AR 40-7, Use of Investigational Drugs in Humans; AR 70-25, Use of Volunteers as Subjects in Research; AR 70-18, Laboratory Animals, Procurement, Transportation, Use, Care, and Public Affairs; HSC Reg 40-23, Management of Clinical Investigation Protocols and Reports, as amended; FAMC Reg 40-18, Institutional Review Committee. This Department provides guidance, assistance, and coordinates the FAMC program with higher headquarters.
**Manpower:** current authorized strength is outlined.

<table>
<thead>
<tr>
<th>Description</th>
<th>Grade</th>
<th>MOS</th>
<th>Br</th>
<th>Auth</th>
<th>Req</th>
<th>Act</th>
<th>Name</th>
<th>Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>C, Dept Clin Inv</td>
<td>06</td>
<td>60P9B</td>
<td>MC</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>PODGORE</td>
<td>COL</td>
</tr>
<tr>
<td>C, Micro Svc</td>
<td>05</td>
<td>68A00</td>
<td>MSC</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Andron</td>
<td>LTC</td>
</tr>
<tr>
<td>C, Psychophys &amp; Biostat Svc</td>
<td>04</td>
<td>68T00</td>
<td>MSC</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>Sherman</td>
<td>MAJ</td>
</tr>
<tr>
<td>C, Biochem Svc</td>
<td>04</td>
<td>68C9C</td>
<td>MSC</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>White</td>
<td>MAJ</td>
</tr>
<tr>
<td>C, Immunol Svc</td>
<td>04</td>
<td>68E00</td>
<td>MSC</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Stewart</td>
<td>MAJ</td>
</tr>
<tr>
<td>C, Cell Phys Svc</td>
<td>03</td>
<td>68J00</td>
<td>MSC</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Ferris</td>
<td>CPT</td>
</tr>
<tr>
<td>C, Animal Res Svc</td>
<td>04</td>
<td>64C9B</td>
<td>VC</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Trahan</td>
<td>MAJ</td>
</tr>
<tr>
<td>NCOIC-Med Lab</td>
<td>E7</td>
<td>92B4R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Engle</td>
<td>SFC</td>
</tr>
<tr>
<td>Sr Med Lab Sp</td>
<td>E6</td>
<td>92B3R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Fernandez</td>
<td>SSG</td>
</tr>
<tr>
<td>Operating Rm Sp</td>
<td>E5</td>
<td>91D2R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Haynes</td>
<td>SGT</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E6</td>
<td>01H3R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Chadwick</td>
<td>SSG</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E6</td>
<td>01H3R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Bradley</td>
<td>SSG</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E5</td>
<td>01H3R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Sanders</td>
<td>SGT</td>
</tr>
<tr>
<td>Vet Sp</td>
<td>E6</td>
<td>91T3R</td>
<td></td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>Barrett</td>
<td>SSG</td>
</tr>
<tr>
<td>Vet Sp</td>
<td>E5</td>
<td>91T2R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Lamb</td>
<td>SGT</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E4</td>
<td>01H1R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Cruz-Saez</td>
<td>SP4</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E4</td>
<td>01H1R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Williams</td>
<td>SP4</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E4</td>
<td>01H1R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Mendez</td>
<td>SP4</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E4</td>
<td>01H1R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Galvin</td>
<td>SP4</td>
</tr>
<tr>
<td>Supv Res Chem</td>
<td>13</td>
<td>1320</td>
<td>GS</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>O'Barr</td>
<td></td>
</tr>
<tr>
<td>Microbiologist</td>
<td>11</td>
<td>0403</td>
<td>GS</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>Lima Paine Hoyt</td>
<td></td>
</tr>
</tbody>
</table>
The four GS11 chemist requirements are as follows:

One authorization changed to a GS644 Medical Technologist (open)
Two authorizations filled with GS11 Chemists
One overhire on board GS11 Chemist (required but not authorized)

Animal Resources Service - FY 88

New office furnishings were received and installed during FY 88, providing a much more professional work atmosphere. An "Investigator Guide" was completed during the year, in sufficient number to issue to each member of the Laboratory Animal Care and Use Committee and to each prospective investigator. This guide is intended to assist the investigator in the preparation of animal use protocols, and to use laboratory animals in ways judged to be both professionally and humanely appropriate. It is intended to assist committee members in making determinations relative to protocol applications, and to meet, at least in part, the requirements of Public Law 99-198 to provide training for scientists, animal technicians and other personnel involved with animal care and treatment.
Full AAALAC accreditation was restored on 10 March 1988. Fiberglass-reinforced plastic ceiling panels were installed in the dropped-ceiling areas of the animal housing facility, replacing the unacceptable acoustical tiles. Emergency eye washes were fitted to three sink faucets in the service. A safety chain was installed around the cage washer pit to prevent personnel injuries. A new floor scrubber was procured and has been invaluable in the prevention of soil buildup on the roughened floor surfaces in the animal facility. A pushbutton security lock system was installed in the animal facility and in surgery.

Due to the AALAS annual meeting being held in Denver in November 1987, all members of Animal Resources Service and the Laboratory Animal Care and Use Committee were able to attend. Mr. Jones, Animal Caretaker Foreman, and secretary of the Mile High Branch of AALAS, was awarded Branch Member of the Year in May 1988. MAJ Creighton J. Trahan successfully completed written and oral examinations and has been installed as a Diplomate of the American College of Veterinary Preventive Medicine.

Biochemistry Service - FY 88

1988 was a year of upgrade and transition for the biochemistry service. Many physical improvements were made to building 600 to include a new roof, improved wiring and plumbing, new walls, floors, ceilings and a fresh coat of paint inside and out! Everyone made it through the mini-renovation in good spirits and we all enjoy working in a more pleasant, safer environment.

In addition to the renovation to the physical layout we brought on board several new instrument systems. The Perkin-Elmer 5100 PC was put in service to perform trace metal analysis. It is a dedicated Zeeman system using heated graphite atomization (HGA). We are gearing up for blood lead and serum aluminum, cooper, cadmium and zinc will follow. In March, we brought the Packard Cobra gamma counter online. It is now our workhorse for glucagon, B_{2} microglobulin, cortisol and other I^{125} procedures. We have also acquired the HP Vectra RS/20, a 386 computer with a color plotter and a laser-jet printer which allows us to generate publication quality text and graphics.

We are very excited about our collaboration with the University of Colorado Health Science Center (UCHSC) in support of the Army physicians in the Pediatric Fellowship at UCHSC. The collaboration includes assays such a physiological amino acids, carbohydrates, and nucleic acids. We continue to support a number of basic medical research protocols involving B_{2} microglobulin, Hemoglobin A_{1C}, and red cell metabolism. We are beginning a blood lead/zinc protoporphyrin comparison study with both FAMC and OTSG input.

Cell Physiology Service - FY 88

Of major importance has been the successful use of athymic mice from the CPS colony as the support system for a human skin model. This model which is applicable for many human skin research projects is currently being used to investigate the biology of
cutaneous lupus. The study is being carried out in collaboration with the CPS; the Dermatology Service, FAMC; and the Dermatology Department, University of Colorado Health Sciences Center. CPS has also supported the cell biology aspects of research being conducted in growth hormone treatment, hypoxia of newborn intestine, melanoma estrogen receptor analysis, erythroid burst forming growth, herpes simplex virus assay evaluation, and radiolabelled TSH as a possible thyroid cancer diagnostic aid. These studies have emanated from the areas of pediatrics, dermatology, pathology, and endocrinology. To provide support of research at the ultrastructural level of cell biology, the CPS has added to its investigative resources both a new scanning electron microscope and a new transmission electron microscope.

Immunology Service - FY 88

The Immunology Service has had some moderate personnel changes over the past year. Two GS-9 medical technologists, Rosella Schaff and Cynthia Harrison, departed and one GS-9 medical technologist, Anita Gulati, came on board as a replacement for Miss Schaff as part of the Natural History and AZT Study support team. The overhire position once occupied by Mrs. Harrison will probably not be filled due to current budgetary considerations. To date over 1000 individuals, approximately evenly divided between military and civilian, have been evaluated and acquired within the database in support of the Natural History and AZT protocols. Flow cytometric procedures continue to include almost exclusively two-color cell surface analysis, but new procedures for DNA analysis of paraffin embedded tumors, anti-nuclear antibody (ANA) analysis by pattern recognition, and neutrophil activation analysis by flow cytometric measurements are increasing. The Immunology Service was again tasked by Department of the Army with hosting a week long Flow Cytometry Quality Assurance Workshop which this year was expanded to include Air Force and R&D personnel. There are two currently active research protocols; one was completed, two are about to commence operations, and an additional three are undergoing feasibility studies and literature review. New equipment acquired this year include two 80386-based microcomputers, an automatic dispenser/diluter, a microelectrophoresis system, and a robotics controlled automated ELISA system (placed in Biochemistry). Programmed for procurement FY89 include an automated densitometry and image analysis workstation as well as a radioisotope imaging scanner.

Microbiology Service - FY 88

The successful performance of the mycobacteriology section on all College of American Pathologists (CAP) proficiency surveys was an important part of the successful accreditation of the Fitzsimons AMC pathology laboratory. The mycobacteriology section also supported two research studies: one done in collaboration with the University of Colorado Health Sciences Center involving evaluation of a gene probe method for identification of mycobacteria in primary isolates; another done in collaboration with Colorado State University investigating the use of a panel of over 30 antigens in the rapid diagnosis of M. avium in AIDS patients.
Microbiology service support of the AIDS natural history and AZT treatment studies includes viral culture, antibody, antigen, helper-cell, and other state-of-the-art tests for FAMC AIDS patients. Patient entry in this 200 patient treatment study should be complete by Feb 89. This study could be a pivotal study for the early treatment of AIDS with AZT.

Over 500 sera from US Army Reservists were tested for Lyme disease antibodies in collaboration with Fort Leonard Wood personnel. Both ELISA and FIAx tests showed some positives. The ELISA seemed to be much less specific than FIAx. Without an accurate antigen detection or other confirmatory methods, these serologies cannot be considered definitive indicators of presence or absence of Lyme infection.

Psychophysiology & Biostatistics Service – FY 88

The service's missions are to (1) provide a modern Psychophysiology/Pain Evaluation Laboratory for clinical and research evaluations as well as psychophysiological treatments, (2) coordinate, provide opportunities for, and encourage the research related efforts of Orthopedic staff and residents, and (3) provide support to all MEDCEN staff and students in design and analysis of studies as well as psychophysiological techniques. During the service's first full year of operations, all major equipment items required for a state of the art Psychophysiology/Pain Evaluation Laboratory have been procured and put into operation and are being operated by grant funded personnel. All first and third year Orthopedic residents are participating in one or two month research rotations during which they are relieved of all regular clinical duties. Seminars on research design and statistical analysis have been presented to four services outside of Orthopedics and Clinical Investigation and numerous investigators have been helped to design and analyze studies. Research breakthroughs have been made in (1) relating muscle tension patterns recorded continuously in the normal environment and onset of low back pain and (2) induction of acute episodes of phantom pain by discrete spasms in the residual limbs of amputees.
Funding

The OMA costs have not been itemized by protocol number because it is not feasible or practical to do so.

<table>
<thead>
<tr>
<th></th>
<th>FY 87</th>
<th>FY 88</th>
</tr>
</thead>
<tbody>
<tr>
<td>OMA Civilian Personnel</td>
<td>653,076.36</td>
<td>668,953.</td>
</tr>
<tr>
<td>OMA Contracts</td>
<td>39,964.93</td>
<td>41,514.</td>
</tr>
<tr>
<td>OMA Supplies</td>
<td>297,881.20</td>
<td>218,000.</td>
</tr>
<tr>
<td>OMA Ceep Equipment</td>
<td>17,215.14</td>
<td>28,599.</td>
</tr>
<tr>
<td>OMA Travel</td>
<td>9,076.18</td>
<td>6,552.</td>
</tr>
<tr>
<td>OPA MFDCASE</td>
<td>241,152.77</td>
<td>282,809.40</td>
</tr>
<tr>
<td>GRANTS VA (Psychophysiology &amp; Biostatics Service)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRANTS MPDC (AZT treatment study)</td>
<td></td>
<td>$116,000</td>
</tr>
</tbody>
</table>

|
PUBLICATIONS

DEPARTMENT OF CLINICAL INVESTIGATION


Arena J, Sherman R, Bruno G, and Young T: Electromyographic Recordings of Five Types of Low Back Pain Subjects and No-Pain Controls in Different Positions. Pain, 1988. (C)

(C) Direct result of approved research protocol.


**Allergy Service**


**Dermatology Service**


Fitzpatrick JE, Reed OM, and Mellette JR: Familial Cervical Hypertrichosis with Underlying Kypho-Scoliosis. J. Amer. Acad. Dermatol. (Accepted for publication, 1988). (C)


(C) Direct result of approved research protocol.


Endocrinology Service


Fortenbery EJ, McDermott MT, and Duncan WE: The Effect of Theophylline on Calcium and Vitamin D Metabolism. Submitted for Publication, 1988. (C)


(C) Direct result of approved research protocol.


McDermott MT, Walden T, Bornemann M, Sjoberg RJ, Hofeldt FD, and Kidd GS: The Effects of Theophylline and Nifedipine on ACTH Stimulated Adrenal Cortisol Secretion. Submitted, accepted pending revisions, revisions have been submitted, 1988. (C)

McDermott MT, Perloff JJ, and Kidd GS: Reduced Bone Mass in Mild Asymptomatic Primary Hyperparathyroidism. J. Bone Min. Res. 3 (Suppl 1): S90 (87A), 1988. (C)

McDermott MT, Fortenbery EJ, and Duncan WE: Theophylline Alters Vitamin D and Calcium Metabolism in Rats. J. Bone Min. Res. 3 (Suppl 1): S115 (88A), 1988. (C)

McDermott MT: Tamoxifen Therapy for Painful Gynecomastia. Endocrinology 122 (Suppl): 339 (1276A), 1988. (C)


(C) Direct result of approved research protocol.


Hematology/Oncology


(C) Direct result of approved research protocol.
Nephrology Service


Rheumatology Service


DEPARTMENT OF NURSING


DEPARTMENT OF PEDIATRICS

Carter BS: Medical Ethics Committee - A Survey of Army Hospitals. Military Medicine 153:8, 1988. (C)


PHARMACY SERVICE


DEPARTMENT OF PRIMARY CARE AND COMMUNITY MEDICINE


(C) Direct result of approved research protocol.

DEPARTMENT OF RADIOLOGY


Blue PW, and Parker S: Parathyroid Imaging. Medical Bulletin of the U.S. Army Medical Department, 88-1:4-6, 1988. (C)


(C) Direct result of approved research protocol.


(C) Direct result of approved research protocol.


Hopper K: The Slit Inferior Vena Cava. (Letter to the Editor), Am. J. Roentgenology, 151:205, 1988. (C)


Tyler HN, and Blue PW: Medical X-Ray of the Month - Nuclear Medicine (Causes of Hepatic Uptake in Bone Scintigraphy). Medical Bulletin of the U.S. Army Medical Department, in press 1988.(C)

(C) Direct result of approved research protocol.

Yakes WF: Percutaneous Retrieval of a Kimray-Greenfield Filter from the Right Heart and Successful Placement in the Inferior Vena Cava. Radiology, in press 1988. (C)


DEPARTMENT OF SURGERY

Anesthesia & Operative Svc


General Surgery Service


Neurosurgery Service


Casey KF: A CSF Hyproproduction Syndrome, Child's Nervous System. Publisher is Springer Verlag (in press), 1988. (C)

Ophthalmology Service


Enzenauer RW, and Enzenauer RJ: Ban Boxing at the Academies (Letter to the Editor), Assembly (USMA Association of Graduates) XVLI(4):2, 1988. (C)


(C) Direct result of approved research protocol.


Orthopedic Service


Arena J, Sherman R, Bruno G, and Young T: Electromyographic Recordings of Five Types of Low Back Pain Subjects and Non-Pain Controls in Different Positions. Pain, 1988. (C)

Speech-Language Rehabilitation Section


(C) Direct result of approved research protocol.
Urology Service


Donatucci, CF, et al: Furosemide Induced Disturbances in Renal Function in Patients Undergoing Turp. Submitted to Urology, June 1988. (C)


Horne DW, and Teuton C: von Recklinghausen's Disease of the Genitourinary Tract. Submitted to Urology, March 1988. (C)

Horne DW, and Fauer E: Primary Signet Ring Cell Carcinoma of the Urinary Bladder: Case Presentation, Description of Unique Diversion, and Review of the Literature. Urology, 30(6):574, December 1987. (C)


Vaught WW, Raife MJ, and Horne DW: Prostatic Involvement by Wegener's Granulomatosis: A Case Presenting with Bladder Outlet Obstruction. Accepted for publication by Urology, 1987. (C)


(C) Direct result of approved research protocol.
PRESENTATIONS
DEPARTMENT OF MEDICINE


Allergy Service


(C) Direct result of approved registered protocol.


(C) Direct result of approved registered protocol.


Dermatology Service


(C) Direct result of approved registered protocol.


Endocrinology Service


McDermott MT, Fortenbery EJ, and Duncans WE: Theophylline Alters Vitamin D and Calcium Metabolism in Rats. Presented: American Society for Bone and Mineral Research - 10th Annual Scientific Meeting, New Orleans, LA, June 1988. (C)


(C) Direct result of approved registered protocol.


General Internal Medicine Service


Rheumatology Service


(C) Direct result of approved registered protocol.

DEPARTMENT OF CLINICAL INVESTIGATION


DEPARTMENT OF MINISTRY & PASTORIAL CARE


DEPARTMENT OF NURSING


(C) Direct result of approved registered protocol.

**DEPARTMENT OF PATHOLOGY**


**DEPARTMENT OF PEDIATRICS**

Brantner L, and Slover RH: A Study Investigating the Use of Clonidine in the Treatment for Constitutional Short Stature. (C)


Slover RH: Reactive Hyperemia as a Function of Control and Duration of Type I Diabetes.

(C) Direct result of approved registered protocol.
Slover RH: A Study Comparing the Growth Hormone Response in Growth Hormone Deficient Children to Two Commercially Available Preparations of Growth Hormones.

**PHARMACY SERVICE**


**DEPARTMENT OF RADIOLOGY**


**SOCIAL WORK SERVICE**


(C) Direct result of approved registered protocol.
DEPARTMENT OF SURGERY

General Surgery Service


Neurosurgery Service


(C) Direct result of approved registered protocol.

Ophthalmology Service


Lid Injury and Repair on the Battlefield. Presented: Association of Military Plastic Surgeons, FAMC, April 1988. (C)

Orthopedics Service


(C) Direct result of approved registered protocol.


Perloff KG: CT-Myelogram versus MRI in Diagnosis of Lumbar Disc Disease. Presented: Society of Military Orthopaedic Surgeons, San Diego, CA, November 1987. (C)


Otolaryngology Section (Speech Rehab)


(C) Direct result of approved registered protocol.


Otolaryngology Service

Barrs DM, Lepore ML, and Carnel SB: Total Right Sided Nasal Obstruction, Secondary to Pyogenic Granuloma. Presented:

Blakeslee DB, Carnel SB, and Barnes M: Treatment of Radiation and Chemotherapy Induced Stomatitis. Presented:


Lanier DM, Clark J, and Simcic: Massive Mediastinal and Neck Presentation of Papillary Thyroid Cancer. Presented:


Plastic Surgery Service


(C) Direct result of approved registered protocol.
Urology Service


(C) Direct result of approved registered protocol.
(1) Date: 30 Sep 88 (2) Protocol WU#: 74/110 (3) Status: Completed

(4) Title: Reactive Hypoglycemia: An Analysis of Glucose-Insulin-Glucagon Interrelationships and Counter Hormonal Regulatory Factors

(5) Start Date: FY 71 (6) Est Compl Date: Indefinite

(7) Principal Investigator: Gerald S. Kidd, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Medicine/Endocrine (10) Associate Investigators:
Fred D. Hofeldt, MD
T.P. O'Barr, Ph.D.
Annelie Shackelford, MT

(11) Key Words:
Insulin Coma
Glucagon
Blood Glucose
Insulin Antagonists

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 0 d. Total Number of Subjects Enrolled to Date: 399 e. Note any adverse drug reactions report to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e''. None

(15) Study Objective: The objectives of the hypoglycemic study is to continue to investigate in our clinic population the glucose-insulin-glucagon and prolactin interrelationships and the response of counter-regulatory hormones to hypoglycemic stress. This project is a continuation of the previous project initiated in 1969 at the University of California Medical Center, Moffatt Hospital, San Francisco, CA.

(16) Technical Approach: The clinical research protocol involves evaluation of control subjects and hypoglycemic patients to assess the interrelationships of beta cell and alpha cell responsiveness to oral and intravenous glucose administration. Based upon findings in controls and patients with disease states, a classification system has been proposed. The data have allowed for an understanding of the basic pathophysiology of reactive hypoglycemia disorders. The clinical studies are being conducted in the Department of Medicine, Endocrine Clinic, with the assistance of an assigned GS-5 Medical Technician to perform blood sampling and to assist during the testing. During the glucose tolerance test, the patient has an indwelling catheter for frequent sampling of blood glucose, and is continually monitored by a cardiac monitor system and blood sampling. After
(16) Technical Approach - continued:
glucose administration, blood insulins, glucagons, growth hormones, prolactins and cortisols are sampled and values are determined by a sensitive radioimmunoassay. Blood glucoses are assessed by the Ames Reflectance Meter immediately after sampling. The procedure is designed to provide a minimum of patient inconvenience in the performance of these well standardized procedures. Many normal individuals experience a low blood sugar state sometime after glucose administration, the significance of a low blood glucose state is observed by recording appropriate adrenergic symptoms at the nadir of the glucose and determining if there is a counter hormonal responsiveness to defend the stress of a low blood glucose state. This approach allows strict definition of bona fide reactive hypoglycemia, and clearly distinguishes it from the benign low blood glucose states.

(17) Progress: This protocol represents a long standing clinical investigation effort which has resulted in multiple presentations and publications. During the current year, however, no patients were admitted to the study. The data from a multitude of previous patients studied has been entered into a computer data base and is being analyzed by two former physicians from Fitzsimons, Dr. Fred Hofeldt and Dr. Michael Bornemann.

Presentations:


Publications:

(1) Abrams, R., Hofeldt, F.D., Adler, R., O'Barr, T.P., and Morse, P.: Late Reactive Hypoglycemia in Hypothyroidism.


FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 79/105  (3) Status: Ongoing

(4) Title: Breathing Pattern Effects on Steady-State DLCO Measurement

(5) Start Date: November 1979  (6) Est Compl Date: Indefinite

(7) Principal Investigator: Michael E. Perry, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Medicine/Pulmonary  (10) Associate Investigators: Neal B. Kindig, Ph.D.

(11) Key Words:
steady state DLCO
breathing pattern

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 2
d. Total Number of Subjects Enrolled to Date: 
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To experimentally confirm theoretically determined corrections for breathing pattern during steady-state diffusion studies.

(16) Technical Approach: Breathing patterns with variations in inspiratory and expiratory breath-holds will be performed while the subject undergoes standard steady state diffusion measurement. If our approach is correct, mathematical corrections for breathing pattern will result in a constant value for diffusion capacity.

(17) Progress: Two subjects have participated in 5 studies of breathing pattern effects. Variation from predicted effects was noted during patterns with short apneustic indexes.

Presentations:

Presentations - continued


Publications:

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 80/120  (3) Status: Ongoing

(4) Title: Evaluation of Carbohydrate Metabolism in Thyrotoxicosis: Investigations into the Frequency, Type and Mechanisms of Carbohydrate Tolerance

(5) Start Date: 1981  (6) Est Compl Date: 1990

(7) Principal Investigator: Gerald S. Kidd, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrinology

(10) Associate Investigators:
    T.P. O'Barr, Ph.D., DAC
    Fred D. Hofeldt, COL, (Ret)
    Robert J. Sjoberg, CPT, MC

(11) Key Words:
    carbohydrate
    Hyperthyroidism

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results: 
    c. Number of Subjects Enrolled During Reporting Period: 0
    d. Total Number of Subjects Enrolled to Date: 11
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The first objective of the study is to determine the frequency and reversibility of carbohydrate intolerance in thyrotoxicosis and to determine the importance of gut factors by doing oral and intravenous glucose tolerance test. The second objective is to study the mechanisms of carbohydrate intolerance. This objective will be approached by measuring glucose, insulin, glucagon and free fatty acids, basally and after oral intravenous glucose and by measuring the responses to exogenous insulin.

(16) Technical Approach: Ten non-diabetic patients who are taking no medications, are less than age 45, are less than 120% of ideal body weight, will be studied while thyrotoxic and after recovery. Each patient will have an oral and an intravenous glucose tolerance test. Each patient will have an insulin tolerance test basally and following glucose infusion.

(17) Progress: A new co-principal investigator has been assigned to this project, John A. Merenich, CPT, MC who is beginning his third year of Endocrinology fellowship. He has begun as of this date actively recruiting patients to try to finish up this study. Because the study is so complex and so time consuming, during the past year there was inadequate time available for the PI to continue this study.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 80/121  (3) Status: Completed

(4) Title: An Evaluation of Pituitary and Thyroid Hormonal Response to a 4-hour Continuous and a Bolus Intravenous Infusion of TRH as a Useful Test of Thyroidal Functional Reserve

(5) Start Date: 1981  (6) Est Compl Date: 1989

(7) Principal Investigator: William J. Georgitis, MAJ, MC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators:
    Gerald S. Kidd, COL, MC
    Michael Bornemann, COL, MC

(11) Key Words:
    thyroid function tests
    pituitary
    thyroid hormones
    Thyrotropin

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results: 
    c. Number of Subjects Enrolled During Reporting Period: 3
    d. Total Number of Subjects Enrolled to Date: 51
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: The objective of this study is to determine if the diagnosis of mild or subclinical hypothyroidism can be more clearly established by some integrated parameter reflecting both the pituitary and thyroidal reserve responses to intravenous thyrotropin releasing hormone.

(16) Technical Approach: Three groups of subjects will be evaluated in this protocol. Group 1 will consist of normal control patients; Group 2 will consist of patients with mild hypothyroidism diagnosed by an elevated TSH level but normal thyroid hormone levels; Group 3 will consist of patients with the thyroid clinic with high-normal TSH values and normal thyroid function tests, but who are clinical suspects of having mild hypothyroidism. The patients will undergo two TRH infusion tests in a random manner consisting of conventional bolus administration of 500 ug of TRH solution and the constant infusion of TRH over a 4-hour period of 500 ug of TRH diluted in normal saline and diffused at a rate of 2 ug/minute over the 4 hours using a Harvard infusion pump. The TSH values in the various groups of patients will be determined and statistically analyzed for differences between the groups.
(17) Progress: Thirty three patients and 15 controls have been studied to date. Further controls would be helpful, but in view of the advent of the new assays for TSH, we are preparing a manuscript based on the group studied to date.

Presentations:


Publications: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 81/117  (3) Status: Ongoing

(4) Title: The Role of Calcitonin in Osteoporosis

(5) Start Date: Reactivate 1987  (6) Est Compl Date:

(7) Principal Investigator: Michael T. McDermott, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine  (10) Associate Investigators: Gerald S. Kidd, COL, MC

(11) Key Words:
    osteoporosis
    bone density
    calcitonin deficiency
    thyroid hormone

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period: 32  
    d. Total Number of Subjects Enrolled to Date: 32  
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine if, longitudinally, thyroid cancer patients who have calcitonin deficiency and are on suppressive doses of thyroid hormone, loose radial bone more rapidly than goiter patients, who are also on suppressive doses of thyroid hormone but are not calcitonin deficient, and then normal controls. Also to compare these 3 groups, cross-sectionally, for bone density of the spine and hip.

(16) Technical Approach: 3 Groups: (a) thyroid cancer patients - not calcium deficient and on thyroid hormone; (b) goiter patients - not calcitonin deficient but are on thyroid hormone, and (b) normal controls. (SPA) single photon absorptiometry-distal and midradius - serially for 5-6 yrs (in progress since 1981) (DPA) dual photon absorptiometry - spinal & hip-cross-sectionally.

(17) Progress: Initial cross-sectional study with SPA of the radius showed significantly lower bone density in the thyroid cancer group compared to the other 2 groups. Longitudinal 2 year data with SPA shows similar rates of radial bone loss among the 3 groups (no significant differences). Longitudinal 5 year data with SPA and cross-sectional data with DPA have not been analyzed yet.
Publications:


Presentations:

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 81/118  (3) Status: Ongoing

(4) Title: Hypothalamic Pituitary Gonadal Function in Hypothyroidism

(5) Start Date: 1981  (6) Est Compl Date: Indefinite

(7) Principal Investigator: Michael T. McDermott, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators: Gerald S. Kidd, LTC, MC

(11) Key Words:
- hypothyroidism
- gonadal dysgenesis
- gonadotropins, pituitary

(12) Accumulative MEDCASE:* *(Refer to Unit Summary Sheet of this Report.)

(13) Est Accum OMA Cost:*

(14) a. Date, Latest TRC Review: ________________
   b. Review Results: ________________
   c. Number of Subjects Enrolled During Reporting Period: ________________
   d. Total Number of Subjects Enrolled to Date: 1
   e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: The objectives of this protocol are to define more clearly the mechanisms of gonadal dysfunction occurring in hypothyroidism and to see if these abnormalities resolve after treatment of the hypothyroid state.

(16) Technical Approach: A prospective study to assess in a pair manner results of alterations in HPG axis as a consequence of hypothyroidism when evaluated with GnRH infusion and TRH testing, clinical stimulation and HCG testing in males and females.

(17) Progress: One patient enrolled and studied. Her serum is frozen and awaiting assay.

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 81/119  (3) Status: Ongoing

(4) Title: The Effect of Thyrotropin Releasing Hormone on Gonadotropin
Releasing Hormone Stimulated Gonadotropin Secretion

(5) Start Date: 1981  (6) Est Compl Date: 

(7) Principal Investigator: Michael T. McDermott, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine  (10) Associate Investigators:

Gerald S. Kidd, LTC, MC

(11) Key Words:
- hypothyroidism
- gonadal dysgenesis

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: 

c. Number of Subjects Enrolled During Reporting Period: 6

d. Total Number of Subjects Enrolled to Date: 16

e. Note any adverse drug reactions reported to the FDA or sponsor for
studies conducted under an FDA-awarded IND. May be continued on a separate
sheet, and designated as "(14)e". None

(15) Study Objective: In order to gain a better insight into the mechanism
of gonadal dysfunction in hypothyroidism, the objective of this protocol is
to study the effect of a thyrotropin releasing hormone (TRH) infusion on
basal and gonadotropin releasing hormone (GnRH) stimulated gonadotropins in
normal subjects.

(16) Technical Approach: Ten normal males will be studied with either a
normal saline infusion or a TRH infusion. During these infusions, GnRH
will be given as a bolus with measurement of appropriate hormon~ to deter-
mine interaction between releasing hormones.

(17) Progress: Sixteen subjects have been studied and the data analysis is
complete. The TRH infusion produced a statistically significant augmenta-
tion of the FSH response (both peak and total integrated response) to GnRH,
while the LH response was unaffected.

Publications: McDermott MT, Bornemann M, Sjoberg RJ, Walden T, Hofeldt F,
Kidd GS: Effects of a continuous TRH infusion on GnRH stimulated
gonadotropin secretion (Submitted for Publication, 1988).

Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 82/104  (3) Status: Ongoing

(4) Title: The Effect of Tamoxifen on Gynecomastia

(5) Start Date: 1982  (6) Est Compl Date: 1989

(7) Principal Investigator: Michael T. McDermott, MAJ, MC
(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine  (10) Associate Investigators:
Fred D. Hofeldt, MD
Gerald S. Kidd, LTC, MC

(11) Key Words: tamoxifen
gynecomastia

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 1
d. Total Number of Subjects Enrolled to Date: 12
e. Note any adverse drug reactions reported to the FDA or sponsor for
studies conducted under an FDA-awarded IND. May be continued on a separate
sheet, and designated as "(14)e".

(15) Study Objective: The objective of this protocol is to evaluate, in a
double-blind placebo controlled prospective trial, the effect of Tamoxifen
on males with gynecomastia and to characterize any co-existent hormonal
changes.

(16) Technical Approach: A randomized, double-blind placebo controlled
study of the effects of Tamoxifen therapy on idiopathic gynecomastia will
be performed. Breast size will be assessed by photographs, palpation and
measurement of tissue.

(17) Progress: Six subjects have completed the study, 5 have been lost to
follow-up or dropped out and one is currently being studied. Compared to
placebo, Tamoxifen significantly reduced pain in all stages of the disease,
but reduced size only in those with stage 3 or less.

Publications: McDermott MT: Tamoxifen therapy for painful gynecomastia.

Presentations: McDermott MT: Tamoxifen therapy for painful gynecomastia.
Date: 30 Sep 88  Protocol WU#: 82/114  Status: Ongoing

Title: Growth of Basal Cell Carcinoma Cells in Defined Medium and Study of their Growth and Immunological Characteristics

Start Date: 1982  Est Compl Date: 1990

Principal Investigator: Charles F. Ferris, CPT, MS

Dept/Svc: DCI  Associate Investigators: Ronald W. Grimwood, MD  J. Clark Huff, MD  Richard A.F. Clark, MC

Key Words: basal cell carcinoma

Accumulative MEDCASE:*  Est Accum OMA Cost:*  Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  Review Results:  Number of Subjects Enrolled During Reporting Period:  Total Number of Subjects Enrolled to Date:  Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: Growth and study of basal cell carcinoma cells in culture.

Technical Approach: The approach to culturing of basal cells has, and will be, the use of the media formulated by Dr. Ham's lab at the University of Colorado in Boulder termed MCDB 153. We have been successful to date in culturing normal cell carcinomas. This has included an attempt utilizing fibronectin coated plates. We next will be attempting growth utilizing basal cell tumors that we have successfully grown in nude mice. There is experimental evidence with other tumors grown in nude mice to suggest that there is a greater success rate of in vitro culture once the tumors have been grown in the animal model.

Progress: The improved tissue culturing of keratinocytes have allowed us to begin investigating the potential growth of BCC's.

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 83/107  (3) Status: Ongoing

(4) Title: Use of Isotretinoin in Prevention of Basal Cell Carcinoma

(5) Start Date: 1984  (6) Est Compl Date: 1992

(7) Principal Investigator: J. Ramsey Mellette, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Dermatology

(10) Associate Investigators:
    John Adnot, LTC, MC
    Richard Gentry, LTC, MC

(11) Key Words:
    retinoids
    basal cell carcinoma

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:          b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period: 0
    d. Total Number of Subjects Enrolled to Date: 98
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". Dry skin, chapped lips, myalgias.

(15) Study Objective: To evaluate the effectiveness of low dosage levels of Isotretinoin in reducing the incidence of basal cell carcinomas in high risk population; to examine possible side effects with long term administration of isotretinoin.

(16) Technical Approach: The study is a double-blind study with participants randomly assigned to the medication. Patients will take the med for three years and will be followed for a total of five years. Compliance side-effects and basal cells are very closely monitored.

(17) Progress: 86 patients remain on the study of the original 98. 3 patients are deceased, four patients have transferred to other study sites. 5 patients are off the study for miscellaneous reasons. 13 patients are off medication permanently, following adverse reactions consisting of back pain, macular degeneration, elevated triglycerides, mild cutaneous side effects, headaches, Steven-Johnson syndrome, others off medication permanently for the following reasons: Relocation to Europe, wanted to stop medication, afraid of long term side effects, miscellaneous medical problems, out of state and unable to follow on a regular basis. Ten patients are on permanent dose modification for the following reasons, mild cutaneous side effects, mild elevation of triglycerides, mild arthralgias, moderate cutaneous side effects and gastrointestinal side effects.
Publications:


Presentations:


FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 83/113  (3) Status: Ongoing
(4) Title: Growth of Human Keratinocytes

(5) Start Date: 1983  (6) Est Compl Date: 1990

(7) Principal Investigator:
Charles F. Ferris, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: DCI

(10) Associate Investigators:
Ronald E. Grimwood, MD
J. Clark Huff, MD
Phillip T. O'Barr, Ph.D., DAC

(11) Key Words: keratin

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for
studies conducted under an FDA-awarded IND. May be continued on a separate
sheet, and designated as "(14)e".

(15) Study Objective: Growth and study of human keratinocytes in culture and
subsequent studies using athymic mice as an in vivo culture system.

(16) Technical Approach: The technical approach has been to grow
keratinocytes obtained from newborn foreskins using serum-free media. A
more successful approach has been to culture the cells in complete MCDB 153
media. A new mechanism of freezing the cells has commenced. The final
phase of the study will include identifying specific proteins expressed by
these cells and the presence of protein hormone receptors on the cell sur-
faces.

(17) Progress: Improved growth of cultures.

Publications:

Grimwood RE, Clark RAF, Baskin JB, Nielson LD, Ferris CF: Fibronectin is
Deposited by Keratinocytes in the Basement Membrane Zone during Tissue Or-
ganization. Accepted for publication in Journal of Investigative Dermatol-
ogy.

Grimwood RE, Ferris CF, Baskin JB, Nielson LD, Clark RAF: Fibronectin is
Deposited by Keratinocytes in the Basement Membrane Zone during Tissue Or-

Presentations: None

44
Date: 30 Sep 88  Protocol WM#: 83/122  Status: Ongoing

Title: The Role of Food Allergy in the Pathogenesis of Migraine Headaches

Start Date: 1983  Est Compl Date: 1990

Principal Investigator:  Thurman R. Vaughan, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Allergy

Associate Investigators:
Grant C. Olson, CPT, MC
Richard W. Weber, COL, MC

Key Words: migraine  food hypersensitivity  mediators

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date: 102
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

Study Objective: To study the value of +6 allergy food skin test in directing and defining a diet which will cause a decrease in the frequency of migraine headaches in affected patients. To determine if immunological mediators can be detected in positive responders.

Technical Approach: Approximately 100 patients with dx of migraine headaches who suffered 3 or more HA/month will keep a 1 month food diary/st diary. They will then be skin tested to 83 common foods and undergo an additional 1 mo diet eliminating suspected food, and skin test positive foods. Positive regimens will be studied with open chal. and double blind food challenge with immunologic mediators precursors.

Progress: 102 patients studied thus far. 4 patients studied with immunologic mediator response.
Presentations:


Publications: None
Study Objective: The objective of this study is to determine in an indirect manner i.e., with prostaglandin synthesis inhibition, if the abnormal suppressibility of vasopressin and/or altered renal sensitivity to vasopressin seen in hypothyroid patients is caused by altered prostaglandin levels. This will be done by measuring serum vasopressin levels and urinary water excretion in response to a water load, as well as the renal response to exogenous vasopressin, in hypothyroid patients with and without prostaglandin synthesis inhibition, both before and after treatment with thyroid hormone to the point of euthyroidism. In the same way, the influence of altered prostaglandin levels on the renin-aldosterone axis of hypothyroidism will be studied by measuring plasma renin activity and aldosterone levels in these patients while in a relatively volume depleted state, that is before the water loading is performed. Altered renal prostaglandin synthesis in hypothyroidism will also be assessed directly by measuring urinary PGE-2 excretion in the hypothyroid and euthyroid states. (Urinary PGE-2 excretion is thought to reflect primarily renal PGE-2 production.)
(16) Technical Approach: By measuring urinary prostaglandin E and water loading responses in hypothyroid patients before and after indomethacin administration as well as measuring plasma, aldosterone, and plasma renin activity we will evaluate the effects of prostaglandin synthesis inhibition on water metabolism.

(17) Progress: No patients have been studied during the last fiscal year because of time constraints in relation to patient care and teaching activities and the performance of other research objectives. The investigators still feel that the hypothesis formulated within this protocol remains valid, and that the experimental methodology is good in terms of investigating that hypothesis. We would like to actively recruit patients within the next several months and so respectively request that this protocol be continued.

Publications and Presentations: None
Title: The Effect of Abnormal Thyroid States on the Metabolism of Theophylline and Methylprednisolone

Study Objective: To determine whether hyperthyroidism and hypothyroidism result in alterations of theophylline and methylprednisolone metabolism.

Technical Approach: Hypo- and hyperthyroid subjects are studied when thyroid function is abnormal and again when it is normal by studying the disappearance rate of theophylline and methylprednisolone from serum after bolus injections.

Progress: 5 hyperthyroid and 2 hypothyroid patients have been studied. Theophylline metabolism is normal in hyperthyroidism and normal in hypothyroidism. Methylprednisolone metabolism is variable but essentially normal in hyper and decreased in hypothyroidism.


Publications: None
Date: 30 Sep 88  Protocol WU#: 84/115  Status: Ongoing

Title: Heterotransplantation of Basal Cell Carcinomas to Nude Mice

Start Date: 1984  Est Compl Date: 1990

Principal Investigator: Charles F. Ferris, CPT, MS

Facility: FAMC

Dept/Svc: DCI

Associate Investigators: R.E. Grimwood, MD  J. Clark Huff, MD

Key Words: carcinoma, basal cell transplantation mice, nude

Accumulative MEDCASE:*  Est Accum OMA Cost:*

Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:  d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To develop an in-vivo model of human basal cell carcinoma in the athymic mouse.

Technical Approach: Basal cell carcinoma tissue obtained from excess tissue obtained from Moh's surgery is transplanted to a subcutaneous pocket created by a linear incision on the abdomen of the nude mouse. The mouse will have been splenectomized and transplantation is followed by weekly intraperitoneal injections of antilymphocyte serum. Tumor weight is taken before implantation and measurements of tumor size taken at weekly intervals. Autoradiography and immunofluorescent studies are performed at the time of tumor harvest as well as routine histology and tumor weight.

Progress: No substantive progress this year. Renewed collaboration with Dr. Grimwood is anticipated.
Presentations:


Publications:


FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 84/119  (3) Status: Ongoing
(4) Title: Treatment of Graves' Ophthalmopathy with Cyclosporin

(5) Start Date: 1984  (6) Est Compl Date: 1987

(7) Principal Investigator:
Michael T. McDermott, MAJ, MC
Leonard Wartofsky, COL, MC

(8) Facility: FAMC
WRAMC
MAMC
BAMC

(9) Dept/Svc: MED/Endocrine
(10) Associate Investigators
Anthony Truxal, CPT, MC

(11) Key Words:
eye disease
cyclosporin
prednisone

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: 2 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". Cyclosporine - Acne (1 pt.) Prednisone - Acne, swelling (1 pt.) Arthralgia on withdrawal (1 pt.)

(15) Study Objective: To determine the effectiveness of cyclosporin in the treatment of Graves' eye disease.

(16) Technical Approach: Patients with Graves' eye disease will receive a 3-week course of cyclosporine or prednisone, then have a 3-week rest. Then, 3 weeks of prednisone or cyclosporine (crossover). They will be followed by complete eye examination and CT scan of the orbits before and after each drug period, and twice weekly with CBC, SMA-18, urinalysis and B-2 microglobulin (urine).

(17) Progress: Two patients have been studied at FAMC. Neither improved on cyclosporine or prednisone. No toxicity noted. Two from WRAMC with acute Graves' ophthalmopathy have shown a good response. The results of other patients studied at other centers are not yet available to me.

Publications and Presentations: None

52
(1) Date: 30 Sep 88  (2) Protocol WU#: 85/100  (3) Status: Ongoing

(4) Title: Adjuvant Chemotherapy with 5-Fluorouracil, Adriamycin and Mitomycin-C (FAM) vs. Surgery Alone for Patients with Locally Advanced Gastric Adenocarcinoma, Phase III SWOG #7804

(5) Start Date: 1978  (6) Est Compl Date: Indefinite

(7) Principal Investigator: Daniel Tell, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
   b. Review Results:  
   c. Number of Subjects Enrolled During Reporting Period:  
   d. Total Number of Subjects Enrolled to Date:  
   e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Continuing to accrue.

Publications and Presentations: None
Date: 30 Sep 88  (2) Protocol WU#: 85/101  (3) Status: Completed

Title: Combined Modality Treatment for Stages III and IV Hodgkin's Disease - MOPP #6, Phase III SWOG #7808

Start Date: 1978  (6) Est Compl Date: Indefinite

Principal Investigator: Daniel Tell, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol

Key Words: drug therapy

Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  b. Review Results:  c. Number of Subjects Enrolled During Reporting Period:  d. Total Number of Subjects Enrolled to Date: 1  e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

Technical Approach: See Protocol

Progress: Completed.

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 85/102  (3) Status: Ongoing

(4) Title: Combined Modality Therapy for Breast Carcinoma, Phase III  
SWOG #7827

(5) Start Date: 1979  (6) Est Compl Date: Indefinite

(7) Principal Investigator:  
Daniel Tell, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators

(11) Key Words:  
drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studies conducted under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in  
the study of adult oncological malignancies.

(16) Technical Approach: See Protocol  
(17) Progress: Continuing to accrue.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 85/114 (3) Status: Completed

(4) Title: Management of Disseminated Melanoma, Master Protocol, Phase III
SWOG #8107

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Daniel Tell, MAJ, MC (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators

(11) Key Words:
drug therapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Completed.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 85/122  (3) Status: Ongoing

(4) Title: Treatment of Advanced Bladder Cancer with Preoperative Irradiation and Radical Cystectomy vs. Radical Cystectomy Alone, Phase III SWOG #8221

(5) Start Date: 1982  (6) Est Compl Date: Indefinite

(7) Principal Investigator: Daniel Tell, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:  c. Number of Subjects Enrolled During Reporting Period:  d. Total Number of Subjects Enrolled to Date:  e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOC group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Continuing to accrue.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 85/132  (3) Status: Ongoing

(4) Title: Evaluation of Adjuvant Therapy and Biological Parameters in Node Negative Operable Female Breast Cancer, Intergroup Study
   SWOG #8294

(5) Start Date: 1982  (6) Est Compl Date: Indefinite

(7) Principal Investigator:
   Daniel Tell, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators

(11) Key Words:
   drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:        b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date: 9
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as ")(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Continuing to accrue.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WG#: 85/133  (3) Status: Ongoing

(4) Title: Treatment of Limited Non-Small Cell Lung Cancer: Radiation Versus Radiation Plus Chemotherapy (FOMi/CAP), Phase III SWOG #8300

(5) Start Date: 1984  (6) Est Compl Date: Indefinite

(7) Principal Investigator: Daniel Tell, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:  c. Number of Subjects Enrolled During Reporting Period:  d. Total Number of Subjects Enrolled to Date:  e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOC group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Continuing to accrue.

Publications and Presentations: None
Date: 30 Sep 88

Protocol WU#: 85/136

Status: Ongoing

Title: Multiple Drug Adjuvant Chemotherapy for Patients with ER Negative Stage II Carcinoma of the Breast, Phase III
SWOG #8313

Start Date: 1974

Est Compl Date: Indefinite

Principal Investigator: Daniel Tell, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol

Associate Investigators

Key Words:
drug therapy

Accumulative MEDCASE:

Est Accum OMA Cost:

Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:

b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

Technical Approach: See Protocol

Progress: Continuing to accrue.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 85/139 (3) Status: Ongoing

(4) Title: National Intergroup Protocol for Intermediate Thickness Melanoma 1.0-4.0 mm. Evaluation of Optimal Surgical Margins (2 vs 4 cm) Around the Primary Melanoma and Evaluation of Elective Regional Lymph Node Dissection

SWOG #8393

(5) Start Date: 1983 (6) Est Compl Date: Indefinite

(7) Principal Investigator: Daniel Tell, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Continuing to accrue.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Date:</strong> 30 Sep 88</td>
<td><strong>Protocol WU#:</strong> 85/141</td>
</tr>
<tr>
<td><strong>Status:</strong> Ongoing</td>
<td></td>
</tr>
<tr>
<td><strong>Title:</strong> Evaluation of DTIC in Metastatic Carcinoid, Phase II SWOG #8411</td>
<td></td>
</tr>
<tr>
<td><strong>Start Date:</strong> 1984</td>
<td><strong>Est Compl Date:</strong> Indefinite</td>
</tr>
<tr>
<td><strong>Principal Investigator:</strong> Daniel Tell, MAJ, MC</td>
<td><strong>Facility:</strong> FAMC</td>
</tr>
<tr>
<td><strong>Dept/Svc:</strong> MED/Hema/Oncol</td>
<td><strong>Associate Investigators</strong></td>
</tr>
<tr>
<td><strong>Key Words:</strong> drug therapy</td>
<td></td>
</tr>
<tr>
<td><strong>Accumulative MEDCASE:</strong></td>
<td><strong>Est Accum OMA Cost:</strong></td>
</tr>
</tbody>
</table>

*Refer to Unit Summary Sheet of this Report.

**Study Objective:** The objective is to participate in the SWOG group in the study of adult oncological malignancies.

**Technical Approach:** See Protocol

**Progress:** Continuing to accrue.

**Publications and Presentations:** None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88
(2) Protocol WU#: 85/142
(3) Status: Ongoing

(4) Title: Evaluation of Tamoxifen in Unresectable and Refractory Meningiomas, Phase II
SWOG #8415

(5) Start Date: 1984
(6) Est Compl Date: Indefinite

(7) Principal Investigator:
Daniel Tell, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators

(11) Key Words:
- drug therapy

(12) Accumulative MEDCASE:*  
(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:    b. Review Results:    
c. Number of Subjects Enrolled During Reporting Period:    
d. Total Number of Subjects Enrolled to Date:    
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Continuing to accrue.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 85/147  Status: Ongoing

Title: HLA and Gm Genes in Systemic Lupus Erythematosus Antibody Expression

Principal Investigator: Christopher LeSueur, MD
Sterling West, MD

Facility: FAMC

Dept/Svc: MED/Rheumatology

Associate Investigators
Moses Shanfield, Ph.D.

Key Words:
lupus erythematosus, systemic
HLA antigens

Study Objective: To see if patients with systemic lupus erythematosus have increased prevalence of any HLA and Gm genes as it relates to their autoantibody expression compared to a control group.

Technical Approach: After patient education and consent form is signed, the patient has eight tubes of heparinized blood drawn for HLA and Gm typing. The patient's clinical symptoms, signs and other laboratory parameters are collected according to protocol and correlated with the patient's HLA and Gm typing.

Progress: We have collected an additional 27 patients.

Publications and Presentations: None
Date: 30 Sep 88
Protocol WU#: 85/157
Status: Ongoing

Title: Phase III Study to Determine the Effect of Combining Chemotherapy with Surgery and Radiotherapy for Resectable Squamous Cell Carcinoma of the Head and Neck
SWOG #8590

Start Date: 1985
Est Compl Date: Indefinite

Principal Investigator:
Daniel Tell, MAJ, MC

Facility: FAMC

Ept/Svc: MED/Hema/Oncol

Associate Investigators

Key Words: chemotherapy

Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

Technical Approach: See Protocol

Progress: Continues to accrue.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 85/158  Status: Ongoing

Title: NCI Intergroup #0035, An Evaluation of Levamisole Alone or Levamisole Plus 5-Fluorouracil as Surgical Adjuvant Treatment for Resectable Adenocarcinoma of the Colon, Phase III-Intergroup

Start Date: 1985  Est Compl Date: Indefinite

Principal Investigator: Daniel Tell, MAJ, MC

Dept/Svc: MED/Hema/Oncol  Associate Investigators

Key Words: drug therapy

Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

Technical Approach: See Protocol

Progress: Continues to accrue.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 85/163  (3) Status: Ongoing

(4) Title: The Effect of Theophylline and Nifedipine on Hormone Secretion

(5) Start Date: Reactivate 1987  (6) Est Compl Date:

(7) Principal Investigator:
   Michael McDermott, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine  (10) Associate Investigators
   Gerald S. Kidd, COL, MC

(11) Key Words: theophylline nifedipine

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: 4
c. Number of Subjects Enrolled During Reporting Period: 4
d. Total Number of Subjects Enrolled to Date: 10
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objectives of this protocol are to study the effect of theophylline and nifedipine on hormone secretion patterns in order to probe the intracellular mechanisms of hormone secretion and to better understand the effects of these medications on endocrine function tests.

(16) Technical Approach: Subjects will have a combined pituitary stimulation study (TRH, GnRH and ACTH) on 3 occasions: control period, during a theophylline infusion, after 2 days of taking nifedipine. Basal and peak hormone responses to the stimulating hormones will be compared among the 3 periods.

(17) Progress: 10 subjects have been studied. Theophylline enhances and nifedipine impairs the cortisol response to ACTH. The data for TSH, T3, prolactin, LH and FSH are not yet analyzed.


Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 85/165  (3) Status: Ongoing

(4) Title: An Evaluation of Cross Allergenicity Among Pollen Extracts of Members of the Chenopodiaceae and Amaranthaceae

(5) Start Date: 1985  (6) Est Compl Date: 1988

(7) Principal Investigator: R.W. Weber, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Allergy  (10) Associate Investigators

(11) Key Words: R. Ledoux

pollen
hypersensitivity
allergens

Bernard L. Crosby, MAJ, MC

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results: 

c. Number of Subjects Enrolled During Reporting Period: 

d. Total Number of Subjects Enrolled to Date: 

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate patterns of cross allergenicity among pollens of the weed families, Chenopodiaceae and Amaranthaceae.


(17) Progress: Three subprotocols completed and presented, now being prepared for publication. Search for effective adjuvant to replace CFA successfully. Rabbit protocol can therefore continue.


Publications: None
(4) Title: Colon Inflammation in Reiter's Syndrome: Response to Sulfasalazine. Results in a Controlled Study

(5) Start Date: 1985

(6) Est Compl Date: 1989

(7) Principal Investigator: David Nordstrom, MD
Sterling West, MD
Peter Andersen, MD

(8) Facility: FAMC

(9) Dept/Svc: MED/Rheumatology

(10) Associate Investigators

(11) Key Words:
Reiter's disease
reactive arthritis

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* 
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 
b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 5

d. Total Number of Subjects Enrolled to Date: 60

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: To see if patients with idiopathic Reiter's syndrome have colon inflammation and to see (in double-blinded fashion) if this responds to Sulfasalazine.

(16) Technical Approach: Colonoscopy with biopsy is performed on Reiter's patients and controls (patients with inflammatory arthritis that is not Reiter's).

(17) Progress: Patients and controls continue to be added to the protocol. Although numbers are still small, patients with Reiter's seem to have a favorable response to Sulfasalazine, and their microscopic inflammation improves as well. A small number of new patients (5) have been added this FY and patients treated with Sulfasalazine continue to be followed closely for 6-8 months. A new manuscript is in preparation.


(1) Date: 30 Sep 88  (2) Protocol WU#: 85/167  (3) Status: Ongoing

(4) Title: The Effect of Age on Thyroid Function Studies: The Perchlorate Discharge Test

(5) Start Date: 1985  (6) Est Compl Date: 1989

(7) Principal Investigator: Gerald S. Kidd, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators
William J. Georgitis, MAJ, MC
Michael T. McDermott, MAJ, MC
Peter Blue, LTC, MC
Stephen M. Manier, MAJ, MC
Tony L. Walden, CPT, MC

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 1
d. Total Number of Subjects Enrolled to Date: 11
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective of this study is to determine the effect of age on the perchlorate discharge test in individuals with thyroid disease.

(16) Technical Approach: Patients over the age of 60 years without thyroid disease by history, physical examination and lab evaluation will be studied. A perchlorate test will be performed in Nuclear Medicine.

(17) Progress: One new patient was studied during FY 83 without complications or difficulties. The data so far analyzed appears to be negative in terms of demonstrating an abnormal perchlorate discharge test in older patients without known thyroid disease. However, during FY 89, we need to study several more patients to finish up this protocol. Request continuation of the protocol.

Publications and Presentations: None
(1) Date: 30 Sep 88 (2) Protocol WU#: 85/173 (3) Status: Completed

(4) Title: The Effects of Gonadal Steroids on Arachidonic Acid Metabolites and Angiotensin Converting Enzyme Activity in Female Rats

(5) Start Date: Nov 85 (6) Est Compl Date: FY 87

(7) Principal Investigator: 
Tony L. Walden, CPT, MC
William J. Georgitis, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators
Gerald S. Kidd, LTC, MC
Michael T. McDermott, MAJ,
Michael Bornemann, COL, MC

(11) Key Words: 
prostaglandins
steroids

(12) Accumulative MEDCASE:* 
(13) Est Accum OMA Cost:* 
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 4 Aug 86   b. Review Results: 
   c. Number of Subjects Enrolled During Reporting Period: 48 rats 
   d. Total Number of Subjects Enrolled to Date: 48 rats 
   e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The investigation will examine the effects of sex steroids on arachidonic acid metabolites and angiotensin converting enzyme activity in female rats.

(16) Technical Approach: This study examines the effects of oophorectomy and sex steroids on serum and lung ACE activity and prostaglandins in female rats. The rats were divided into four groups - shams, castrates, castrates treated with estradiol, and castrates treated with progesterone delivered by Alzet osmotic minipumps.

(17) Progress: No alterations in prostaglandins were found. ACE results are to be incorporated in a report with results found from a previous study in male rats. Further investigation of prostaglandins could be done in this area but should probably involve different methodology. Protocol is completed this FY.
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

1. **Date:** 30 Sep 88  
2. **Protocol WU#:** 85/167  
3. **Status:** Ongoing  

4. **Title:** The Effect of Age on Thyroid Function Studies: The Perchlorate Discharge Test  

5. **Start Date:** 1985  
6. **Est Compl Date:** 1989  

7. **Principal Investigator:** Gerald S. Kidd, COL, MC  
8. **Facility:** FAMC  

9. **Dept/Svc:** MED/Endocrine  
10. **Associate Investigators:**  
    - William J. Georgitis, MAJ, MC  
    - Michael T. McDermott, MAJ, MC  
    - Peter Blue, LTC, MC  
    - Stephen M. Manier, MAJ, MC  
    - Tony L. Walden, CPT, MC  

11. **Key Words:**  
    - thyroid diseases  
    - thyroid function tests  
    - thyroid gland  

12. **Accumulative MEDCASE:**  
13. **Est Accum OMA Cost:**  
    *Refer to Unit Summary Sheet of this Report.*  

14. **a. Date, Latest IRC Review:**  
15. **b. Review Results:**  
16. **c. Number of Subjects Enrolled During Reporting Period:** 1  
17. **d. Total Number of Subjects Enrolled to Date:** 11  
18. **e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".**  

19. **Study Objective:** The objective of this study is to determine the effect of age on the perchlorate discharge test in individuals with thyroid disease.  

20. **Technical Approach:** Patients over the age of 60 years without thyroid disease by history, physical examination and lab evaluation will be studied. A perchlorate test will be performed in Nuclear Medicine.  

21. **Progress:** One new patient was studied during FY 88 without complications or difficulties. The data so far analyzed appears to be negative in terms of demonstrating an abnormal perchlorate discharge test in older patients without known thyroid disease. However, during FY 89, we need to study several more patients to finish up this protocol. Request continuation of the protocol.  

**Publications and Presentations:** None
Presentations:


Publications:

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 -s amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 85/174  (3) Status: Ongoing

(4) Title: Evaluation of Combination Chemotherapy Using High Dose ARA-C in Adult Acute Leukemia and Chronic Granulocytic Leukemia in Blastic Crisis, Phase III SWOG 8326/27

(5) Start Date: 1983  (6) Est Compl Date: Indefinite

(7) Principal Investigator:
Daniel Tell, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators

(11) Key Words:
  drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
  *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 1  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as ") (14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 86/10X-001 (3) Status: Ongoing

(4) Title: Feasibility Study to Determine If Estrogen and Progestrone Affect in-vitro Growth of Cultured Malignant Melanoma (MM) Cell Lines

(5) Start Date: 1986 (6) Est Compl Date: 1990

(7) Principal Investigator: James Fitzpatrick, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Dermatology

(10) Associate Investigators
    Donald B. Mercill, DAC
    Thomas P. O'Barr, DAC
    Charles F. Ferris, CPT, MS

(11) Key Words: malignant melanoma receptors estrogen progesterone

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine whether malignant melanoma cell lines previously obtained and stored (frozen) have estrogen and progesterone receptors. If receptors can be identified, then a full scale protocol can be undertaken to determine if estrogen and progesterone have an effect on cell growth.

(16) Technical Approach: Malignant melanoma cells lines currently stored in the Cell Physiology Service will be grown to confluence. Specific binding will be characterized utilizing a dextran-coated charcoal technique.

(17) Progress: Control receptor analysis is completed, investigation has commenced on possible positive cell lines.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 86/100  (3) Status: Ongoing

(4) Title: Assessment of Nonspecific Decrease in Skin Test Reactivity During Immunotherapy

(5) Start Date: 1986  (6) Est Compl Date: 1989

(7) Principal Investigator: Richard W. Weber, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Allergy  (10) Associate Investigators

(11) Key Words: skin test  Bernard L. Crosby, MAJ, MC
     immunotherapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
     *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:
     b. Review Results:
     c. Number of Subjects Enrolled During Reporting Period:
     d. Total Number of Subjects Enrolled to Date: 6
     e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine whether there is a nonspecific decrease in skin test reactivity to unrelated extracts during immunotherapy.

(16) Technical Approach: Patients placed on immunotherapy will receive periodic titrated skin tests to allergens in the treatment sets, as well as allergens not in the treatment sets, as well as skin tests to histamine and compound 48/80.

(17) Progress: In progress, active, 5 are completed. The consent form is updated.

Publications and Presentations: None at present.
Date: 30 Sep 88  Protocol WU#: 86/103  Status: Ongoing

Title: Evaluation of Low Dose Ara-C versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes (ECOG EST 4483) SWOG #8592

Start Date: 1985  Est Compl Date: Indefinite

Principal Investigator: Daniel Tell, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol

Associate Investigators

Key Words: drug therapy

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  Review Results:  Number of Subjects Enrolled During Reporting Period:  Total Number of Subjects Enrolled to Date:  Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To participate in the SWOG group in the study of adult oncological malignancies.

Technical Approach: See Protocol

Progress: Continues to accrue.
Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 86/104 (3) Status: Terminated

(4) Title: Comparison of Quantitative Immunoelectrophoresis (QIE), Skin Prick Testing, RAST Inhibition, and ELISA Inhibition (EI) Methods for Determination of Allergen Extract Potency

(5) Start Date: 1986 (6) Est Compl Date:

(7) Principal Investigator: William K. Dolen MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Allergy (10) Associate Investigators

(11) Key Words: Robert L. Ledoux, DAC
immunoelectrophoresis
enzyme-linked immunosorbent assay

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To examine the correlation between several methods by which an allergen extract of unknown potency can be compared to a reference extract.

(16) Technical Approach: Sera will be collected from persons allergic to cat, artemesia, and used to assess the potency of allergic extracts by EAST (ELISA) inhibition.

(17) Progress: No progress in past year. Request termination of protocol.

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 86/105  (3) Status: Completed

(4) Title: Immune Response in Dialysis Patients Receiving Desferrioxamine

(5) Start Date: 1986  (6) Est Compl Date: 

(7) Principal Investigator:  (8) Facility: FAMC
James A. Hasbargen, MAJ, MC

(9) Dept/Svc: MED/IntMed/Neph  (10) Associate Investigators

Robert Hull, MD

(11) Key Words:
dialysis
deferoxamine

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:   b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 
d. Total Number of Subjects Enrolled to Date: 12
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: This study is designed to assess immunologic parameters in a cohort of 12 dialysis patients before, during, and at the completion of desferrioxamine therapy. Serial serum trace element determinations will be made before and at the completion of therapy. Study was amended by COL Shetler at the time of approval to include controls.

(16) Technical Approach: We are measuring T lymphocytes subsets and mitogen stimulation using Con A and PHA.

(17) Progress: No further enrollement. No adverse effects, study is completed.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 86/107  (3) Status: Ongoing

(4) Title: In-Vitro Drug Sensitivity Utilizing the Guinea Pig Airway Smooth Muscle Model

(5) Start Date: 1986  (6) Est Compl Date: 1988

(7) Principal Investigator: T. Ray Vaughan, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Allergy

(10) Associate Investigators
    Richard W. Weber, COL, MC
    Anthony R. Henry, LTC, MC

(11) Key Words:
    drug sensitivity

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: __________ b. Review Results: __________
    c. Number of Subjects Enrolled During Reporting Period: __________
    d. Total Number of Subjects Enrolled to Date: __________
    e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: We have previously demonstrated in the guinea pig tracheal model the development of subsensitivity to beta-adrenergic agonists, it would now be useful to have an animal model to study the effect of B-agonists and anticholinergic meds on B-blockade induced tracheal contractions.

(16) Technical Approach: In-vivo blockade of B receptors in guinea pigs with propranolol will be achieved with either po ingestion or serial injections. Subsequently in in-vitro studies we will excise tracheal ring segments, induce contraction with methylcholine and/or histamine and study the comparative effects of an anticholinergic drug and a B-agonist.


Presentations: American College of Allergist National Meeting, 1986

79
Study Objective: This experiment is designed to investigate whether the activity of angiotensin converting enzyme in male Sprague-Dawley rats is altered by prolactin.

Technical Approach: Four groups of rats were treated with vehicle, pergolide, metoclopramide, and metoclopramide plus testosterone delivered by Alzet osmotic minipumps for two weeks.

Progress: A treatment effect was achieved but ACE and parameters of gonadal status were unaltered by the different states of prolactin achieved by the drugs. Further work may be done on frozen specimens in storage.

Publications:


Presentations:


Date: 30 Sep 88  (2) Protocol WU#: 86/109  (3) Status: Ongoing

Title: The Effect of INH and Combination INH-Rifampin Therapy on Calcium and Vitamin D Metabolism

Start Date: 1986  (6) Est Compl Date:

Principal Investigator: John Merenich, CPT, MC

Facility: FAMC

Dept/Svc: MED/Endocrine

Associate Investigators
Gerald S. Kidd, LTC, MC
Michael E. Perry, COL, MC
Michael T. McDermott, MAJ, MC
Fred Negron, CPT, MC
Peter Blue, LTC, MC
Nasser Ghaed, COL, MC

Key Words:
calcium
vitamin D rifampin
vitamin D deficiency

Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: 

b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 1

d. Total Number of Subjects Enrolled to Date: 7

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

Study Objective: The purpose of this study is to see if INH therapy alters vitamin D and/or calcium metabolism in a significant manner. This may then lead to further evaluation to determine if patients would benefit from vit D or calcium supplementation while receiving INH therapy.

Technical Approach: Ten to 20 patients will be begun on INH therapy for their recent PPD conversion. Determinations of Vit D (25-OH, 1,25-OH), serum calcium, PTH, 24-hour urine calcium and SMA-18 are drawn at baseline, 2 weeks, 6 and 9 months. Bone densitometry is obtained before and after therapy.

Progress: Seven patients have been entered in the study as of this date. Once again key investigators have departed Fitzsimons making enrollment and follow-up of patients difficult. The sole principal investigator now (CPT Menerich) has re-established contact with the pulmonary clinic in order to facilitate patient recruitment. Further, CPT Menerich has contacted the original protocol developer, MAJ A. Asp, now stationed at Eisenhower AMC. MAJ Asp plans to submit the protocol to his local IRC, thus making the study a two-center venture. Request continuation of the protocol.

Publications and Presentations: None
Study Objective: To determine the optimum concentration of standardized allergen extracts for routine use in prick skin testing.

Technical Approach: Atopic and nonatopic patients will receive skin testing with standardized and nonstandardized extracts in order to determine whether the standardized extracts differ from the conventional ones in potency and incidence of false positive reactions.

Progress: Work in progress, active. Eleven nonatopic patients have been tested, and 5 atopic subjects. Anticipate completion by July, 1988. New Fellows to be assigned to protocol.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 86/114  Status: Ongoing

Title: Natural History of HTLV-III Infection and Disease in a United States Military Community

Start Date: 1986  Est Compl Date: 1992

Principal Investigator: Shannon M. Harrison, LTC, MC

Facility: FAMC

Dept/Svc: MED/Inf Dis

Associate Investigators
Leo A. Andron, LTC, MC
Roland N. Hannon, PA-C, CW3 (RET)
Richard W. Burris, PA-C, GS12
Robert H. Gates, MAJ, MC

Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review: 9/86  Review Results: Ongoing
Number of Subjects Enrolled During Reporting Period: 75
Total Number of Subjects Enrolled to Date: 300
Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

Study Objective: To develop an accurate, thorough understanding of the pattern of disease progression and clinical course in individuals with documented HTLV-III infection within the general military population including active duty, dependents, and retirees. This will provide critical information for clinical and administrative management of patients.

Technical Approach: Collect data on all patients who are required to be staged by DA directives and any who request staging.

Progress: As noted an additional 75 patients have been added to the Natural History Study in the previous year. However, there is about a 25% attrition rate in terms of new patients added that dropped from follow-up either through death, moving to another facility or being separated from military beneficiary status. The data to date would suggest that 30% of all persons followed more than 12 months will progress at least 1 Walter Reed stage. (This information of sensitive nature for Official Use Only).

Publications: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 86/115  (3) Status: Ongoing

(4) Title: A Prospective Evaluation of Neuropsychiatric Sequelae of HTLV-III Disease

(5) Start Date: 1986  (6) Est Compl Date:

(7) Principal Investigator: William Clayton, MAJ, MC  (8) Facility: FAMC

(9) Dept/Svc: of Medicine  (10) Associate Investigators

(11) Key Words:
    human immunodeficiency virus
    neuropsychological tests

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:____________________ b. Review Results:____________________
c. Number of Subjects Enrolled During Reporting Period:____________ 7

d. Total Number of Subjects Enrolled to Date:____________ 43
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine the prevalence and progression of neuropsychiatric disease in an HTLV-III positive military population.

(16) Technical Approach: Patients have been enrolled in the Neuropsychiatric Protocol from the umbrella Protocol dealing with Natural History of HTLV-III Disease. This allocation has been random except for expectation of good follow up. There have been no significant changes in overall protocol approach.

(17) Progress: Twenty-five individuals have been lost to follow-up due to separation from the service and relocation from this geographic area. No other patients being enrolled.

Presentations:


Publications: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 86/116  (3) Status: Ongoing

(4) Title: Endocrine Function in the Acquired Immune Deficiency Syndrome

(5) Start Date: 1986  (6) Est Compl Date: July 1987

(7) Principal Investigator:
   John Merenich, CPT, MC
   Michael T. McDermott, MAJ, MC
   Arnold A. Asp, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators
   Gerald S. Kidd, LTC, MC
   Michael Bornemann, COL, MC
   William J. Georgitis, MAJ, MC
   Shannon Harrison, MAJ, MC
   David R. Haburchak, COL, MC

(11) Key Words:
   acquired immunodeficiency syndrome
   adrenal glands

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:
   b. Review Results:
   c. Number of Subjects Enrolled During Reporting Period: 3 pt., 15 controls
   d. Total Number of Subjects Enrolled to Date: 40 pt., 20 controls
   e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: The objectives of this study are to detect, define, and determine the incidence of abnormalities of the pituitary gland, adrenal gland, thyroid gland and gonads in patients with acquired immune deficiency syndrome and its variants.

(16) Technical Approach: Patients who are detected as being positive for HTLV III are staged and the endocrine function is studied with a combined pituitary test consisting of the intravenous injection of ACTH, TRH and GnRH with subsequent measurement over the next 3 hours for cortisol, aldosterone, TRH, T4, T3, FSH and LH.

(17) Progress: We completed the data collection phase late 1987 and began data analysis at that time. The adrenal gland data was presented at the 1988 meeting of Endocrine Society. The remainder of the data is currently being analyzed and hope to publish the data within the next few months.

Presentations:

(2) 1988 Fitzsimons Hugh Mahon Competition (2nd place).

Publications: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 86/118  (3) Status: Ongoing
(4) Title: Maintenance vs. No Maintenance BCG Immunotherapy of Superficial Bladder Cancer  SWOG #8507
(5) Start Date: 1985  (6) Est Compl Date: Indefinite
(7) Principal Investigator: Daniel Tell, MAJ, MC
(8) Facility: FAMC
(9) Dept/Svc: MED/Hema/Oncol
(10) Associate Investigators
(11) Key Words: chemotherapy
(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.
(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".
(15) Study Objective: To participate in the SWOG group in the study of adult oncological malignancies.
(16) Technical Approach: See Protocol
(17) Progress: Continues to accrue.
Publications and Presentations: None
(1) Date: 30 Sep 88 (2) Protocol WU#: 86/119 (3) Status: Ongoing

(4) Title: Randomized Comparison of Cisplatin + 5-Fluorouracil vs. CBDCA + 5-Fluorouracil vs. Methotrexate in Advanced Squamous Cell Carcinoma of the Head and Neck, Phase III SWOG #8514

(5) Start Date: 1986 (6) Est Compl Date: Indefinite

(7) Principal Investigator: Daniel Tell, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See protocol.

(17) Progress: Continues to accrue.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 86/120 (3) Status: Ongoing

(4) Title: A Phase II Comparison of CHOP versus m-BACOD versus ProMaCE-CytaBOM versus MACOP-B in Patients with Intermediate or High Grade Non-Hodgkin's Lymphoma

SWOG #8516

(5) Start Date: 1986 (6) Est Compl Date: Indefinite

(7) Principal Investigator: Daniel Tell, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: 2 e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Continues to accrue.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 86/122  Status: Ongoing

Title: Pulmonary Function Standards at FAMC: Correlation with Anthropomorphic Measurement

Start Date: 1986  Est Compl Date:

Principal Investigator: Michael E. Perry, COL, MC

Facility: FAMC

Dept/Svc: MED/Pulmonary

Associate Investigators

Key Words:
anthropometry
pulmonary gas exchange

Accumulative MEDCASE:*

Est Accum OMA Cost:* Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 19
d. Total Number of Subjects Enrolled to Date: 70
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To determine the spirometry, body plethysmography and diffusion capacity normal standards for Fitzsimons Army Medical Center.

Technical Approach: As pointed out in original protocol, non-smoking volunteers undergo spirometry, body plethysmography DLCO, at the PFT lab, chest measurements/height/weight recorded and this data included for regression analysis and assess any correlation.

Progress: Severe staffing shortages prevent work on this protocol.

Publications and Presentations: None
Date: 30 Sep 88 (2) Protocol WU#: 86/123 (3) Status: Ongoing

Title: Phase II Evaluation of Methyl-Glyoxal Bis-Guanylhydrazone (MGBG) in Patients with Advanced Bladder Cancer
SWOG #8519

Start Date: [Blank] (6) Est Compl Date: [Blank]

Principal Investigator: Daniel Tell, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol

Associate Investigators

Key Words: drug therapy

Accumulative MEDCASE:* (13) Est Accum OMA Cost: *
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review: [Blank] b. Review Results: [Blank]
c. Number of Subjects Enrolled During Reporting Period: [Blank]
d. Total Number of Subjects Enrolled to Date: [Blank]
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To participate in the SWOG group in the study of adult oncological malignancies.

Technical Approach: See Protocol

Progress: Continues to accrue.

Publications and Presentations: None

91
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 86/124  (3) Status: Ongoing

(4) Title: Treatment of Limited Small Cell Lung Cancer with Concurrent Chemotherapy, Radiotherapy and Intensification with High Dose Cyclophosphamide

SWOG #8573

(5) Start Date: 1985  (6) Fst Compl Date: Indefinite

(7) Principal Investigator:
Daniel Tell, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators

(11) Key Words:
drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
   b. Review Results:  
   c. Number of Subjects Enrolled During Reporting Period:  
   d. Total Number of Subjects Enrolled to Date:  
   e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Continues to accrue.

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 86/125  (3) Status: Ongoing

(4) Title: A Randomized Comparative Trial of Lobectomy versus Limited Resection for Patients with Cancer of the Lung

LCSG #821

(5) Start Date:

(6) Est Compl Date:

(7) Principal Investigator: Elder Granger, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: ________ b. Review Results:________
c. Number of Subjects Enrolled During Reporting Period:________
d. Total Number of Subjects Enrolled to Date:________
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the LCSG group protocols.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 86/126  Status: Ongoing

Title: A Prospective Randomized Trial to Determine the Benefit of Surgical Resection of Residual Disease Following Response of Small Cell Lung Cancer to Combination Chemotherapy
LCSG #832

Start Date:  Est Compl Date:

Principal Investigator: Elder Granger, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol  Associate Investigators

Key Words:
drug therapy

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 1
d. Total Number of Subjects Enrolled to Date: 1
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To participate in the LCSG group protocols.

Technical Approach: See Protocol

Progress: Ongoing

Publications and Presentations: None
Date: 30 Sep 88
Protocol WU#: 86/127
Status: Completed

Title: Phase II Pilot Program of Concurrent Chemotherapy and Radiation Therapy Before Surgery in Patients with Stage III Non-Small Cell Lung Cancer
LCSG #852

Start Date: 
Est Compl Date:

Principal Investigator:
Daniel Tell, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol

Associate Investigators

Key Words: drug therapy

Accumulative MEDCASE:* 
Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:
 b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 1
d. Total Number of Subjects Enrolled to Date: 1
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To participate in the LCSG group protocols.

Technical Approach: See Protocol

Progress: Completed.

Publications and Presentations: None

95
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 86/128 (3) Status: Ongoing

(4) Title: A Clinical Trial in Patients with Stage II and III Completely Resected Non-Small Cancer of the Lung Comparing Chemotherapy vs. No Therapy Following Surgery

LCSG #853

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator:

Elder Granger, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the LCSG group protocols.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing

Publications and Presentations: None
Date: 30 Sep 88

Protocol WU#: 86/129

Status: Ongoing

Title: Evaluation of Ambulatory Recording Oximetry and Holter Monitoring in Screening for Sleep Apnea

Start Date: 1988

Principal Investigator:
Gary L. Jackson, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Pulmonary Dis.

Associate Investigators:
Jean Foucauld, CPT, MC
Michael Perry, COL, MC

Key Words:
oximetry
sleep apnea syndromes

Accumulative MEDCASE:* (Refer to Unit Summary Sheet of this Report.)

Est Accum OMA Cost:

Date, Latest IRC Review:

Review Results:

Number of Subjects Enrolled During Reporting Period:

Total Number of Subjects Enrolled to Date:

Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To investigate a cost saving method to screen clinically suspected sleep apnea patients with a non-invasive recording pulse oximeter measuring oxyhemoglobin desaturation. No medications will be used. Patients will be seen and evaluated for SAS by the Pulmonary Disease Service.

Technical Approach: Patients are selected on the basis of clinically suspected sleep apnea. Patients are then screened with overnight recording pulse oximetry and studied with holter monitoring simultaneously. Within 24 hours the patients are then studied with a formal sleep study to validate the findings in a positive predictive manner.

Progress: The screening study has been ongoing and is current with respect to data collection and assessment. An abstract was accepted by AM Thoracic Society for publication Apr 88 with the patient number as above, we cannot show a spearman rank differential correlation between screening and formal SAS studies. In the study design, the best evaluation of patients occurs without esophageal balloons in the formal overnight studies.


Title: The Effect of Theophylline on Calcium and Vitamin D Metabolism in Male Sprague-Dawley Rats

Study Objective: The objectives of the study are to determine the effect of chronic theophylline administration on calcium and Vitamin D metabolism and bone mineral content in rats.

Technical Approach: Theophylline (n=25) or saline (n=24) are administered by continuous infusion with an Alzet osmotic pump for a period of 4 weeks. After 2 1/2 weeks, measurements are made of 24 hour calcium intake, urine calcium, and fecal calcium excretion and overall calcium balance is calculated. After 4 weeks, the rats are sacrificed and serum calcium PTH, 25 (OH) Vitamin D and 1,25 (OH)\textsubscript{2} vitamin D are measured. The rats are ashed for determination of total body calcium.

Progress: Theophylline treated rats (n=25) had significantly greater urinary calcium excretion and significantly lower 25(OH) Vitamin D levels than did control rats (n=24). They also had slightly lower 1,25 (OH)\textsubscript{2} vitamin D levels and total body calcium per gram of body weight. PTH levels are pending.
Presentations:


Publications:

(1) McDermott MT, Fortenbery EJ, Duncan WE: Theophylline alters vitamin D and calcium metabolism in rats. J Bone Min Res 3(Suppl. 1): 5115 (188A)

(2) Fortenbery EJ, McDermott MT, Duncan WE: The effect of theophylline on calcium and vitaminD metabolism (Submitted).
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/102  (3) Status: Ongoing

(4) Title: Anti-Histone Antibody Production in Procainamide Associated Drug-Induced Lupus Erythematosus: Association of Serologic Patterns and Lymphocyte Subsets

(5) Start Date:  (6) Est Compl Date: 1989

(7) Principal Investigator: James D. Singleton, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Rheumatology  (10) Associate Investigators

Peter A. Andersen, LTC, MC
West, Sterling, LTC, MC

(11) Key Words: procainamide
drug-induced lupus
histones

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 14  d. Total Number of Subjects Enrolled to Date: 18  e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: There are two study objectives: a) to survey the population of patients receiving procainamide to determine baseline data and b) to evaluate a subgroup of patients chosen randomly from patient populations determined by amount of drug administered, serologic status, and the presence of symptomatology.

(16) Technical Approach: Autoantibodies are one of the hallmarks of SLE yet mechanisms of their production and their pathogenetic import remain unclear. Drug-induced lupus makes feasible the investigation of potential early immunologic abnormalities which would lead to autoantibody production. Demographic, clinical and serologic data will be obtained on patients taking procainamide. Selected patients will, additionally, have T-cell and B-cell lymphocyte studies and be followed serially to discover correlates, if any, in studied parameters.

(17) Progress: Although only 18 patients have been enrolled in the study and baseline data obtained, approximately 110 individuals receiving procainamide have been identified. Efforts to contact these, obtain informed consent and finally enroll them in the study are ongoing.

Publications and Presentations: None

100
Date: 30 Sep 88  Protocol WU#: 87/103  Status: Ongoing

Title: Identification of Those at Risk for Osteoporotic Hip Fractures, by a Noninvasive Measurement

Start Date: Jan 87  Est Compl Date: 1989

Principal Investigator: Jan J. Perloff, CPT, MC
Michael McDermott, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Rheumatology

Associate Investigators

Key Words:
osteoporosis
hip fractures

Gerald S. Kidd, COL, MC

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  Review Results: 
Number of Subjects Enrolled During Reporting Period: 25
Total Number of Subjects Enrolled to Date: 70
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

Study Objective: To evaluate possible risk factors for osteoporosis by comparing hip fracture patients and matched controls for bone density, calcium intake, smoking, medications, mental status, visual acuity, vitamin D levels and exercise history.

Technical Approach: Hip fracture patients, within 5 days of fracture, and normal matched controls will have measurement of bone density at 3 sites in the unaffected hip and in the spine by dual photon absorptiometry and in the non-dominant midradius by single photon absorptiometry. All subjects will have a history and physical examination to include dietary and exercise history. Twenty subjects from each group will have visual acuity and 25-hydroxy vitamin D levels evaluated.

Progress: 20 hip fracture patients and 50 controls have been studied. Hip fracture patients had significantly lower bone density in the hips, marginally lower bone density in the spine, lower calcium intake, more smoking, less exercise, lower vit D levels, worse visual acuity and significantly more organic brain disorders.
Presentations:


Publications:


FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/104  (3) Status: Ongoing

(4) Title: A Randomized Investigation of High-Dose Versus Standard Dose Cytosine Arabinoside with Daunorubicin in Patients with Acute Non-Lymphocytic Leukemia, Phase III SWOG 8600

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: Daniel Tell, MAJ, MC  (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Continuing to accrue.

Publications and Presentations: None

103
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HS-R 40-23 as amended)**

<table>
<thead>
<tr>
<th>(1) Date:</th>
<th>30 Sep 88</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2) Protocol WU#:</td>
<td>87/105</td>
</tr>
<tr>
<td>(3) Status:</td>
<td>Ongoing</td>
</tr>
</tbody>
</table>

| (4) Title: | Pre-operative Cimetidine Therapy in Patients Undergoing Parathyroid Exploration: Efficacy and Mechanisms of Action |

<table>
<thead>
<tr>
<th>(5) Start Date:</th>
<th>(6) Est Compl Date:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(7) Principal Investigator:</th>
<th>(8) Facility:</th>
</tr>
</thead>
<tbody>
<tr>
<td>John A. Merenich CPT, MC</td>
<td>FAMC</td>
</tr>
<tr>
<td>Jeffrey R. Clark, COL, MC</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(9) Dept/Svc:</th>
<th>(10) Associate Investigators</th>
</tr>
</thead>
<tbody>
<tr>
<td>MED/Endocrine Svc</td>
<td>Michael T. McDermott, MC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(11) Key Words:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>hyperparathyroidism</td>
<td></td>
</tr>
<tr>
<td>postoperative hypocalcemia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(12) Accumulative MEDCASE:*</th>
<th>(13) Est Accum OMA Cost:*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refer to Unit Summary Sheet of this Report.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(14) a. Date, Latest IRC Review:</th>
<th>b. Review Results:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(15) Study Objective:</td>
<td>To determine whether or not pre-operative cimetidine therapy can reduce the incidence of post-operative hypocalcemia in patients undergoing parathyroid explorative surgery.</td>
</tr>
</tbody>
</table>

| (16) Technical Approach: | Patients are given placebo or cimetidine for 10 days prior to their surgery in a double-blind fashion. Calcium and its regulatory hormones are monitored before and after surgery to see if cimetidine favorably alters calcium homeostasis. |

| (17) Progress: | Since the study's implementation, informed consent has been obtained from all but one patient undergoing parathyroid exploration at FAMC. Because the study is double-blinded, no comments concerning the efficacy of cimetidine can be made. |

Publications and Presentations: None
Date: 30 Sep 88  
Protocol WU#: 87/106  
Status: Ongoing

Title: Effect of Concomitant Alcohol and Exercise on High Density Lipoprotein Subfractions and Lipolytic Enzymes in Sedentary, Healthy Men

Start Date: 1987  
Est Compl Date: 1988

Principal Investigator:  
Kerry C. Prewitt, CPT, MC  
John A. Merenich, CPT, MC

Facility: FAMC

Dept/Svc: MED/Endocrine

Key Words:  
alcohol  
lipoproteins  
apolipoproteins  
lipase

Associate Investigators:  
William Georgitis, MAJ, MC  
Robert Eckel, MD  
Gerald S. Kidd, COL, MC

Accumulative MEDCASE:*  
Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

Study Objective: To determine the effects of alcohol alone and in conjunction with exercise on lipid status (and the enzymes that control lipids) in healthy men.

Technical Approach: Participants asked to completely abstain from alcohol or to drink alcohol at social levels while activity levels are manipulated. Lipids and lipoprotein activities are determined before and after these manipulations to assess their effect.

Progress: One of the co-investigators (Dr. Prewitt) has departed Fitzsimons compounding the already difficult recruitment problem. Several participants withdrew from the study citing their unwillingness to abstain from alcohol for 4-8 weeks and/or their inability to maintain the required exercise routine. Fourteen individuals have completed the protocol. We plan on analyzing their specimens and reviewing the data prior to further recruitment attempts.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/107  (3) Status: Completed

(4) Title: Weekly Low Dose CCNU for Extensive Adenocarcinoma of the Colon and Rectum

(5) Start Date: 1987  (6) Est Compl Date: 1989

(7) Principal Investigator: Michael Stone, MAJ, MC  (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 2 d. Total Number of Subjects Enrolled to Date: 16 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14) e".

(15) Study Objective: To determine the efficacy and toxicity of low dose oral CCNU in colon cancer.

(16) Technical Approach: CCNU 60mg/wk p.o. x 6 wks. If no toxicity increase to 70mg p.o Q wk x 6wks, then 80mg p.o Q wk. Continue therapy as long as disease is stable and responsive.

(17) Progress: Sufficient patients accrued to complete study.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 87/108  Status: Terminated

Title: Prostaglandin Synthesis Inhibition and Glucose Counter-Regulatory Hormone Secretion in Diabetes Mellitus

Start Date: 1989

Principal Investigator: Robert J. Sjoberg, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Endocrine Svc

Associate Investigators
John Merenich, CPT, MC
Gerald S. Kidd, COL, MC
T.P. O'Barr, DAC

Key Words:
prostaglandin synthesis
glucose counter regulation
diabetes mellitus
hypoglycemia

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To determine if and how well choline magnesium trisalicylate reverses the glucose counter-regulatory hormone defect and delayed hypoglycemia recovery associated with Type I diabetes mellitus.

Technical Approach: To study 25 patients with Type I diabetes mellitus who are not excluded from the study (see exclusion criteria in protocol). The patients will be given an insulin infusion to cause slow onset hypoglycemia. Glucagon, epinephrine, glucose nadir, and the rate of glucose recovery will be determined with and without prior treatment with choline magnesium trisalicylate.

Progress: Because of the complexity of this protocol (especially the time commitment) from the subject participation point of view, it has been impossible to recruit participants. We see no other logistically easier way to answer the scientific question posed by this protocol and therefore wish to terminate this study.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/109  (3) Status: Completed

(4) Title: The Efficacy of Conjugated Estrogens in Reducing Blood Loss During and After Cardiac Surgery; Decreased Endothelial Prostacyclin Production as a Possible Mechanism

(5) Start Date: June 1987  (6) Est Compl Date: June 1988

(7) Principal Investigator: James A. Hasbargen, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Internal Med.  (10) Associate Investigators

R. Hull, MD
S. Fall, MD
T.P. O'Barr, Ph.D.

(11) Key Words:
estrogen
bypass loagulopathy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 7
d. Total Number of Subjects Enrolled to Date: 16
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: a. Efficacy of conjugated estrogens in reducing blood loss of bypass surgery and, b. Explore effects on prostacyclin production as a possible mechanism.

(16) Technical Approach: Patient receives I.V. conjugated estrogens 3 days prior to surgery. Venous PGF1 levels before and after infusion period. Vein sample also assayed for prostacyclin production. Blood loss of surgery and post-op period recorded for analyses between placebo and experimental groups.

(17) Progress: Enrolled proposed patients. No adverse effects.

Publications and Presentations: None

108
Date: 30 Sep 88  Protocol WU#: 87/110  Status: Ongoing

Title: The Role of Excess Prostaglandin Production in Causing The Abnormal Hemodynamic Status of Adrenalectomized Rats

Start Date: 1987  Est Compl Date: 1989

Principal Investigator: Robert J. Sjoberg, MAJ, MC

Dept/Svc: MED/Endocrine Svc  Associate Investigators
John Merenich CPT, MC  Gerald S. Kidd, COL, MC  T.P. O'Barr, DAC

Key Words: prostaglandins  adrenal insufficiency

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Study Objective: To clarify the role of altered renal and arterial prostaglandin production in mediating the hemodynamic alterations associated with adrenal insufficiency.

Technical Approach: The approach used involved investigations of a) comparison of the physiologic response of adrenalectomized rats to prostaglandin synthesis inhibitors and to glucocorticoid replacement and b) the ex vivo elaboration of prostaglandins by renal and arterial tissue taken from adrenalectomized rats.

Progress: This study as outlined in the original protocol has been completed. An addendum to this protocol was presented to the Laboratory Animal Care & Use Committee on 24 Feb 1988. Data from the original protocol suggests that renal prostaglandins are increased post-adrenalectomy, that this is due to intravascular volume depletion, and that this does not contribute to natriuresis and hyperreninemia. A known physiologic dose of a glucocorticoid did not, however, correct these abnormalities, giving into question the animal model used. The addendum presented addresses this issue further. It is anticipated that these further studies will be completed within the next year.


Publications: None
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(1)</strong> Date:</td>
<td>30 Sep 88</td>
</tr>
<tr>
<td><strong>(2)</strong> Protocol WU#:</td>
<td>87/111</td>
</tr>
<tr>
<td><strong>(3)</strong> Status:</td>
<td>Ongoing</td>
</tr>
<tr>
<td><strong>(4)</strong> Title:</td>
<td>A Prospective Double Blind Study of Retrovir in Early HIV Infection</td>
</tr>
<tr>
<td><strong>(5)</strong> Start Date:</td>
<td></td>
</tr>
<tr>
<td><strong>(6)</strong> Est Compl Date:</td>
<td>1991</td>
</tr>
<tr>
<td><strong>(7)</strong> Principal Investigator:</td>
<td>Shannon Harrison, LTC, MC</td>
</tr>
<tr>
<td><strong>(8)</strong> Facility:</td>
<td>FAMC Denver Health &amp; Hospitals</td>
</tr>
<tr>
<td><strong>(10)</strong> Associate Investigators:</td>
<td>R.N. Hannon, PA-C Leo Andron, LTC, MS Robert H. Gates, MAJ, MC</td>
</tr>
<tr>
<td><strong>(11)</strong> Key Words:</td>
<td></td>
</tr>
<tr>
<td><strong>(12)</strong> Accumulative MEDCASE:*</td>
<td></td>
</tr>
<tr>
<td><strong>(13)</strong> Est Accum OMA Cost:*</td>
<td>Refer to Unit Summary Sheet of this Report. (Feced HSC/HIV monies &amp; P6 MED R&amp;D Grant</td>
</tr>
<tr>
<td><strong>(14)</strong> a. Date, Latest IRC Review:</td>
<td></td>
</tr>
<tr>
<td>b. Review Results:</td>
<td></td>
</tr>
<tr>
<td>c. Number of Subjects Enrolled During Reporting Period:</td>
<td>59FAMC/100DH&amp;H</td>
</tr>
<tr>
<td>d. Total Number of Subjects Enrolled to Date:</td>
<td>59 &amp; 100</td>
</tr>
<tr>
<td>e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as &quot;(14)e&quot;.</td>
<td>None</td>
</tr>
<tr>
<td><strong>(15)</strong> Study Objective:</td>
<td>To look for efficacy and toxicity in terms of difference in natural history of Walter Reed Stage II through early V, HIV infected individuals given zidovudine at 200mg every 6 hours vs placebo.</td>
</tr>
<tr>
<td><strong>(16)</strong> Technical Approach:</td>
<td>See protocol.</td>
</tr>
<tr>
<td><strong>(17)</strong> Progress:</td>
<td>Protocol is actively inputing patients and enrollment is expected to close 1 January 1989.</td>
</tr>
<tr>
<td>Publications and Presentations:</td>
<td>None</td>
</tr>
</tbody>
</table>
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/112  (3) Status: Ongoing

(4) Title: (RTOG-85-01) Prospective Trial for Localized Cancer of The Esophagus: Comparing Radiation as a Single Modality to the Combination of Radiation Therapy and Chemotherapy, Phase III Intergroup SWOG-8598

(5) Start Date:  (6) Est Compl Date: Indefinite

(7) Principal Investigator: Daniel Tell, MAJ, MC  (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators

11) Key Words:

12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as ",(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol
(17) Progress: In progress.

Publications and Presentations: None

111
FAMC A.P.R. (MED 2aa) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/113  (3) Status: Ongoing

(4) Title: A Phase II Randomized Trial of Combination Therapy for Multiple Myeloma: Comparison of (1) VMCP/VBAP to VAD or VMCPP/VBAPP for Induction, (2) Alpha-2b Interferon or No Therapy for Maintenance; and (3) Alpha-2b Interferon + Dexamethasone for Incomplete or Nonresponders

SWOG 8624

(5) Start Date:  (6) Est Compl Date: Indefinite

(7) Principal Investigator: Daniel Tell, MAJ, MC  (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators

(11) Key Words:

drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol
(17) Progress: Protocol ongoing.
Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 87/114  (3) Status: Ongoing

(4) Title: Patient Evaluation of Physicians' Humanistic Qualities

(5) Start Date:          (6) Est. Compl Date: 

(7) Principal Investigator:  (8) Facility: FAMC
Michael J. Weaver, COL, MC

Cathy L. Ow, CPT, MC

(11) Key Words:
humanistic qualities
medical residents

(12) Accumulative MEDCASE:*  (13) Est. Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 
d. Total Number of Subjects Enrolled to Date: 
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: a) to determine what behaviors are considered by patients to be important markers of humanistic qualities in their physicians; b) to develop and test a questionnaire for a patient to rate the humanistic qualities of their own physician, and (c) to determine whether feedback, based on their own patients' ratings, can result in a change in physicians' humanistic behaviors.

(16) Technical Approach: The study consists of three phases: (a) open-ended interviews with patients to elicit important physicians' humanistic behaviors; (b) development and testing of a questionnaire from the responses generated in Phase a, and (c) we will give back feedback to physicians, based on their own patients' evaluation of their humanistic behaviors, using the questionnaire developed, and measure whether there is any change on a repeat questionnaire, post-feedback.

(17) Progress: Protocol is ongoing. Data is being collected for phase (b).

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/113  (3) Status: Ongoing

(4) Title: A Phase II Randomized Trial of Combination Therapy for Multiple Myeloma: Comparison of (1) VMCP/VBAP to VAD or VMCPP/VBAPP for Induction, (2) Alpha-2b Interferon or No Therapy for Maintenance; and (3) Alpha-2b Interferon + Dexamethasone for Incomplete or Nonresponders

SWOG 8624

(5) Start Date:  (6) Est Compl Date: Indefinite

(7) Principal Investigator: Daniel Tell, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:________  b. Review Results:________  
c. Number of Subjects Enrolled During Reporting Period:________  
d. Total Number of Subjects Enrolled to Date:________  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.


(17) Progress: Protocol ongoing.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)


4. Title: Patient Evaluation of Physicians' Humanistic Qualities

5. Start Date:  

6. Est Compl Date:  

7. Principal Investigator: Michael J. Weaver, COL, MC

8. Facility: FAMC


10. Associate Investigators  
    Cathy L. Ow, CPT, MC

11. Key Words:  
    - humanistic qualities  
    - medical residents

12. Accumulative MEDCASE:*  
13. Est Accum OMA Cost:*  

   *Refer to Unit Summary Sheet of this Report.

14. a. Date, Latest IRC Review:  
    b. Review Results:  
    c. Number of Subjects Enrolled During Reporting Period:  
    d. Total Number of Subjects Enrolled to Date:  
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

15. Study Objective:  
   a) to determine what behaviors are considered by patients to be important markers of humanistic qualities in their physicians;  
   b) to develop and test a questionnaire for a patient to rate the humanistic qualities of their own physician, and  
   c) to determine whether feedback, based on their own patients' ratings, can result in a change in physicians' humanistic behaviors.

16. Technical Approach: The study consists of three phases:  
   a) open-ended interviews with patients to elicit important physicians' humanistic behaviors;  
   b) development and testing of a questionnaire from the responses generated in Phase a, and  
   c) we will give back feedback to physicians, based on their own patients' evaluation of their humanistic behaviors, using the questionnaire developed, and measure whether there is any change on a repeat questionnaire, post-feedback.

17. Progress: Protocol is ongoing. Data is being collected for phase (b).

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 87/115  (3) Status: Ongoing

(4) Title: Double Blind, Multicenter, Placebo Controlled Clinical
Trial to Evaluate the Efficacy and Safety of HA-1A Human
Monoclonal Antibody in Patients with Severe Gram-
Negative Sepsis/Gram-Negative Septic Shock

(5) Start Date:       (6) Est Compl Date: 1990

(7) Principal Investigator: (8) Facility: FAMC
James D. Bales, Jr., COL, MC

(9) Dept/Svc: MED/Inf Dis Svc. (10) Associate Investigators

(11) Key Words:
gram negative shock
gram negative sepsis
monoclonal antibody
HA-1A monoclonal antibody

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for
studies conducted under an FDA-awarded IND. May be continued on a
separate sheet, and designated as "(14)e".

(15) Objective: To determine the efficacy of HA-1A monoclonal antibody
in reducing the mortality and/or direct morbidity of gram-negative sepsis as compared to a placebo treated control group. To determine the
impact that HA-1A has on patient benefit. To determine the impact that
HA-1A has on laboratory parameters/clinical signs associated with sepsis. To determine the safety and potential for immunogenicity of HA-1A
monoclonal antibody administration in patients presenting with clinical
syndrome of gram-negative sepsis.

(16) Technical Approach: Patients with the clinical diagnosis of septic
shock or sepsis suspected of being secondary to gram-negative organisms
will be treated with one dose of either placebo or HA-1A monoclonal an-
tibody. A comparison of morbidity and mortality between the placebo and
HA-1A group will be made to determine efficacy and safety of the drug.

(17) Progress: None. The drug has been unavailable. The drug is due to
be available mid-September 1988. No progress this FY.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 49-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/116  (3) Status: Ongoing

(4) Title: Effect of Iodine Containing Water Purification Tablets on Thyroid Function in Man

(5) Start Date: Aug 87  (6) Est Compl Date:

(7) Principal Investigator:
   Michael T. McDermott, MAJ, MC
   Gerald S. Kidd, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrinology

(10) Associate Investigators
    John R. Barrett, LTC, MC
    William J. Georgitis, LTC, MC
    Robert J. Sjoberg, MAJ, MC
    John A. Merenich, CPT, MC
    Kenneth Simcic, CPT, MC

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:       b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date:
    e. Note any adverse drug reactions reported to the FDA or sponsor for
       studies conducted under an FDA-awarded IND. May be continued on a
       separate sheet, and designated as "(14)e".

(15) Study Objective: The objectives of this study are to investigate
    the effects of iodine containing water purification tablets on thyroid
    function and job performance in soldiers in a field environment.

(16) Technical Approach: See Protocol

(17) Progress: This is a new study just approved in August, 1987.
    No one volunteered for the study during the Spring 1988. Field training
    exercises and volunteers are now being sought for the Fall 1988 and/or
    Spring 1989 FTX's.

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 87/117  (3) Status: Ongoing

(4) Title: Analysis of von Willebrand Factor Multimers Before and After Cardiopulmonary Bypass

(5) Start Date: 1987  (6) Est Compl Date:  

(7) Principal Investigator: Scott Brantley, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hem/Oncol  (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 25  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine the effect of the cardiopulmonary bypass machine on the multimeric structure of von Willebrand's factor and to provide clinical research experience for FAMC residents and staff.

(16) Technical Approach: See Protocol

(17) Progress: No results are currently available. No risks have been identified. Benefit lies in revealing the etiology of hemostatic abnormalities associated with bypass surgery. There has been no new published data of the kind proposed. Problems encountered: successful performance of the von Willebrand multimer electrophoresis procedures and this problem is slowly being rectified. Enrollment of adequate control patients due to decreased surgical load.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 88/100  Status: Completed

Title: LCSG 861 Pilot Study to Evaluate the Efficacy of Intrapleural Chemotherapy in the Management of Malignant Pleural Effusions

Start Date:  
Est Compl Date:  

Principal Investigator: Daniel T. Tell, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Hemo/Oncol  Associate Investigators

Key Words:

Accumulative MEDCASE:*  Est Accum ORA Cost:*
*Refert to Unit Summary Sheet of this Report.

Study Objective: See Protocol

Technical Approach: See Protocol

Progress: Completed

Publications and Presentations: None
Date: 30 Sep 88  (2) Protocol WU#: 88/101  (3) Status: Ongoing

(4) Title: LCSG 871 Centralized Non-Small Cell Lung Cancer Specimen Repository and DNA/RNA Bank

(5) Start Date:  

(6) Est Compl Date:  

(7) Principal Investigator:  
Daniel T. Tell, MAJ, MC

(8) Facility:  
FAMC

(9) Dept/Svc: MFD/Hem/Oncol  

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:*  
(13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: See Protocol

(16) Technical Approach: See Protocol

(17) Progress: Protocol is ongoing.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 88/102  Status: Ongoing

Title: Effect of Chronic Coumadin Therapy on Cortical and Trabecular Bone Density in Man

Start Date:  Est Compl Date:

Principal Investigator:
Wheaton Williams, CPT, MC
Jan J. Perloff, CPT, MC
Michael McDermott, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Endocrine Svc.

Associate Investigators
Gerald S. Kidd, COL, MC
Peter Blue, LTC, MC

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*  Refer to Unit Summary Sheet of this Report.

Study Objective: The objective of this study is to investigate the bone density of cortical and trabecular bone in patients on chronic coumadin therapy and in age-matched controls.

Technical Approach:


Publications and Presentations:
Date: 30 Sep 88  
Protocol WU#: 88/103  
Status: Ongoing

Title: Clinical Efficacy of Phenindamine as Determined by Skin Test Suppression

Start Date:  
Est Compl Date:

Principal Investigator: Richard W. Weber, COL, MC

Facility: FAMC

Dept/Svc: MED/Allergy Svc  
Associate Investigators  
Grant C. Olson, CPT, MC

Key Words: antihistamine  
phenindamine

Accumulative MEDCASE:*  
Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  
Review Results:  
Number of Subjects Enrolled During Reporting Period:  
Total Number of Subjects Enrolled to Date:  
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To examine the null hypotheses that there is no difference in skin test suppression and side effects produced by phenindamine 25mg qid, chlorpheniramine 8mg tid, and placebo in 2 week trials in normal subjects.

Technical Approach: Twenty subjects will take part in a placebo controlled crossover study of the skin test suppression produced by phenindamine, chlorpheniramine, and placebo. Results will be used to evaluate the efficacy, as determined by skin test suppression, of phenindamine compared to chlorpheniramine and placebo.

Progress: Assigned to fellow for initiation. Consent form updated.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88   (2) Protocol WU#: 88/104   (3) Status: Ongoing

(4) Title: A Descriptive Study of Pastoral Care Interventions Designed to Assist HIV+/AIDS Patients in Achieving Their Maximum Quality of Life

(5) Start Date:   (6) Est Compl Date: 1990

(7) Principal Investigator:   (8) Facility: FAMC
F. William Miles, LTC, USAR (Chaplain)

(9) Dept/Svc: Minis. & Past. Care   (10) Associate Investigators
(11) Key Words: Shannon M. Harrison, LTC, MC
psycho-social-spiritual
Robert L. Campbell (CH), COL
cognitive, moral & faith development

(12) Accumulative MEDCASE:*   (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: Tst/178/Intr/76
d. Total Number of Subjects Enrolled to Date: Tst/178/Intr76
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". NA

(15) Study Objective: (a) To observe and document the continuity of pastoral care with a traumatically stressed patient population (FAMC and beyond). (b) To conduct a longitudinal descriptive study that shows process from the point of view of patient, family member, supervisor and pastoral care giver. (c) To encourage personal processing of issues that impact on a sense of well being, decision making, psycho-social-spiritual growth through the use of an intentional and prescribed series of pastoral interventions. To provide the patient personal gain from telling his/her own "story." (d) To look at life histories, values, moral/faith development, personality types as they inform the pastoral care giver for ministry.

(16) Technical Approach: We are developing a pastoral data base of information relative to providing pastoral care to HIV+/AIDS patients. This is accomplished through regular personality inventories and interviews every six months during the HIV staging process, as well as follow-up questionnaires and support visits/calls to determine continuity of pastoral care and individuals functioning at unit/home.

121
(17) Progress: The protocol is still in the data gathering phase. During the past year, the following testing was completed in the HIV Pastoral Research Project (began testing o/a 1 Oct 87):

a. Patients tested - 178 [(B=81,W=81,H=18) (WOMEN=27,P=15) (HIV-=31)]
b. Second testings - 44
c. Third testings - 3
d. Values inven. - 156 (+17 HIV-)
e. D.I.T. - 141 (+14 HIV-)
f. MBTI - 175
g. TJTA - 220 (150+, 23-)
h. Fowler Interviews 76
i. 2nd Interviews 6

There is an observation that the Taylor Johnson Temperament Analysis seems to indicate in the upper/lower 20 percentiles that an individual is showing signs of stress, which are confirmed by other psychological testing and psychiatric interviews. None of the prisoners tested prefer "Intuitive" on the Myers-Briggs Type Indictaor.

Publications:

(1) For the General Convention of the Episcopal Church, Detroit, Michigan, July 1988, Short article describing the research projects being conducted in Infectious Disease Service/DMPC at FAMC.

Presentations:


**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Date:</td>
<td>30 Sep 88</td>
</tr>
<tr>
<td>(2) Protocol WU#:</td>
<td>88/105</td>
</tr>
<tr>
<td>(3) Status:</td>
<td>Ongoing</td>
</tr>
<tr>
<td>(4) Title:</td>
<td>Detection of Unsuspected Disease by the Complete Physical Exam</td>
</tr>
<tr>
<td>(5) Start Date:</td>
<td></td>
</tr>
<tr>
<td>(6) Est Compl Date:</td>
<td>1989</td>
</tr>
<tr>
<td>(7) Principal Investigator:</td>
<td>Homer J. LeMar, Jr., MAJ, MC</td>
</tr>
<tr>
<td>(8) Facility:</td>
<td>FAMC</td>
</tr>
<tr>
<td>(10) Associate Investigators</td>
<td>Michael J. Weaver, COL, MC</td>
</tr>
<tr>
<td>(11) Key Words:</td>
<td>physical exam screening</td>
</tr>
<tr>
<td>(12) Accumulative MEDCASE:*</td>
<td></td>
</tr>
<tr>
<td>(13) Est Accum OMA Cost:*</td>
<td>Refer to Unit Summary Sheet of this Report.</td>
</tr>
</tbody>
</table>

(14) a. Date, Latest IRC Review:     
b. Review Results:     
c. Number of Subjects Enrolled During Reporting Period:     
d. Total Number of Subjects Enrolled to Date:     
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine which specific areas of routine screening physical examination of patients at the time of hospital admission detects unsuspected disease, and leads to significant changes in medical management.

(16) Technical Approach: The study will consist of a chart review of inpatient records of patients who were admitted to, and discharged alive from the general medicine wards, after a hospital stay of more than three days. Only charts with a complete admission history and physical examination on the chart will be reviewed. We will begin with 100 charts, and will review more if needed to find sufficient "unexpected" findings. One investigator will review the admission history, including the presenting or chief complaint, the history of the present illness, the past medical history, and the review of systems, without knowledge of the physical examination. All positive findings in the history will be listed, and for each historical finding, we will determine what areas of the physical examination would be pertinent, or in which abnormal findings should be sought and might be expected. These areas of the physical examination will be considered "diagnostic" rather than "screening." The other investigator will review the physical examination, without knowledge of the history, listing all abnormal physical findings, by area. We will then compare the results of the review of
the history with the review of the physical examination to determine the yield of the "screening" examination, that is, which physical findings, if any, would not have been expected from the history, or would not have been discovered on examination of only historically relevant or indicated areas. We will then review each chart in detail to determine what tests were done to evaluate the unexpected physical findings, and what changes in management or therapy occurred as a result of these unexpected findings. Based on this, we will determine the utility, or contribution to patient care, of the "screening" physical examination.

(17) Progress: To date we have reviewed over 60 charts. Our goal is to review 100 charts.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/106  (3) Status: Ongoing

(4) Title: Use of Nifedipine Gastrointestinal Therapeutic System in the Treatment of Hypertension

(5) Start Date:  (6) Est Compl Date: 1989

(7) Principal Investigator:
J. Hasbargen, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Nephrology Svc.

(10) Associate Investigators
V. Bray
J. Lockard

(11) Key Words:
nifedipine
hypertension

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 3  
d. Total Number of Subjects Enrolled to Date: 3  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To assess the efficacy of the gastrointestinal therapeutic system utilizing nifedipine in the control of hypertension.

(16) Technical Approach: Study with baseline, titration, and efficacy phases study. Blood studies and baseline and after 12 week efficacy period.

(17) Progress: Three patients enrolled in week 2-3 of study.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88   (2) Protocol WU#: 88/108   (3) Status: Ongoing

(4) Title: The Effect of Thyroid Hormone Administration in Acute Renal Failure

(5) Start Date:        (6) Est Compl Date: 1991

(7) Principal Investigator: J. Lockard, MD

(8) Facility: FAMC

(9) Dept/Svc: MED/Nephrology Svc.  (10) Associate Investigators M. Porogy

(11) Key Words: acute renal failure thyroxine

(12) Accumulative MEDCASE:*        (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 1
d. Total Number of Subjects Enrolled to Date: 1
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Efficacy of thyroxine in amelioration of acute renal failure.

(16) Technical Approach: Thyroxine vs placebo to patients with ARF. Serum creatinine, urine output followed. T4, TSH will be assayed at WRAMC.

(17) Progress: This is a collaborative study. One patient enrolled and no adverse effects.

Publications and Presentations: None
(4) Title: Methotrexate in the Treatment of Steroid Dependent Asthmatics

(5) Start Date: 30 Sep 88 (6) Est Compl Date: 1989

(7) Principal Investigator: Richard W. Weber, COL, MC
(8) Facility: FAMC

(9) Dept/Svc: MED/Allergy Svc. (10) Associate Investigators
Thurman R. Vaughan, MAJ, MC
Philip D. Dyer, MAJ, MC

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate the effectiveness of weekly methotrexate in reducing the steroid requirements of steroid dependent asthmatics. The purpose is to demonstrate a statically significant reduction in the steroid dose over the placebo control, without involvement of the other parameters.

(16) Technical Approach: Double blind crossover design with methotrexate and placebo following pulmonary function tests, symptom scores with attempt to taper corticosteroids.

(17) Progress: 7 patients enrolled.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 88/110A  Status: Ongoing

Title: Biological Investigation of Cutaneous Lupus Employing Athymic Mice as Skin Heterotransplant Recipients

Principal Investigator: Ramsey Mellette, COL, MC  Lela Lee, M.D.

Associate Investigators
Larry Urry, MAJ, MC
Don Mercill, DAC
Silvija Coulter, UCHSC
James Fitzpatrick, LTC, MC
William Weston, MD, UCHSC
Charles F. Ferris, CPT, MS

Dept/Svc: MED/Dermatology Svc.

Key Words: Don Mercill, DAC
Silvija Coulter, UCHSC
James Fitzpatrick, LTC, MC
William Weston, MD, UCHSC
Charles F. Ferris, CPT, MS

Study Objective: To develop an in vivo model demonstrating cutaneous lupus as manifested in humans and to use such model to sequentially study the biological causes of the diseases.


Progress: Protocol does not come up for continuing review until 1989.

Publications and Presentations: None
Date: 30 Sep 88  
Protocol WU#: 88/111  
Status: Ongoing

Title: The Use of Fibrin Monomer and D-Dimer in the Evaluation of Patients with Chest Pain

Start Date: April 1988  
Est Compl Date: April 1989

Principal Investigator:  
Mark E. Dorosy, CPT, MC  
Robert W. Hull, CPT, MC

Facility: FAMC

Dept/Svc: MED/Internal Med Svc

Associate Investigators  
Leo W. Jordan, MAJ, MC  
Steven H. Atchley, MAJ, MCC

Key Words: fibrin monomer  
D-dimer  
unstable coronary artery disease

Accumulative MEDCASE:*  
Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

Study Objective: To determine the diagnostic usefulness of fibrin monomer and D-dimer in patients presenting with chest pain requiring evaluation for unstable coronary disease. To determine the prognostic value of these levels in patients with unstable angina and acute myocardial infarction.

Technical Approach: Patients admitted to the CCU for evaluation of chest pain are divided into two groups - those with unstable coronary disease (MI, unstable angina), and those determined to have noncardiac chest pain based on initial history and physical, EKG, serial CK determinations and additional workup (TMST, cardiac cath, etc.). Blood is drawn at the time of admission for determination of fibrin monomer and D-dimer levels.

Progress: To date, 21 patients have been enrolled. Further enrollment has been postponed pending review of results from the initial series. We are currently in the process of running the fibrin monomer and D-dimer assays.

Publications and Presentations: Information is to be presented in abstract form at the 1988 Army ACP meetings, Cardiology Section by Dr. Hull.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/112  (3) Status: Ongoing

(4) Title: Long Term 5-Fluorouracil Infusion for Recurrent Head and Neck Cancer

(5) Start Date: 1988  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
Patrick W. Cobb, CPT, MC
Daniel T. Tell, MAJ, MC

(9) Dept/Svc: MED/Hem/Oncol Svc  (10) Associate Investigators
(11) Key Words:
Frank Ward, MAJ, MC
Denis Lanier, LTC, MC

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The study is designed to assess the effectiveness of a continuous infusion of 5-FU on patients with recurrent head and neck cancer. Tumor response, toxicity and survival will be monitored.


Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 88/113  Status: Ongoing

Title: Methotrexate versus D-Penicillamine in Rheumatoid Arthritis: A Randomized Comparative Study

Start Date:  
Est Compl Date:  

Principal Investigator:  James D. Singleton, CPT, MC
Facility:  FAMC

Dept/Svc: MED/Rheumatology Svc  Associate Investigators  Sterling G. West, LTC, MC  David M. Nordstrom, MAJ, MC

Key Words:  methotrexate  D-penicillamine  rheumatoid arthritis

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 12 
d. Total Number of Subjects Enrolled to Date: 12 
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To compare clinical efficacy, toxicity and radiographic progression of joint disease in patients receiving methotrexate or D-penicillamine.

Technical Approach: Patients with rheumatoid arthritis will be randomly assigned to receive either methotrexate or D-penicillamine. Clinical assessment will be performed every 3 months and radiographic assessment every year.

Progress: A total of 12 pts have now been enrolled in the study and are undergoing serial assessments.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/114  (3) Status: Ongoing

(4) Title: Crossover Comparison of Maximum Dose Glyburide and Glipizide

(5) Start Date: 1988  (6) Est Compl Date: 1989

(7) Principal Investigator: Kenneth J. Simcic, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrinology

(10) Associate Investigators
    Michael T. McDermott, LTC, MC
    William J. Georgitis, LTC, MC
    Gerald Kidd, COL, MC
    Nancy Pfander, MAJ, MC

(11) Key Words:
    diabetes (type II)
    oral hypoglycemic agents
    glyburide
    glipizide

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 28  
d. Total Number of Subjects Enrolled to Date: 28  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To examine whether or not significant improvements in fasting serum glucose, hemoglobin A1C1 and blood lipids occur when type II diabetic patients' failing therapy with either glyburide or glipizide are switched to the alternate second generation sulfonylurea agent.

(16) Technical Approach: This trial is a single-center prospective, open crossover study in which type II diabetic patients are switched from a maximum dose of one second-generation sulfonylurea agent (glyburide or glipizide) to the maximum dose of the other agent.

(17) Progress: Thus far, 28 patients have been enrolled and no further patient enrollment is planned. One patient has been withdrawn because of a recurrence of breast cancer. All but 3 patients are at or beyond phase II (crossover phase) of the study. It is expected that most patients will have completed the study by Dec. 88. A few will require continuation until approx. 1 March 88. No complications or adverse reactions have occurred.

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 88/115  (3) Status: Ongoing

(4) Title: The Impact of an Ambulatory Care Rotation on Interns Psychosocial Attitudes

(5) Start Date:  

(6) Est Compl Date:  

(7) Principal Investigator:  
  Michael J. Weaver, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Int. Med. Svc.  (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
  *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
    b. Review Results:  
    c. Number of Subjects Enrolled During Reporting Period: 
    d. Total Number of Subjects Enrolled to Date:  
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: We propose to test the hypotheses that this ambulatory care rotation will result in increased awareness of psychosocial problems and the increase in awareness will be correlate with an increase in knowledge of psychosocial content.

(16) Technical Approach:

(17) Progress: No progress as this is a new study.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 88/116A (3) Status: Ongoing

(4) Title: Mouse Anti-Chenopod/Amaranth Pollen Monoclonal Antibody Production

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Richard W. Weber, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Allergy Svc. (10) Associate Investigators

Thurman R. Vaughan, MAJ, MC
Lawrence V. Larsen, CPT, MC

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:________  b. Review Results:________

c. Number of Subjects Enrolled During Reporting Period:________

d. Total Number of Subjects Enrolled to Date:________

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14) e".

(15) Study Objective: To develop mouse monoclonal antibodies to chenopod-amaranth pollen antigens. The purpose is to use these antibodies to study the crossreactivity of chenopod-amaranth pollen antigens. The importance of the latter is the eventual improvement of allergen extracts for diagnostic and therapeutic utilizations.

(16) Technical Approach: Stage I: Characterization of allergen extracts by PAGE and Western Blot. Stage II: Monoclonal antibody production and characterization by injecting mice with allergen extract, screen for antibody with ELISA, and develop hybridomas.

(17) Progress: Stage I shows good characterization of extract by PAGE. Mice presently being injected and boosted.

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 88/117  (3) Status: Ongoing

(4) Title: A Comparison of Amitriptyline vs. Trazodone vs. Placebo as Adjuvants to Opiate Analgesics in the Management of Pain in Cancer Patients

(5) Start Date: 1988  (6) Est Compl Date:

(7) Principal Investigator: Daniel T. Tell, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hemo/Oncol Svc  (10) Associate Investigators Rose A. Gates, MAJ, ANC

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: ________ b. Review Results: ________
c. Number of Subjects Enrolled During Reporting Period: ________
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: a. To compare the relative effectiveness of amitriptyline and trazodone as adjuvants to opiate analgesics for the management of pain of malignant diseases; b. Quantify the "opiate sparing" effect of these two agents when used in conjunction with morphine sulfate; c. Evaluate the cost-efficiency/effectiveness of trazodone and amitriptyline, as adjuvants to opiate analgesics in the treatment of pain associated with malignant disease.

(16) Technical Approach:

(7) Progress: No progress as this is a newly approved study.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88
(2) Protocol WU#: 88/118
(3) Status: Ongoing

(4) Title: CAP Study 12-21-87 - Use of Nifedipine (Gastrointestinal Therapeutic System) in the Treatment of Angina Pectoris

(5) Start Date: 1988
(6) Est Compl Date: 1989

(7) Principal Investigator: Richard C. Davis, Jr., COL, MC
(8) Facility: FAMC

(9) Dept/Svc: MED/Cardiology Svc
(10) Associate Investigators
John M. VanDeren, III, CPT, MC

(11) Key Words:
nifedipine GITS
angina pectoris
silent ischemia

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: To establish the efficacy of Nifedipine GITS as monotherapy or combined therapy with beta blockers in angina pectoris. Secondly, to try to clarify some of the issues regarding mechanism of action of a new delivery system, Nifedipine GITS compared to other antianginal therapies.

(16) Technical Approach: Qualified patients will be placed on Nifedipine GITS placebo in a single blind fashion after all other antianginal therapy except beta blockers are discontinued. They will then undergo Holter monitoring. Those with objective evidence of ischemia will be placed on Nifedipine GITS and dose titrated over 7-12 weeks to maximum efficacy with Holter monitoring performed at the completion of the efficacy phase. A single blind placebo control period will then be repeated with Holter monitoring at the completion.

(7) Progress: To date, the ST segment Holter monitoring equipment has been installed and its proper function is being validated. The first study patients should be enrolled in the next 1-2 weeks.

Publications and Presentations: None
Clinical Study of Intraocular Lens

Dept/Svc: SUR/Ophthalmology

Key Words: intraocular lens
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 78/201  (3) Status: Ongoing

(4) Title: Clinical Study of Intraocular Lens

(5) Start Date: ________________________________  (6) Est Compl Date: ________________________________

(7) Principal Investigator: Luis Colon, MAJ, MC  (8) Facility: FAMC General Leonard Wood Army Community Hospital

(9) Dept/Svc: SUR/Ophthalmology  (10) Associate Investigators

(11) Key Words: intraocular lens

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: ____________ b. Review Results: ____________
    c. Number of Subjects Enrolled During Reporting Period: 42
    d. Total Number of Subjects Enrolled to Date: 62
    e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To establish the safety and effectiveness of intraocular lens implantation of the cataract patient. (See original protocol)

(16) Technical Approach: Extracapsular cataract extraction with posterior chamber IOL.

(17) Progress: No adverse effects noted to date.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 78/201  (3) Status: Ongoing

(4) Title: Clinical Study of Intraocular Lens

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:
Jeffrey L. Bezier, CPT, MC

(8) Facility: FAMC
Reynolds Army Hospital
Ophthalmology, Box 21
4700 Hartell Blvd.
Ft. Sill, OK 73503-6304

(9) Dept/Svc: SUR/Ophthalmology  (10) Associate Investigators

(11) Key Words:
intraocular lens

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:
 b. Review Results:
 c. Number of Subjects Enrolled During Reporting Period: 35
 d. Total Number of Subjects Enrolled to Date: 85
 e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine postoperative visual acuity of patients receiving intraocular lens, and to compare those results with those of a control group of patients who undergo cataract surgery but do not receive an intraocular lens.

(16) Technical Approach: Post-operative examinations include: visual acuity testing and keratometry. Contraindications to surgery include: Proliferative diabetic retinopathy, rubeosis irides.

Implanting CILCO lenses now, but also authorized to implant Precision Commet, 3M, Alcon, and IOLAB.

(17) Progress: Cataract surgery with the intraocular lens implantation has been satisfactory with no unusual post operative complications to date. There has been one retina detachment occurring 5 weeks post secondary intraocular lens implant. Approximately 75 posterior chamber and 10 anterior chamber lenses have been implanted by Dr. Bezier at RACH between August 86 and August 88.

Publications and Presentations: None
Date: 30 Sep 88 (2) Protocol WU#: 78/201 (3) Status: Ongoing

(4) Title: Clinical Study of Intraocular Lens

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Ricardo J. Ramirez, MC
(8) Facility: FAMC
Irwin Army Community Hospital
Ft. Riley, Kansas 66442

(9) Dept/Svc: SUR/Ophthalmology (10) Associate Investigators

(11) Key Words: intraocular lens

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date: 326
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine postoperative visual acuity of patients receiving intraocular lens, and compare those results with those who undergo cataract surgery without an implant. To determine the occurrence and time of postoperative ocular complications and adverse reactions for intraocular lens implant; to identify subgroups within the implant group that are risk of a particular complication.

(16) Technical Approach: After completing his residency, didactic courses, laboratory practice and assistance with an experienced surgeon, a surgeon who can perform a successful cataract surgery is then allowed to perform intraocular lens surgery. Postoperative examination includes: refraction, pachymetry, keratometry and a complete anterior and posterior segment examination. Contraindications to surgery with intraocular implants include: patients with good visual potential in only one eye, proliferative diabetic retinopathy, rubeosis irides, high axial myopia, any history of anterior or posterior uveitis. History of glaucoma would preclude the use of an anterior chamber implant.

(17) Progress: We have now implanted 326 intraocular implants. Our study includes tabulation of operative complications, visual acuities, endothelial cell loss, changes in corneal astigmatism and residual refractive error. As a result of similar studies many intraocular lens have been removed from the market because of particular complications or as a result of the development of better lens.

Publications and Presentations: None
Date: 30 Sep 88 (2) Protocol WU#: 78/201E (3) Status: Ongoing

Title: Clinical Study of Intraocular Lens

Start Date:

Principal Investigator: Charles E. Aronson, COL MC

Facility: FAMC

Evans Army Community Hospital

Ophthalmology,

Ft. Carson, CO

Dept/Svc: SUR/Ophthalmology

Associate Investigators

Key Words:

intraocular lens

Accumulative MEDCASE:*

Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:

b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 88

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: Participation in IOL implantation.

Technical Approach: See protocol.

Progress: In the last Fiscal Year the Ophthalmology Service has implanted exclusively either the Coburn #72 UV Posterior Chamber or the Coburn #121 UV lens. We have implanted 85 of the 72 UV lens and 3 of the 121 UV lens. The 72 UV lens is our primary lens of choice in patients undergoing extracapsular cataract extractions and we find it to be an excellent lens with good centering ability over a prolonged period. We have not had to reposition or remove any lens because of subluxation or dislocation. There is no evidence of chronic uveitis or late onset hyphema or glaucoma with these lenses. The 121 UV lens (Anterior Chamber) is used as the lens to be placed in patients undergoing secondary lens implantation following a previous cataract extraction or in those patients with vitreous loss due to posterior capsular rupture at the time of the initial extracapsular cataract extract. We have had two complications using this lens, both in the same patient. This is the onset of cystoid macular edema in both eyes of one patient following secondary anterior chamber IOL implants. This patient had had previous intracapsular cataract extractions and there was evidence of vitreous stands through the pupils of both eyes post-op suggesting that vitreous tractions is most likely the etiology of the C.M.E. and not the fault of the anterior chamber 121 UV IOL.

Publications and Presentations: None
(1) Date: 30 Sep 88 (2) Protocol WU#: 78/20X-001 (3) Status: Ongoing

(4) Title: Repair of Femoral Artery by Microvascular Technique in Rabbits and Rats

(5) Start Date: 

(6) Est Compl Date: Indefinite

(7) Principal Investigator: James C. Johns, Jr. MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: SUR/Orthopedic

(10) Associate Investigators

(11) Key Words: microvascular education and training

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 
   b. Review Results: 
   c. Number of Subjects Enrolled During Reporting Period: 
   d. Total Number of Subjects Enrolled to Date: 
   e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To increase microsurgical technique for orthopedic staff and residents.

(16) Technical Approach: Perform all microvascular studies/techniques prior to human surgery.

(17) Progress: Ongoing education in microvascular surgery continues.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 78/20X-002 (3) Status: Ongoing

(4) Title: Repair of Femoral Artery by Microvascular Technique in Rabbits and the Rat

(5) Start Date: (6) Est Compl Date: Indefinite

(7) Principal Investigator: Kenneth F. Casey, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: SUR/Neurosurgery (10) Associate Investigators

(11) Key Words:
    microvascular education
    and training

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date:
    e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To increase microsurgical technique for staff and residents.

(16) Technical Approach: Perform all microvascular studies/techniques prior to human surgery.

(17) Progress: This protocol is continuing with excellent results. Animal use over the last several months has been curtailed with deference to the current budgetary difficulties. We anticipate, with continued approval of the protocol, resumption of activities with new fiscal year. This will coincide with the arrival of the first University of Colorado Health Sciences Center resident, and will not hamper the ongoing training of FAMC residents.

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 78/20X-003  (3) Status: Ongoing

(4) Title: Microsurgical Training in Free Flap Transfer and Vessel and Nerve Repair Utilizing the Rabbit and Rat

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: John D. Rich, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: SUR/Plastic Surgery

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective:

(16) Technical Approach:

(17) Progress: Five plastic surgery fellows have been trained in microvascular surgery. This has resulted in several revascularizations of compromised extremities in human patients. We feel that the rat has proven to be a suitable animal model. It is less expensive to use rats than to use rabbits, therefore, we are modifying to protocol to include a rat model only. The only problem we note has been the inability to perform a second procedure on an animal in order to check a previous anastomosis.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 84/20X-001  Status: Ongoing

Title: Microvascular Arterial and Venous Anastomosis in Laboratory Rats

Principal Investigator: Michael J. Riafe  LTC, MC

Associate Investigators:
Daniel W. Horne, LTC, MC
Craig Donatucci, MAJ, MC
Clyde R. Roy, II, MAJ, MC
Deogracia Quinones, MAJ, MC

Key Words: Craig Donatucci, MAJ, MC  Clyde R. Roy, II, MAJ, MC  Deogracia Quinones, MAJ, MC

Accumulative MEDCASE:*  Refer to Unit Summary Sheet of this Report.

Study Objective: To develop and maintain microvascular skills.

Technical Approach: Microsurgical exercises of increasing complexity will be performed under anesthesia.

Progress: Due to resident personnel shortages in 1987, the protocol was generally inactive over the past year. We do plan to restart training in October, 1988. The protocol has been valuable in the past.

Publications and Presentations: None
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

1. **Date:** 30 Sep 88  
2. **Protocol WU#:** 85/200  
3. **Status:** Completed

4. **Title:** Differential Fixation of Centrifuged and Non-Centrifuged Acrylic Bone Cement Specimens

5. **Start Date:** 1985  
6. **Est Compl Date:** 1988

7. **Principal Investigator:** Joseph N. Wilson, MAJ, MC

8. **Facility:** FAMC

9. **Dept/Svc:** SUR/Orthopedics  
10. **Associate Investigators:** Joe K. Ozaki, COL, MC

11. **Key Words:**  
    - bone cements  
    - acrylic resins

12. **Accumulative MEDCASE:**  
13. **Est Accum OMA Cost:**  
   *Refer to Unit Summary Sheet of this Report.

14. **(a) Date, Latest IRC Review:**  
    **(b) Review Results:**  
    **(c) Number of Subjects Enrolled During Reporting Period:**  
    **(d) Total Number of Subjects Enrolled to Date:**  
    **(e) Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

15. **Study Objective:** We propose to study volumetric change in acrylic cement as it is used in surgery with and without centrifugation; strength of bonding of acrylic cement to bone and to the prosthesis by "pull out" strength testing comparing cements with and without centrifugation and the variability of the shrinkage in the different type of acrylic cement available for orthopedic surgical use.

16. **Technical Approach:** Acrylic bone cement will be mixed and changes recorded by direct and indirect (fluid displacement) methods. Model systems of initial/cement/bone will be tested to determine bonding strength of interface using a tensiometer.

17. **Progress:** First stage of experiments are complete and have been presented at national and international meetings, fixation experiments are ongoing at this time. Study is completed.

**Presentations:**


**Publications:** In preparation.
Title: NSABP Protocol C-02 - A Clinical Trial Evaluating the Postoperative Portal Vein Infusion of 5-Fluorouracil and Sodium Heparin in Patients with Resectable Adenocarcinoma of the Colon

Start Date: 1985

Principal Investigator: William H. Marx, MAJ, MC


Key Words: colonic neoplasms, heparin, fluorouracil

Accumulative MEDCASE: * Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: 
b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 4
d. Total Number of Subjects Enrolled to Date: 13
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To determine the efficacy of perioperative portal vein infusion as an adjuvant therapy in patients with Duke's A, B, and C adenocarcinoma of the colon as compared to standard therapy which is surgery alone. The study is designed to determine whether there will be prolongation of the disease-free interval and increasing survival in patients undergoing curative resection of colonic adenocarcinoma and treated in this manner.

Technical Approach: Patients will be assigned by random selection to one of the following groups: a) surgery alone; b) surgery plus additional continuous portal vein infusion with 5-FU 600 mg/M² and 5000 units sodium heparin per day, given for a total of 7 consecutive days. Portal vein catheters will be inserted intraoperatively after the colonic anastomosis has been completed. All portal vein infusions will be started within 6 hours of the operative procedure.


Publications and Presentations: None
Date: 30 Sep 88 Protocol WU#: 86/200 Status: Ongoing

Title: Treatment of Urinary Tract Trauma in the Porcine Animal Model

Start Date: 1986 Est Compl Date: Indefinite

Principal Investigator: Michael J. Raife, LTC, MC

Facility: FAMC

Dept/Svc: SUR/Urology Svc

Associate Investigators
James B. Thrasher, CPT, MC
Daniel W. Horne, LTC, MC
Clyde R. Roy, CPT, MC
Deogracia Quinones, MAJ, MC
Craig Donatucci, MAJ, MC

Key Words:
renal trauma
renovascular surgery
bladder augmentation and substitution

A. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To provide an opportunity for urologists in training to develop expertise in the surgical techniques which are useful in the management of urinary tract trauma, to include renovascular surgery, renal autotransplantation, and use of various types of bowel segments for augmentation or substitution.

Technical Approach: Animals are subjected, under anesthesia, to simulated urinary tract trauma. Various surgical procedures are performed to allow resident training in management of these situations.

Progress: Due to resident personnel problems, the protocol was underutilized in the past year. However, we did perform the first continent diversion of urine in a patient ever done at FAMC, using the techniques of this protocol. We will resume in October, 1988. This is an important teaching protocol for urology.

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 86/201  (3) Status: Ongoing

(4) Title: Vasovasostomy in the Porcine Animal Model

(5) Start Date: 1986  (6) Est Compl Date: Indefinite

(7) Principal Investigator: Michael J. Raife, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: SUR/Urology Svc

(10) Associate Investigators
    Craig Donatucci, MAJ, MC
    Daniel W. Horne, LTC, MC
    Clyde R. Roy II, CPT, MC
    James B. Thrasher, CPT, MC
    Deogracia Quinones, CPT, MC

(11) Key Words:
    vasectomy
    vasovasostomy
    microsurgery

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:
    b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date:
    e. Note any adverse drug reactions reported to the FDA or sponsor for
       studying under an FDA-awarded IND. May be continued on a separate sheet,
       and designated as "(14)e".

(15) Study Objective: To develop and maintain microvascular surgical skills
    for vasovasostomy.

(16) Technical Approach: The vasa are isolated, severed, and reanastomosed
    using the operating microscope.

(17) Progress: Due to shortages in resident personnel, the protocol was
    under-utilized in 1987. We are scheduled to resume in October, 1988. This
    has been a very helpful teaching protocol in the past.

Publications and Presentations: None
Date: 30 Sep 88

Protocol WU#: 86/208A

Status: Terminated

Title: Medical Readiness Support Program

Start Date:

Est Compl Date:

Principal Investigator:
Stephen M. Fall, LTC, MC

Facility: FAMC

Dept/Svc: MED/Card Surg

Associate Investigators:

Key Words:

Accumulative MEDCASE:

Est Accum OMA Cost:

Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:

b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The United States Air Force Medical Readiness Program requires that all dental officers be trained to participate as first or second assistants in the operating room during a general mobilization. The dental activity at Lowry Air Force Base is not associated with the USAF Hospital through which this requirement can be met. The Department of Surgery, Fitzsimons Army Medical Center, has been requested to provide an annual exercise to familiarize the dental officers with the skills necessary to assist in the operating room.

Technical Approach: Training protocol.

Progress: The protocol was rewritten and given a new work unit number so this work unit number is terminated.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 86/209A  (3) Status: Ongoing

(4) Title: Effects of Nonsteroidal Anti-Inflammatory Agents on Tendon Healing

(5) Start Date:  

(6) Est Compl Date:  

(7) Principal Investigator:  
Michael D. Getter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: SUR/Orthopedics  
(10) Associate Investigators

(11) Key Words:  
tendon healing  
non-steroidal anti-inflammatory agent

(12) Accumulative MEDCASE:*  
(13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine if NSAID's effect heal rate of strength in rat tendon model.

(16) Technical Approach: Suture tendon laceration followed by healing with and without NSAID's.

(17) Progress: No progress on this protocol due to changes in principal investigator.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/200  (3) Status: Ongoing

(4) Title: Military Boxing Related Injuries, Amended Protocol

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
Robert W. Enzenauer, MAJ, MC

(9) Dept/Svc: SUR. Ophthalmology  (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objectives of this investigation are the following: (a) to retrospectively determine the impact of significant boxing-related injuries on the US Army, (b) to determine the specific risk of ocular injuries sustained during an instructional boxing program, and (c) to evaluate the advisability of continued promotion of boxing in the military community.

(16) Technical Approach:

(17) Progress: Protocol will come up for continuing review April 1989.


Publications: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 87/201 (3) Status: Terminated

(4) Title: Lipid Composition of Normal and Abnormal Foot Pads

(5) Start Date: (6) Est Compl Date: 1990

(7) Principal Investigator:
William G. Winter, MD
David B. Hahn LTC, MC
Oscar K. Reiss, Ph.D.

(8) Facility: FAMC
VAMC, Denver, CO
FAMC
UCHSC

(9) Dept/Svc: SUR/Orthopedics (10) Associate Investigators

(11) Key Words:
foot pads
lipid analysis

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 
d. Total Number of Subjects Enrolled to Date: 
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: We propose a) to establish the biochemical composition of the human plantar foot pads, b) to investigate their metabolic activities compared to similar (adipose) tissues at other anatomical sites and c) to attempt to correlate the chemical composition and metabolic activities with their functional performance.


(17) Progress: VA funding was not approved. Funds not available through FAMC.

Publications and Presentations: None

154
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/202  (3) Status: Ongoing

(4) Title: Improving Cancer Management Through the Tumor Conference

(5) Start Date:  (6) Est Compl Date: 1989-1990

(7) Principal Investigator: Jeffrey R. Clark, COL, MC

(8) Facility: FAMC

   Daniel T. Tell, MAJ, MC  Harris W. Hollis, Jr., LTC, MC

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
   *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:
   c. Number of Subjects Enrolled During Reporting Period:
   d. Total Number of Subjects Enrolled to Date:
   e. Note any adverse drug reactions reported to the FDA or sponsor for
      studies conducted under an FDA-awarded IND. May be continued on a
      separate sheet, and designated as "(14)e".

(15) Study Objective: FAMC Tumor Board will be one of 22 in the state
    where in a randomized controlled fashion, multifaceted educational in-
    tervention (maintaining a randomly selected control group) will be in-
    troduced. The hypothesis is: Given emphasis on stimulating case
    presentations in a concert of patient management decision making, tumor
    boards can function as key elements in patient care and medical educa-
    tion.

(16) Technical Approach: The first 6 months will be baseline evalua-
    tion of tumor boards as they now exist. Then an interventional education
    package is randomly introduced to half the boards over one year and im-
    pact is seen. the other half receive no intervention. A crossover of
    intervention will occur after one year for one year's time. Then, six
    months of final analysis and recommendation made to NCI.

(17) Progress: Progress to date-FAMC is control and as such only atten-
    dance figures and case presentations are being forwarded to the project
    office to date. Protocol started one month ago.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/203  (3) Status: Ongoing

(4) Title: Comparison of Thermography and Standard Techniques for Detection, Diagnosis and Tracing of Disorders Marked by Altered Patterns of Peripheral Blood Flow

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: Joe Ozaki, COL, MC
    Richard A. Sherman, MAJ, MS

(8) Facility: FAMC

(9) Dept/Svc: SUR/Orthopedics  (10) Associate Investigators

(11) Key Words:
    thermography
    pain
    orthopedic disorders

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:  c. Number of Subjects Enrolled During Reporting Period: 66  d. Total Number of Subjects Enrolled to Date: 66
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine the optimal utilization of thermography in clinical evaluation of the vascular status of the affected area for patients with orthopedic related pain disorders.

(16) Technical Approach: We will make thermographic recordings of groups of ten subjects having one of the following conditions each time they come to Orthopedic Clinic from the initial diagnostic appointment through post-resolution follow-up: Frostbite, Charcot Joints, Carpel Tunnel Syndrome, Fibrositis, Sympathetic Distrophy and Peripheral Neuropathy, Pre-amputation preparation, and Prediction of Bed Sore Formation. The clinical evaluations will not be related to the thermographic evaluations until the subject has completed participation in the study.

(17) Progress: Too few subjects have completed participation in each subgroup to permit definitive analysis of the data. However, it is clear that thermography is a powerful tool for tracking changes in knee pain and RSD.


Presentations: None

156
(1) Date: 30 Sep 88  (2) Protocol WU#: 88/200  (3) Status: Ongoing

(4) Title: ALCON Surgical Intraocular Lens Study

(5) Start Date:  

(6) Est Compl Date:  

(7) Principal Investigator:  
Floyd M. Cornell, LTC, MC

(8) Facility:  
FAMC

(9) Dept/Svc: SUR/Ophthalmology

(10) Associate Investigators  
Jonathan Stock, MAJ, MC  
Norman T. Byers, COL, MC  
Eric A. Sieck, CPT, MC  
William M. Mauldin, LTC, MC  
John Pope, COL, MC  
Miles Whitaker, CPT, MC  
Robert W. Enzenauer, MAJ, MC  
William Walton, CPT, MC  
David R. Pernelli, CPT, MC

(11) Key Words:  
intraocular lens

(12) Accumulative MEDCASE:*  
(13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 10  
d. Total Number of Subjects Enrolled to Date: 14  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Adjunctive study with FDA for intraocular lenses used following cataract extraction.

(16) Technical Approach: Intraocular lenses are implanted into the anterior segment of the eye following cataract extraction either as a primary procedure or as a secondary procedure.

(17) Progress: All lenses in place are doing well. No adverse reactions.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 48-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 88/201A (3) Status: Ongoing

(4) Title: Use of Goats for Training in Advanced Trauma Life Support

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC
Stephen M. Fall, LTC, MC

(9) Dept/Svc: SUR/Cardiothoracic (10) Associate Investigators
Dick F. Smith, COL, MC

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To conduct training courses in Advanced Trauma Life Support (ATLS).

(16) Technical Approach:

(17) Progress: The protocol is scheduled for continuing review January 1989.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/202  (3) Status: Ongoing

(4) Title: A Comparison of Clinical Features of Ulnar Nerve Compression at the Elbow Before and After Medial Epicondylectomy

(5) Start Date:  (6) Est Compl Date: 1989

(7) Principal Investigator: David Bizousky, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: SUR/Orthopedics  (10) Associate Investigators
James C. Johns, MAJ, MC
Effy Brewster, COL, MC
Jack Fullerton, MAJ, MC

(11) Key Words: nasal compression
carduction velocity

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 12  
d. Total Number of Subjects Enrolled to Date: 12  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Assess results of medial epicondylectomy in the treatment of cobital tunnel syndrome.

(16) Technical Approach: Comparison of pregerative and postgerative clinical and electrical parameters.

(17) Progress: Patients currently enrolled and followed in study until sufficient number reached.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/203  (3) Status: Ongoing
(4) Title: Evaluation of Current Nasal Surgical Techniques Used to Improve Nasal Obstruction (Subjective and Objective) Utilizing Anterior Rhinometric Techniques
(5) Start Date:  (6) Est Compl Date: 1990
(7) Principal Investigator: Michael L. Lepore, COL, MC
(8) Facility: FAMC
(9) Dept/Svc: SUR/Otolyn/Hd&NkSur.  (10) Associate Investigators
(11) Key Words: rhinomanometry, nasal obstruction, nasal surgery
(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.
(14) a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".
(15) Study Objective: (a) to utilize anterior rhinometric principles in the pre-op assessment of patients prior to nasal surgery, (b) to utilize anterior rhinometric principles in the post-op evaluation of patients who have had either septoplasty surgery and/or total nasal septal reconstructive surgery (opened or closed), and (c) to determine, utilizing anterior rhinomanometric techniques, if the unobstructive nasal cavity after nasal surgery (opened or closed) is significantly altered at the expense of correcting the pre-op obstructive side, and if this subjectively noted by the patient to the point of causing secondary obstructive symptoms, of any degree on the unobstructive side which will be objectively measured.
(16) Technical Approach: Measurements of nasal airflow utilizing anterior rhinomanometry will be performed before surgery and after surgery at definite periods. Correlation will be made between the various surgical procedures and the measured test results to note if any significant alterations on the unobstructed side have resulted from the surgical procedures.
(17) Progress: Since receiving the equipment in transfer from Brooke Army Medical Center in July, I have not yet tested the equipment. The room that was to be utilized has since been occupied by a new staff member. We are currently making arrangements to occupy another room in building 505. Project should begin in November after it has been tested by the company and principal investigator.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/204  (3) Status: Completed

(4) Title: Biomechanical Analysis of Tibial Fractures Treated with Intramedullary Nails

(5) Start Date:  

(6) Est Compl Date:  

(7) Principal Investigator:  
    Alexander Pruitt, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: SUR/Orthopedics  

(10) Associate Investigators  
    Thomas G. Friermood, MD

(11) Key Words:  
    tibia fractures  
    biomechanics  
    intramedullary nails

(12) Accumulative MEDCASE:*  

(13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
    b. Review Results:  
    c. Number of Subjects Enrolled During Reporting Period:  
    d. Total Number of Subjects Enrolled to Date:  
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To show whether or not the compression forces across the tibia fracture may be of benefit in predicting fracture healing.

(16) Technical Approach: Cadaveric tibias were reamed and nailed with a standard tibial nail that is routinely used in tibia fractures and this was biomechanically analyzed with the Instron dynamic loading apparatus. This was correlated with another study and looking at retrospective analysis of patients that were treated this way.

(17) Progress: This study has been completed as it is currently written and an addendum is currently pending to analyze not only reamed intramedullary nails which has already been done; but unreamed intramedullary nails and dynamic compression plates were two other alternative methods of fixation of tibia fractures. The equipment is available here at Fitzsimons through normal channels and amounts to just repeating the original biomechanical analysis with different types of fixation. This should be a minimal addendum to the study.

Publications and Presentations: This paper, after its completion, was presented at the American Academy of Orthopedic Surgeons in Atlanta, GA, in February 1988, at a Scientific Exhibit, and is currently being processed as a manuscript for publication in the Journal of Bone and Joint Surgery.
(1) Date: 30 Sep 88  (2) Protocol WU#: 88/205A  (3) Status: Ongoing

(4) Title: The Use of Gore-Tex Soft Tissue Patches in Repair of Lid and Adnexal Defects in New Zealand White Rabbits

(5) Start Date:  (6) Est Compl Date: 

(7) Principal Investigator: Norman T. Byers, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: SUR. Ophthalmology  (10) Associate Investigators Eric A. Cohn, CPT, MC David R. Pernelli, CPT, MC

(11) Key Words: 

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:* 

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results: 

c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine if the animal species in question, the New Zealand White rabbit, will demonstrate specific orbital and anatomical considerations to enable further research in lid reconstruction with Gore-Tex soft tissue patch (polytetrafluoroethylene-PTFE) for lid defects secondary to tumor or wartime injuries.

(16) Technical Approach:

(17) Progress: This study is scheduled for continuing review March 1989.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 88/206  Status: Ongoing

Title: An Analysis of the Effect of Nonsteroidal Anti-Inflammatory Medications on Regeneration of Articular Cartilage in New Zealand White Rabbits Treated by Intermittent Active Motion and Continuous Passive Motion

Start Date:  
Est Compl Date: 1990

Principal Investigator:  
Alexander Pruitt, MAJ, MC  
Anthony W. Colpini, MAJ, MC

Facility: FAMC

Dept/Svc: SUR/Orthopedics

Key Words:  
articular cartilage regeneration  
continuous passive motion  
nonsteroidal anti-inflammatory

Accumulative MEDCASE:*  
Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

Study Objective: The object of this protocol is to determine whether non-steroidal anti-inflammatory medications have an effect upon the regeneration of articular cartilage in rabbit knees. We are also attempting to delineate whether two separate nonsteroidal anti-inflammatories have different effects on regenerative of articular cartilage treated with continuous passive motion.

Technical Approach: The rabbit knees will be arthrotonized and pieces of the articular cartilage will be moved and the knees will be closed, and then the rabbits will either be put on continuous passive motion on one leg and active intermittent motion on the other, after both arthrotomies. Then they will be reoperated at 4, 8 & 12 weeks, and one group will get no nonsteroidal, one group will get Piroxicam, one group will get Acetylsalicylic acid.

Progress: Currently the continuous passive motion machine is being fabricated at the metal shop here on post; we are waiting for completion of this; once this is done then we will immediately start with the habituation of the animals to the apparatus. There has been no operation performed on any of these animals for this study.

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 88/207A  (3) Status: Ongoing

(4) Title: Biomechanical and Histological Analysis of Achilles Tendon Healing After Open and Percutaneous Repair in a Rabbit Model

(5) Start Date:  

(6) Est Compl Date:  

(7) Principal Investigator: Anthony W. Colpini, MAJ, MC  

(8) Facility: FAMC

(9) Dept/Svc: SUR. Orthopedic  

(10) Associate Investigators  

(11) Key Words: 

(12) Accumulative MEDCASE:*  

(13) Est Accum OMA Cost:*  

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  

b. Review Results:  

c. Number of Subjects Enrolled During Reporting Period:  

d. Total Number of Subjects Enrolled to Date:  

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective of this study is to compare the biomechanical strengths and histologic characteristics of healing Achilles tendon in rabbits that have been repaired using either an open or percutaneous technique.

(16) Technical Approach:

(17) Progress: This study is scheduled for continuing review April 1989.

Publications and Presentations: None
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

| (1) Date: | 30 Sep 88 |
| (2) Protocol WU#: | 88/208 |
| (3) Status: | Ongoing |

| (4) Title: | A Retrospective Analysis of the Incidence of Pseudarthrosis in Posterior Spine Fusion Done Between 1971 and 1986, at St. Anthony's Hospital and Denver Children's Hospital |

| (5) Start Date: | |
| (6) Est Compl Date: | |

| (7) Principal Investigator: | Alexander Pruitt, MAJ, MC  
| John A. Odom, MD |
| (8) Facility: | FAMC  
| Lakewood Clinic, Denver, CO |

| (9) Dept/Svc: | SUR. Orthopedic |
| (10) Associate Investigators | John L. Brugman, LTC, MC |

| (11) Key Words: | |

| (12) Accumulative MEDCASE:* | |
| (13) Est Accum OMA Cost:* | *
| *Refer to Unit Summary Sheet of this Report. |

| (14) a. Date, Latest IRC Review: |  
| b. Review Results: |  
| c. Number of Subjects Enrolled During Reporting Period: |  
| d. Total Number of Subjects Enrolled to Date: |  
| e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". |

| (15) Study Objective: | The purpose of this study is to evaluate those patients with pseudarthrosis and compare them with an age, sex, and diagnosed matched group of controls who also underwent posterior spine fusion but did not develop pseudarthrosis. We propose to evaluate the contributions of several factors which may effect the incidence of pseudarthrosis in these patients. |

| (16) Technical Approach: | |

| (17) Progress: | This study is scheduled for continuing review May 1989. |
| Publications and Presentations: | None |
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/209  (3) Status: Ongoing

(4) Title: A Comparison of Percutaneous Repair Versus Open Repair of Achilles Tendon Ruptures

(5) Start Date:  (6) Est Compl Date: 1990

(7) Principal Investigator:  (8) Facility: FAMC
R. Todd Hockenbury, CPT, MC

(9) Dept/Svc: SUR/Orthopedics  (10) Associate Investigators

(11) Key Words: achilles tendon ruptures
           percutaneous repair of achilles tendon ruptures

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date:
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: (a) To compare the clinical results of percutaneous repair to open repair of achilles tendon rupture and to investigate the complications and long-term outcome of these techniques. (b) To compare the initial repair strengths of these techniques.

(16) Technical Approach: Patients are now being randomized into 2 separate groups and surgery is being performed. The cadaver study is completed.

(17) Progress: The cadaver study is completed (biomechanical study). Ten patients have been included into the prospective study thus far. The proposed total number of patients to be included is forty. The biomechanical study portion of this protocol has been completed. The percutaneous repair was found to be 50% weaker than the open repair. Also the sural nerve was found to be entrapped in three out of five specimens undergoing percutaneous repair. The prospective study is ongoing with patients being randomized into percutaneous and open repair groups. We plan to obtain a total of 20 patients in each group. A chart review of patients having undergone achilles repair at Fitzsimons is also partially completed. No patients have been cybex tested as of yet.
Publications:

"A Biomechanical Comparison of Percutaneous Versus Open Repair of Achilles Tendon Defects" (Submitted for publication, Journal of Foot and Ankle Surgery).

Presentations:


"A Biomechanical Comparison of Percutaneous Versus Open Repair of Achilles Tendon Defects" Presented: Rocky Mountain Chapter Meeting of the Western Orthopedic Society Barnard Lecture Competition. February 1988, and was selected as one of the five finalist papers.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 88/210A (3) Status: Ongoing

(4) Title: Delayed Repair of Traumatic Intratemporal Facial Nerve Palsy in the Pig

(5) Start Date: May 1988 (6) Est Compl Date: Feb 1989

(7) Principal Investigator: David M. Barrs, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: SUR/Otolaryngology

(10) Associate Investigators

Kenneth F. Casey, MAJ, MC

(11) Key Words: traumatic facial palsy nerve graft intraoperative monitoring

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: __________ b. Review Results: __________
c. Number of Subjects Enrolled During Reporting Period: __________
d. Total Number of Subjects Enrolled to Date: __________
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: a. Determine optimal timing for facial nerve repair following temporal bone trauma; b. measure effect of stretch injury to facial nerve in cerebellopontine angle; c. refine direct facial nerve stimulation technique in the temporal bone; and d. develop an animal model for facial nerve study in the temporal bone.

(16) Technical Approach: The facial nerve is cut in the temporal bone and nerve grafted at intervals from immediately to three months after trauma. Histologic and electrophysiologic examinations will determine differences in return of function for different times of repair.

(17) Progress: Sixteen of the twenty study animals will have had their initial surgery performed by the date of this report, and all survival surgery is scheduled to be completed by November 7, 1988. No untoward complications have occurred. Exposure keratitis which was the major concern after facial paralysis has failed to be a problem. This is a new protocol for FY 88.

Publications and Presentations: None-no data yet available.
(1) Date: 30 Sep 88  (2) Protocol WU#: 88/211  (3) Status: Ongoing

(4) Title: Double Blind Crossover Study of Cyclobenzaprine versus Placebo in Patients with Primary Fibrositis: Correlation of Symptomatic versus Thermographic Criteria of Improvement

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:
Anthony W. Colpini, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: SUR/Orthopedic

(10) Associate Investigators
Alexander Pruitt, MAJ, MC
Richard A. Sherman, MAJ, MS

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objectives of this study are to compare Flexeril versus Placebo in the treatment of fibrositis, and to evaluate how subjective improvement of either drug or placebo corresponds to normalization of the thermogram.

(16) Technical Approach:

(17) Progress: This study was approved pending revisions. Revision has not been received as of this date.

Publications and Presentations: None
(1) Date: 30 Sep 88   (2) Protocol WU#: 88/212   (3) Status: Ongoing

(4) Title: Prevention of Nosocomial Pneumonia and Gastroduodenal Ulcer Prevention in Mechanically-Ventilated Patients

(5) Start Date:   (6) Est Compl Date: 

(7) Principal Investigator: William Marx, DO, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: SUR/Intensive Care

(10) Associate Investigators
      Kevin Dwyer, MD
      Brant Thrasher, MD

(11) Key Words:
      nosocomial pneumonia
      gastroduodenal ulcer

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* 
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 
    b. Review Results: 
    c. Number of Subjects Enrolled During Reporting Period: 
    d. Total Number of Subjects Enrolled to Date: 
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To decrease the incidence of pneumonia (nosocomial) in mechanically ventilated patients receiving antiulcer prophylaxis.

(16) Technical Approach: 4 groups of patients will be sequentially assigned to high, low, and moderate risk (based on APACHE score) to receive either Cimetidine and antacids; Cimetidine, antacids, Tobramycin, Polymixin B, Amphotericin; Famotidine or Sulcralfate; GI bleeding will be noted; routine cultures will be performed.

(17) Progress: Awaiting funding via Henry B. Jackson Foundation.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88
(2) Protocol WU#: 72/302
(3) Status: Ongoing

(4) Title: Comparison of Metabolic and Functional Changes in Defects of Platelet Function

(5) Start Date: 1972
(6) Est Compl Date:

(7) Principal Investigator: T.P. O'Barr, DAC
(8) Facility: FAMC

(9) Dept. of Clin Investigation
(10) Associate Investigators

(11) Key Words:
platelet function tests

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To correlate biochemical and functional parameters to gain a better understanding of the pathophysiology of the disorders of platelet function.

(16) Technical Approach: Platelet Function Studies: When indicated clinically, platelet counts, bleeding times, platelet adhesion, and whole blood and PRP aggregation in response to ADP, collagen, epinephrine, or ristocetin will be performed in the Coagulation Section, Department of Pathology or the Biochemistry Service, Department of Clinical Investigation. Biochemical Studies: Assessment of the content and release of the content of the platelet's subcellular storage organelles (alpha and dense granules) and evaluation of the platelet membrane will include, but not be limited to the following: a) Electron microscopy and mepacrine staining of dense granules; b) Content of platelet factor 4 and B-thromboglobulin activity in the alpha granules; c) Production of platelet-derived growth factor by 3H-thyamide incorporation in 3T3 mouse fibroblasts by platelet lysates; d) Measurement of secretable acid hydrolases (B-glucuronidase, B-galactosidase and membrane P-nitrophenyl phosphatase) activities; e) Membrane glycoprotein and phospholipid content; f) Release of arachidonate from membrane phospholipids by phospholipase C and diglyceride lipase; g) Mobilization of Ca++; h) Other studies as they become available.
(17) Progress: No progress was made this reporting period due to the transfer of the principal investigator. Plan to keep this study ongoing for FY 89, in case a member of the medical staff is interested in this area of research.

Presentations:


Publications:


(1) Date: 30 Sep 88 (2) Protocol WU#: 77/300 (3) Status: Ongoing

(4) Title: Immunologic Disorders in Children and Adults.  
I. Correlation of Immune Function in the Immunodeficiency State. II. Correlation of Immune Function of Leukemia and other Childhood Malignancies

(5) Start Date: 1977 (6) Est Compl Date: Open-Ended

(7) Principal Investigator: Robert S. Stewart, MAJ, MS

(8) Facility: FAMC

(9) Dept of Clin Investigation

(10) Associate Investigators

   John K. Podgore, COL, MC

(11) Key Words: immunologic diseases

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Oct 87 b. Review Results: Ongoing c. Number of Subjects Enrolled During Reporting Period: 103 d. Total Number of Subjects Enrolled to Date: 1129 e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Existing specialized immunochemical procedures will be consolidated into a registered protocol for use on a consultative basis by the FAMC hospital staff.

(16) Technical Approach: Serum gammapathics evaluated by SPEP, IEP, and rate nephelometry. Lymphocyte phenotyping, DNA analysis, and neutrophil activation potential by flow cytometry. Lymphocyte activation determined by quantitative mitogenesis.

(17) Progress: Ongoing.

Presentations:


Publications:

(4) Title: The Evaluation of Recently Introduced, Commercially Available Clinical Microbiology Products for Possible Use in the FAMC Diagnostic Microbiology Laboratory

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate introduced products which are of interest to the Microbiology Service, Department of Pathology, FAMC, but which cannot adequately be evaluated within the laboratory due to time, personnel, and monetary constraints. This evaluation will include cost effectiveness, ease of use, reproducibility and speed.

(16) Technical Approach: A separate protocol will be designed for each product evaluated.
Presentations:


Publications:

**Date:** 30 Sep 88  
**Protocol WU#:** 86/300  
**Status:** Ongoing

**Title:** Early Identification of *Borrelia burgdorferi* Antibody in Human Sera

**Start Date:** 1986  
**Est Compl Date:**

**Principal Investigator:** Sandy L. Tessier, DAC

**Facility:** FAMC

**Dept of Clin Investigation**

**Associate Investigators**  
Alan G. Barbour, MD, NIH  
Hamilton, MT

**Key Words:**  
borrelia  
lyme disease  
spirochete

**Accumulative MEDCASE:**

**Est Accum OMA Cost:**  
*Refer to Unit Summary Sheet of this Report.

**a. Date, Latest IRC Review:**  
**b. Review Results:**

**c. Number of Subjects Enrolled During Reporting Period:**

**d. Total Number of Subjects Enrolled to Date:**

**e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

**Study Objective:** To develop a sensitive and specific screening assay to detect human IgM directed against *B. burgdorferi*. The procedure proposed here will determine if the avidin-biotin system can detect IgM antibody bound to *B. burgdorferi* on nitrocellulose paper (NCP).

**Technical Approach:** Last year our preliminary studies indicated that the probes currently available against IgG are more sensitive and much more specific than the anti IgM probes. We are evaluating a new IFA kit using the FIA X fluorometer system that detects IgG/IgM antibodies to *B. burgdorferi*. The patient sera is being screened by ELISA using anti-human IgG conjugate and then by the FIA X kit.

**Progress:** We have received 582 serum samples (paired and unpaired) from soldiers at Ft. McCoy. 459 (including 12 controls) have been screened by ELISA and 250 of those have been FIA X-tested. Of the FIA X-tested sera, 94 are paired and in 23 of those soldiers spirochetes were recovered from the ticks. Eight samples of the 250 were FIA X positive, including 3 paired sera, indicating the soldiers were pre-exposed. The eight FIA X-positive samples were also ELISA positive and RPR negative.

**Publications and Presentations:** None
(1) Date: 30 Sep 88 (2) Protocol WU#: 86/301 (3) Status: Terminated

(4) Title: ELISA and Western Blot Detection of Pneumocystis carinii Antigen in Rat Lung and Human Tissue Culture Models

(5) Start Date: 1986 (6) Est Compl Date:

(7) Principal Investigator: Richard M. Conran, MAJ, MC
Donald D. Paine, DAC

(8) Facility: FAMC

(9) Dept of Clin Investigation
(10) Associate Investigators
Leo A. Andron, MAJ, MS
Carmen Ramirez, DAC
Sandy Tessier, DAC
Pari Morse, DAC

(11) Key Words:
enzyme-linked immunosorbent assay
pneumocystis carinii

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:
   b. Review Results:
   c. Number of Subjects Enrolled During Reporting Period:
   d. Total Number of Subjects Enrolled to Date:
   e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To identify Pneumocystis carinii (PC) antigens useful for distinguishing clinical from sub-clinical pneumonitis.

(16) Technical Approach: Steroid induced PC pneumonia is produced in rats. Blood and lung tissue are harvested from control and clinically ill animals to study PC specific antibodies and antigens. Antigens are analyzed by gel electrophoresis, transblotting and reaction with specific antibodies. Finding unique antigens in clinically ill animals will indicate the feasibility of applying this diagnostic approach to humans.

(17) Progress: Study terminated due to PCS of principal investigator.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88    (2) Protocol WU#: 87/300    (3) Status: Ongoing

(4) Title: Etiology of Low Back Pain Due to Muscle Tension

(5) Start Date: 1987    (6) Est Compl Date: 1990

(7) Principal Investigator: Richard A. Sherman, MAJ, MS

(8) Facility: FAMC

(9) Dept/Svc: Clin Investgn

(10) Associate Investigators

Joe E. Ozaki, COL, MC
Timothy Young, MD, Augusta, VAMC
Robert Rodinelli, Ph.D., Denver, VAMC
Bertram Rothschild, Ph.D., Denver, VAMC
John Arena, Ph.D., Augusta, VAMC

(11) Key Words:

low back pain
environmental recording
surface EMG

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:

b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 11

d. Total Number of Subjects Enrolled to Date: 11

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine the relationship between (a) the intensity and duration of work, (b) patterns of muscle tension, and (c) onset of low back pain. To determine whether patterns of muscle tension occurring during normal daily activities are different among people with (a) chronic low back pain, (b) intermittent pain, and (c) no pain. To determine relationships between patterns of muscle tension observed among relatively young active duty soldiers with intermittent low back pain and relatively older veterans with intermittent and chronic low back pain of muscle tension origin. To determine whether simple preventive measures can decrease intensity and frequency of episodes of pain by changing response patterns of low back muscle tension.

(16) Technical Approach: We will do two week long, continuous muscle tension, activity, and pain recordings of relatively young active duty soldiers with duties ranging from strenuous to sedentary who are either pain free, report intermittent low back pain due to muscle tension, or report almost continuous low back pain due to muscle tension. We will do similar recordings of relatively older veterans having similar activity patterns and similar back pain problems.
If we are able to identify abnormal patterns, we will provide people who clearly show these patterns with behaviorally oriented muscle control treatments or mild muscle relaxants in order to determine the effect of these interventions on muscle contractions patterns and pain.

(17) Progress: Relationships between low back muscle tension, pain, and movement remain consistent as long as subjects are pain free. When they report low back pain, the relationship changes. Consistency decreases as pain intensity and duration increases.

Publications and Presentations: None.
Date: 30 Sep 88  Protocol WU#: 87/301  Status: Ongoing

Title: Determination of Mechanisms of Phantom Limb Pain: Phase 2

Start Date: 1987  Est Compl Date: 1990

Principal Investigator: Richard A. Sherman, MAJ, MS

Facility: FAMC

Dept/Svc: Clin. Invstgn.

Associate Investigators:
- Joe E. Ozaki, COL, MC
- Timothy Young, MD, Augusta, VAMC
- Robert Rodinelli, MD, Ph.D., Denver, VAMC

Key Words:
- phantom limb pain
- mechanisms

Study Objective: To use MRI, nerve recording, and other techniques to monitor veteran and active duty amputees who report shocking, shooting, and stabbing descriptors of phantom limb pain while they are experiencing various intensities of pain in order to ascertain the physiological changes which are related to changes in pain intensity.

Technical Approach: We will carry out the pilot for a full proposal in which we would record groups of twenty active duty or veteran amputees four times. In the pilot, only two amputees from each group will participate. Two of the recordings will be at one particular pain intensity while the other two will be at two different intensities. This will permit factoring changes due to time from those due to changes in pain intensity. Each subject will be recorded at about weekly intervals but the exact timing will have to depend on when their pain intensity...
changes. The groups will consist of two amputees with (1) only stabbing phantom pain, (2) only shooting phantom pain, (3) only shocking phantom pain, (4) a combination of all three (which is common), and (5) no phantom pain. The fifth group of amputees without phantom pain is necessary to further evaluate changes which occur in the normal stump over time so we can differentiate them from abnormal changes. We know from our experience in Phase I of this study that twenty is the minimum number of amputees we can have in a group due to normal physiological variability and in variability in reporting pain intensity. However, two per group will give us an idea of whether the following techniques are likely to show any differences at all. We propose to use MRI to record overall stump anatomy, plethysmography to record swelling and internal stump pressure, and signals from the neuroma to record responses to mechanical and other stimuli. Because of its invasive nature, we will carry out only one nerve signal study from the stump. For subjects who report phantom pain, we will perform the test on a day when they report the maximum phantom pain they usually experience. We will compare the results of this recording with those from pain free amputees. Due to its cost, we will do MRI recordings of only one subject per pilot group. Two MRI's will be done for each pilot subject. One will be while the subject is as pain free as they get and the other will be while they are experiencing the most pain they generally expect.

(17) Progress: Only a few subjects have completed participation so results are very initial. However, we have clearly demonstrated that among amputees who experience discrete episodes of cramping phantom pain, spike activity in the surface EMG always begins before report of an episode and the spikes are not present when episodes are not reported. We have also determined that phantom pain changes in intensity with changes in stress, fatigue, and barometric pressure.

Publications:


Presentations:

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/302  (3) Status: Terminated

(4) Title: Psychophysiological Etiology and Self-help Treatment of Headache

(5) Start Date:            (6) Est Compl Date:            

(7) Principal Investigator:            (8) Facility: FAMC
John G. Arena, PhD. Augusta, VAMC

(9) Dept/Svc: Clin. Invstgn.            (10) Associate Investigators
            Richard A. Sherman, MAJ, MS

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: ___________  f. Review Results: ___________
     c. Number of Subjects Enrolled During Reporting Period: ___________
     d. Total Number of Subjects Enrolled to Date: ___________
     e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective:

(16) Technical Approach:


Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 87/303 (3) Status: Ongoing

(4) Title: Mechanism Based Treatments of Phantom Limb Pain

(5) Start Date: 1987 (6) Est Compl Date: 1990

(7) Principal Investigator: Richard A. Sherman, MAJ, MS

(8) Facility: FAMC


(10) Associate Investigators

Joseph K. Ozaki, COL, MC
Timothy Young, MD, Augusta, VAMC
Robert Rodinelli, MD, Denver, VAMC

(11) Key Words:
phantom limb pain treatments

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 7
d. Total Number of Subjects Enrolled to Date: 7
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To demonstrate the effectiveness of treatments for burning phantom limb pain.

(16) Technical Approach: We will treat four groups of ten amputees each with the same six interventions. The amputees will be grouped by the description of their phantom pain. We will work with those describing their phantom pain as (1) only burning, (2) only cramping, (3) mixed cramping and burning, and (4) shooting / stabbing / shocking. Before treatment begins, there will be a three week baseline in which each amputee will be interviewed and stump muscle tension and heat outflow patterns will be recorded. Each amputee will receive each treatment for one month unless side effects force withdrawal. Treatment months will alternate with three week "washout" periods to permit phantom pain to return to baseline. The treatments will be: (1) topical application of nitroglycerine for mainly venous-side vasodilatative effects, (2) tretical to reduce blood viscosity so more blood can reach tissues in the
stump having compromised vascular beds, (3) Nifedipine as a Calcium channel blocker for its known peripheral vasodilatative effects, (4) Cyclobenzaprine for its ability to reduce spasms of local origin without interfering with muscle function, (5) muscle tension recognition and relaxation training for its proven ability to reduce microspasms and tension related to intensification of phantom pain, and (6) body surface temperature recognition and control training for its ability to help people control vasodilation of peripheral vessels while under stress. Subjects will be recorded the same way they were during the baseline at each session to permit objective verification of physiological changes. They will come to the clinic every other week during treatments. At the end of the last treatment, there will be another three week baseline. Following the final baseline, the treatment which proved most effective, if any, will be continued for one year. Subjects will be recorded at monthly intervals. If no treatments are effective, subjects will still be followed for one year but will be recorded at six and twelve months.

17) Progress: Short term results indicate that spasm and muscle tension reduction treatments work well with cramping phantom pain. Insufficient data has been gathered from FAMC subject to report more details.

Publications:


Date: 30 Sep 88  (2) Protocol WU#: 87/304  (3) Status: Terminated

Title: Use of Heat Patterns in Evaluation of Spinal Cord Injured Veterans

Start Date: 1987  (6) Est Compl Date: 1989

Principal Investigator:
Richard A. Sherman, MAJ, MS
Jeffrey L. Ernst, Ph.D., Augusta, VAMC

Facility: FAMC
Augusta, VAMC

Dept/Svc: Clin. Investgn.

Associate Investigators
Janusz Markowski, MD, Augusta, VAMC

Key Words:
spinal cord injury
thermography
phantom body pain

Study Objective: To confirm the results of two trials in which surface body heat patterns produced by spinal cord injured (SCI) veterans were compared with (a) completeness of injury and (b) reported location of sensations which appear to emanate from areas of the body no longer connected to the brain through the spinal cord (phantom sensations).

Technical Approach: (a) Differences in trunk heat patterns produced by complete and incomplete SCI veterans will be evaluated through multiple recordings of twenty surgically complete SCI veterans and twenty veterans having similar but incomplete injuries who are matched on all other clinically important parameters; (b) relationships between heat patterns and location of phantom sensations will be evaluated by doing four thermographic recordings of each of 100 veterans diagnosed as having complete SCIs and then comparing the patterns with sensations maps filled out at each session.

Progress: This study was not funded. No subjects were run at FAMC and the study is now closed. Initial data from the Augusta VA showed significant differences between complete and incomplete SCI patients.

(5) Start Date: 1987
(6) Est Compl Date: 1989

(7) Principal Investigator: Richard A. Sherman, MAJ, MS
John G. Arena, Ph.D.

(8) Facility: FAMC
Augusta, VAMC


(10) Associate Investigators
Joe Ozaki, COL, MC
Timothy Young, MD, Augusta, VAMC

(11) Key Words:
low back pain
thermography
surface EMG
MMPI

(12) Accumulative MEDCASE:* Refer to Unit Summary Sheet of this Report.

(13) Est Accum OMA Cost:*

(14) a. Date, Latest IRC Review:

b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 51

d. Total Number of Subjects Enrolled to Date: 51

e. Note any adverse drug reactions reported to the FDA or sponsor for
studies conducted under an FDA-awarded IND. May be continued on a
separate sheet, and designated as "(14)e". None

(15) Study Objective: To test the effectiveness of paraspinal surface
EMG, the MMPI, videothermography, physical examination, and standard
diagnostic procedures for ascertaining objective data concerning the
patient's actual low back pain intensity and underlying physical
problems.

(16) Technical Approach: We are in the process of performing paraspinal
surface EMG and videothermographic recordings of at least 360 subjects
with low back pain of six diagnostic categories and who hurt most while
in one of six different positions (6 x 6 cell design with ten subjects
in a group). Each subject is being recorded four times: Twice while
their pain intensity is the same and twice while it varies up or down
from the two similar recordings. Thus, each subject is recorded at be-
tween two and three pain intensities. This provides data on change with
time while pain is constant. All of these subjects are given a modified
version of the MMPI designed to differentiate between psychological fac-
tors and changes in responses due to presence or absence of low back
pain. Each subject is also given a complete orthopedic physical ex-
amination and any standard diagnostic procedures not already well docu-
mented is done.

(17) Progress: Fifty-one patients have been entered into the study at
FAMC to date. There is a consistent relationship between low back
muscle tension and low back pain intensity. Thermographic results are
inconsistent.
Publications:


Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/300A  (3) Status: Ongoing

(4) Title: Effect of Clonidine on Longitudinal Bone Growth in Juvenile Sprague-Dawley Rats

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: John K. Podgore, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Clin. Invstgn.  (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 
d. Total Number of Subjects Enrolled to Date: 
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective of this study is to determine if clonidine hydrochloride administration to juvenile rats, over a thirty day period, will increase longitudinal bone growth.

(16) Technical Approach:


Publications and Presentations: None
Date: 30 Sep 88  
Protocol WU#: 88/301  
Status: Ongoing

Title: Continuous Environmental Recording of Activity, Headache, and Muscle Contraction Level Among Subjects with Tension, Migraine or No Headache

Start Date: 1988  
Est Compl Date: 1989

Principal Investigator: Richard A. Sherman, MAJ, MS

Facility: FAMC

Dept/Svc: Clin. Invstgn.
Associate Investigators:
  John G. Arena, MD, Augusta, VAMC
  John Brugman
  Richard Calkins
  Crystal Sherman
  David Hahn
  Jeffrey Ginther

Key Words:
  headache
  muscle tension
  environmental recording

Accumulative MEDCASE:*  
Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:          b. Review Results:          
c. Number of Subjects Enrolled During Reporting Period: 3          
d. Total Number of Subjects Enrolled to Date: 3          
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

Study Objective: To determine relationships between motion, muscle tension in the frontal and trapezius muscles, and onset and intensity of headaches among subjects recorded in their normal environments.

Technical Approach: Subjects wear a small EMG and motion recorder during all working hours for one week. They keep an hourly log of types and activity and pain intensity while wearing the recorder.

Progress: New protocol, no results yet.

Publications and Presentations: None
Training Support Summary

During the year, eighty-four 91A, B and C personnel were trained in suturing techniques. Ten were from the Department of Pediatrics and 74 from Emergency Medicine Service. Training consisted of an overview of operating room procedure, including aseptic technique and operating room rules of etiquette, instruction in the surgical scrub, proper gowning and gloving technique, and hands-on experience in dry and wet labs. Training was conducted on 21 days, using 29 rats and 15 rabbits. 294 hours of training were provided, requiring 105 hours of training support by Animal Resources Service personnel.

One hundred eleven microsurgery training sessions were conducted, providing 273 hours of training to 16 staff surgeons and residents. Forty-two sessions were conducted for Orthopedic Service, 40 for Plastic Surgery Service, and 30 for Urology Service. One hundred eleven hours of training support were required by Animal Resources Service personnel, and utilized 67 rats and 44 rabbits.

Cardiothoracic Surgery Service utilized three pigs in three sessions in the training with and evaluation of the Bio-medicus pump. Three staff surgeons received 45 hours of training, requiring 36 hours of support by Animal Resources Service personnel.

Three Advanced Trauma Life Support (ATLS) exercises were conducted during the year, using 12 goats in the training of 60 staff physicians in the emergency management of casualties. 240-plus hours of training were received, requiring 150 hours of support by personnel of Animal Resources Service for planning, preparation, pre-op anesthesia induction, surgical preps, anesthesia monitoring, circulating and clean-up.

Seven renal trauma exercises were conducted by Urology Service, using seven pigs in the training of two staff physicians and two residents. Forty-two hours of training were received, requiring 84 hours of support by Animal Resources Service personnel in pre-op anesthesia, surgical preps, circulating and anesthesia monitoring, passing instruments and assisting surgeries, and clean-up.

One kitten intubation exercise was conducted for The American College of Obstetricians and Gynecologists/Indian Health Service Postgraduate Course in Obstetrics, Gynecology and Neonatology. Ninety physicians and nurses received 90-plus hours of training in resuscitative methods and endotracheal intubation, using 13 kittens and requiring 30-plus hours of support by Animal Resources Service personnel in planning, preparation, anesthesia and clean-up.
### Cost of Training

<table>
<thead>
<tr>
<th>Training Type</th>
<th>(Rabbits)</th>
<th>(Rats)</th>
<th>Calculation</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suture Labs</td>
<td>$115</td>
<td>$105</td>
<td>15 sessions x $115/session</td>
<td>$1,725</td>
</tr>
<tr>
<td>Microsurgery</td>
<td>$95</td>
<td>$85</td>
<td>44 sessions x $95/session</td>
<td>$4,180</td>
</tr>
<tr>
<td>Cardiothoracic Surgery</td>
<td>$175</td>
<td></td>
<td>3 sessions x $175/session</td>
<td>$525</td>
</tr>
<tr>
<td>Renal Trauma Exercises</td>
<td>$175</td>
<td></td>
<td>7 sessions x $175/session</td>
<td>$1,225</td>
</tr>
<tr>
<td>ATLS Exercises</td>
<td>$175</td>
<td></td>
<td>3 sessions x $175/session</td>
<td>$525</td>
</tr>
</tbody>
</table>

Total: $16,920

Under a Memorandum of Agreement, one high school student from the Aurora Public Schools T.H. Pickens Technical Center took on-the-job vocational training as a veterinary aide, receiving 111 hours of training, requiring 166 hours of instruction and supervision by personnel of Animal Resources Service.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 82/35X-001  Status: Ongoing

(4) Title: Repair of Femoral Artery and Fallopian Tube of Rabbit and Rat

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: Edward G. Lundblad, COL, MC  (8) Facility: FAMC

(9) Dept of OB-GYN  (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date:
    e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective:

(16) Technical Approach:

(17) Progress: Continued training for staff and residents is essential. Experience will make it possible to evaluate suture material and techniques for publication.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 80/351  Status: Ongoing

Title: Section A: Master Protocol for Phase II Drug Studies in the Treatment of Advanced Recurrent Pelvic Malignancies

GOG 26

Start Date:  Est Compl Date:

Principal Investigator: George Phillips, COL, MC

Facility: FAMC

Dept of OB-GYN

Associate Investigators

Key Words:
pelvic neoplasms

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 1
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To participate in the GOG protocol in the study of cancer.

Technical Approach: See protocol

Progress: Master protocol that is still ongoing for many phase II agents.

Publications and Presentations: Multiple by GOG, none by FAMC.
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(1)</strong> Date:</td>
<td>30 Sep 88</td>
</tr>
<tr>
<td><strong>(2)</strong> Protocol WU#:</td>
<td>80/352</td>
</tr>
<tr>
<td><strong>(3)</strong> Status:</td>
<td>Ongoing</td>
</tr>
<tr>
<td><strong>(4)</strong> Title:</td>
<td>Section C: A Phase II Trial of CIS-Platinum GOG 26</td>
</tr>
<tr>
<td><strong>(5)</strong> Start Date:</td>
<td></td>
</tr>
<tr>
<td><strong>(6)</strong> Est Compl Date:</td>
<td></td>
</tr>
<tr>
<td><strong>(7)</strong> Principal Investigator:</td>
<td>George Phillips, COL, MC</td>
</tr>
<tr>
<td><strong>(8)</strong> Facility:</td>
<td>FAMC</td>
</tr>
<tr>
<td><strong>(9)</strong> Dept of OB-GYN</td>
<td></td>
</tr>
<tr>
<td><strong>(10)</strong> Associate Investigators</td>
<td></td>
</tr>
<tr>
<td><strong>(11)</strong> Key Words:</td>
<td>pelvic neoplasms</td>
</tr>
<tr>
<td><strong>(12)</strong> Accumulative MEDCASE:*</td>
<td></td>
</tr>
<tr>
<td><strong>(13)</strong> Est Accum OMA Cost:*</td>
<td></td>
</tr>
<tr>
<td>*Refer to Unit Summary Sheet of this Report.</td>
<td></td>
</tr>
<tr>
<td><strong>(14)</strong> a. Date, Latest IRC Review:</td>
<td></td>
</tr>
<tr>
<td>b. Review Results:</td>
<td></td>
</tr>
<tr>
<td>c. Number of Subjects Enrolled During Reporting Period:</td>
<td></td>
</tr>
<tr>
<td>d. Total Number of Subjects Enrolled to Date:</td>
<td>3</td>
</tr>
<tr>
<td>e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as &quot;(14)e&quot;.</td>
<td></td>
</tr>
</tbody>
</table>

**(15)** Study Objective: To participate in the GOG protocol in the study of cancer.

**(16)** Technical Approach: See protocol

**(17)** Progress: Three patients; one partial remission, two with stable disease. No serious adverse reactions.

Publications and Presentations: Multiple by GOG, none by FAMC.
FAMC A.P.R. (RCS MEW 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 80/353  (3) Status: Completed

(4) Title: Section D: A Phase II Trial of VP 16

GOG 26

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: George Phillips, COL, MC

(8) Facility: FAMC

(9) Dept of OB-GYN

(10) Associate Investigators

(11) Key Words: pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for 
studying under an FDA-awarded IND. May be continued on a separate sheet, 
and designated as "(14)e".

(15) Study Objective: To participate in the GOG protocol in the study of 
cancer.

(16) Technical Approach: See protocol

(17) Progress: VP 16 appears to have minimal activity against ovarian and 
endometrial adenocarcinoma, squamous cell of the cervix at the dose and 
schedule tested. This study is completed.

Publications and Presentations: Multiple by GOG, none by FAMC.
Date: 30 Sep 88  
Protocol WU#: 80/355  
Status: Completed  
Title: Section N: A Phase II Trial of DHAD
GOG 26

Start Date:  
Est Compl Date:  
Principal Investigator: George Phillips, COL, MC  
Facility: FAMC  
Dept of OB-GYN  
Associate Investigators

Key Words: pelvic neoplasms

Accumulative MEDCASE:*  
*Refer to Unit Summary Sheet of this Report.

Est Accum OMA Cost:*  

Date, Latest IRC Review:  
Review Results:  
Number of Subjects Enrolled During Reporting Period:  
Total Number of Subjects Enrolled to Date:  
Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To participate in the GOG protocol in the study of cancer.

Technical Approach: See protocol

Progress: Minimal activity in ovarian cancer previously treated with doxorubicin. Also minimal activity in previously treated carcinoma of the cervix and non-squamous carcinoma of the cervix. This study is completed.

Publications and Presentations: Multiple by GOG, none by FAMC.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 80/356  (3) Status: Completed

(4) Title: Section 0: A Phase II Trial of AZQ

  GOG 26

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC

  George Phillips, COL, MC

(9) Dept of OB-GYN  (10) Associate Investigators

(11) Key Words:

  pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

  *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol

(17) Progress: Open only for patients with ovarian carcinoma who are ineligible for the #26-N(DHAD) because of prior doxorubicin exceeding 400mg. This study is completed.

Publications and Presentations: Multiple by GOG, none by FAMC.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 80/357  (3) Status: Completed

(4) Title: Section Q: A Phase II Trial of Aminochiadiazole

GOG 26

(5) Start Date:    (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility:  FAMC
George Phillips, COL, MC

(9) Dept of OB-GYN  (10) Associate Investigators

(11) Key Words:
pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for
studying under an FDA-awarded IND. May be continued on a separate sheet,
and designated as "(14)e".

(15) Study Objective: To participate in the GOG protocol in the study of
cancer.

(16) Technical Approach:  See protocol

(17) Progress: Minimal activity in previously treated ovarian carcinoma and
squamous cell of the cervix. This study is completed.

Publications and Presentations: Multiple by GOG.
Date: 30 Sep 88  
Protocol WU#: 80/358  
Status: Completed

Title: Section R: A Phase II Trial of Progestin

GOG 26

Start Date:  
Est Compl Date:  
Principal Investigator: George Phillips, COL, MC  
Facility: FAMC

Dept of OB-GYN  
Associate Investigators

Key Words: pelvic neoplasms

Accumulative MEDCASE:*  
Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To participate in the GOG protocol in the study of cancer.

Technical Approach: See protocol

Progress: This study is completed.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 80/359  (3) Status: Ongoing

(4) Title: Section S: A Phase II Trial of VM26
GOG 26

(5) Start Date: 

(6) Est Compl Date: 

(7) Principal Investigator: 
George Phillips, COL, MC

(8) Facility: FAMC

(9) Dept of OB-GYN

(10) Associate Investigators

(11) Key Words: 
pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 
  b. Review Results: 
  c. Number of Subjects Enrolled During Reporting Period: 0
  d. Total Number of Subjects Enrolled to Date: 4
  e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol

(17) Progress: Modest activity in previously treated epithelial ovarian carcinoma and squamous cell cervical carcinoma. Four patients; 3 progressive disease, 1 stable, 2 patients living, no adverse effects.

Publications and Presentations: Multiple by GOG.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 80/362 (3) Status: Ongoing

(4) Title: A Clinical-Pathologic Study of Stages I and II Uterine Sarcomas
   GOG 40

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: George Phillips, COL, MC

(8) Facility: FAMC

(9) Dept of OB-GYN

(10) Associate Investigators

(11) Key Words:
   pelvic neoplasms

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date: 3
    e. Note any adverse drug reactions reported to the FDA or sponsor for
       studying under an FDA-awarded IND. May be continued on a separate sheet,
       and designated as "(14)e".

(15) Study Objective: To participate in the GOG protocol in the study of
    cancer.

(16) Technical Approach: See protocol

(17) Progress: Three patients, surgical-pathological study only, patients
    benefit from careful surgical staging, no adverse effects.

Publications and Presentations: Multiple by GOG.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 80/369 (3) Status: Ongoing

(4) Title: The Treatment of Women With Malignant Tumors of The Ovarian Stroma with Combination VCR, Dactinomycin and Cytoxan (Phase III)
GOG 54

(5) Start Date:  

(6) Est Compl Date:

(7) Principal Investigator: George Phillips, COL, MC

(8) Facility: FAMC

(9) Dept of OB-GYN

(10) Associate Investigators

(11) Key Words:
pelvic neoplasms

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 
d. Total Number of Subjects Enrolled to Date: 1 
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: *See protocol

(17) Progress: Treatment with Adriamycin has been deleted. One patient who is living and free of disease, no adverse effects.

Publications and Presentations: None

206
Date: 30 Sep 88  Protocol WU#: 80/370  Status: Completed

Title: Hormonal Contraception and Trophoblastic Sequelae After Hydatidiform Mole (Phase III)  GOG 55

Start Date:  Est Compl Date:

Principal Investigator: George Phillips, COL, MC

Facility: FAMC

Dept of OB-GYN

Associate Investigators

Key Words:
pelvic neoplasms

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  Review Results:  Number of Subjects Enrolled During Reporting Period:
Total Number of Subjects Enrolled to Date:
Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To participate in the GOG protocol in the study of cancer.

Technical Approach: See protocol

Progress: Completed

Publications and Presentations: None
(1) Date: 30 Sep 88 (2) Protocol WU#: 80/374 (3) Status: Completed

(4) Title: A Clinical-Pathologic Study of Stages II-B, III and IV-A, Carcinoma of the Cervix
GOG 63

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC
George Phillips, COL, MC

(9) Dept of OB-GYN (10) Associate Investigators

(11) Key Words:
pelvic neoplasms

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol

(17) Progress: Study is completed.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 80/376 (3) Status: Ongoing

(4) Title: Ultrastructural Staging and Therapeutic Consideration in Small Cell Carcinoma of the Cervix (Phase II)
   GOG 66

(5) Start Date: (6) Est Compl Date: 

(7) Principal Investigator: George Phillips, COL, MC

(8) Facility: FAMC

(9) Dept of OB-GYN

(10) Associate Investigators

(11) Key Words: pelvisc neoplasms

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
   c. Number of Subjects Enrolled During Reporting Period: 0
   d. Total Number of Subjects Enrolled to Date: 1
   e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as ",(14)e".

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol

(17) Progress: One patient; surgical-pathological study only, no treatment involved, no adverse effects.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 80/378  (3) Status: Ongoing

(4) Title: Ovarian Tumors of Low Malignant Potential: A Study of the Natural History and a Phase II Trial of Melphalan and Secondary Treatment with Cisplatin in Patients with Progressive Disease

GOG 72

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  George Phillips, COL, MC

(8) Facility:  FAMC

(9) Dept of OB-GYN  (10) Associate Investigators

(11) Key Words: pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date: 1
    e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol

(17) Progress: One patient, surgical pathological study only, no treatment involved and no adverse effects.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 80/379  (3) Status: Ongoing

(4) Title: Early Stage I Vulvar Cancer Treated with Ipsilateral Superficial Inguinal Lymphadenectomy and Modified Radical Hemivulvectomy (Phase III)

GOG 74

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: George Phillips, COL, MC

(8) Facility: FAMC

(9) Dept of OB-GYN

(10) Associate Investigators

(11) Key Words: pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: ________ b. Review Results: ________
c. Number of Subjects Enrolled During Reporting Period: ________
d. Total Number of Subjects Enrolled to Date: ________
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol

(17) Progress: Ongoing

Publications and Presentations: None
(1) Date: 30 Sep 88 (2) Protocol WU#: 80/380 (3) Status: Ongoing

(4) Title: A Clinical Pathologic Study of Primary Malignant Melanoma of the Vulva Treated by Modified Radical Hemivulvectomy

GOG 73

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: George Phillips, COL, MC

(8) Facility: FAMC

(9) Dept of OB-GYN

(10) Associate Investigators

(11) Key Words:
pelvic neoplasms

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol

(17) Progress: Acquiring acceptable number of patients nationally.

Publications and Presentations: None
Date: 30 Sep 88  (2) Protocol WU#: 80/381  (3) Status: Ongoing

Title: Postoperative Pelvic Radiation in Stages I and II Mixed Mesodermal Tumors of the Uterus (Phase III) GOG 75

Start Date:  Est Compl Date:

Principal Investigator: George Phillips, COL, MC

Facility: FAMC

Dept of OB-GYN

Associate Investigators

Key Words: pelvic neoplasms

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To participate in the GOG protocol in the study of cancer.

Technical Approach: See protocol

Progress: Ongoing

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 80/384  (3) Status: Completed

(4) Title: Evaluation of Adjuvant Vinblastine, Bleomycin and Cisplatinum Therapy in Total Resected Choriocarcinoma, Endodermal Sinus Tumor, or Embryonal Carcinoma of the Ovary Pure and Mixed with Other Elements

GOG 78

(5) Start Date:  
(6) Est Compl Date:

(7) Principal Investigator: George Phillips, COL, MC  
(8) Facility: FAMC

(9) Dept of OB-GYN  
(10) Associate Investigators

(11) Key Words: pelvic neoplasms

(12) Accumulative MEDCASE:*  
(13) Est Accum SMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
   b. Review Results:  
   c. Number of Subjects Enrolled During Reporting Period:  
   d. Total Number of Subjects Enrolled to Date:  
   e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol

(17) Progress: This study is completed.

Publications and Presentations: None

214
(1) Date: 30 Sep 88  (2) Protocol WU#: 83/351  (3) Status: Ongoing
(4) Title: Danazol in the Treatment of Premenstrual Syndrome
(5) Start Date: 1985  (6) Est Compl Date: 1989
(7) Principal Investigator: Diane C. Garrow, CPT, MS
(8) Facility: FAMC
(9) Dept of OB-GYN
(10) Associate Investigators Edward Lundblad, COL, MC
(11) Key Words: pms therapy
(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
   *Refer to Unit Summary Sheet of this Report.
(14) a. Date, Latest IRC Review:  b. Review Results:  
    c. Number of Subjects Enrolled During Reporting Period:  
    d. Total Number of Subjects Enrolled to Date:  
    e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".
(15) Study Objective: To determine if Danazol is effective in treating symptoms of pre-menstrual syndrome.
(16) Technical Approach: A double-blind, cross-over, placebo study in which patients who have documented PMS are treated for 2 months with Danazol and 2 months with placebo. While being treated, patients keep a diary of their symptoms.
(17) Progress: In FY 87 an improvement in PMS patients was shown when patients were treated with Danazol. We are now looking at subgraphs of symptoms for improvement with Danazol therapy.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 84/352  (3) Status: Ongoing

(4) Title: Characterization of Steroid Hormones Produced by Short-Term Incubation of Luteal Cells Obtained from Macaca fascicularis with Induced Luteal Phase Defects

(5) Start Date: 1985  (6) Est Compl Date: Unknown

(7) Principal Investigator:
Edward Miller, CPT, MC
Charles F. Ferris, CPT, MS

(8) Facility: FAMC

(9) Dept of OB-GYN

(10) Associate Investigators
Donald G. Corby, COL, MC
Albert H. McCullen, MAJ, VC
Edward Lundblad, LTC, MC

(11) Key Words:
corpus luteum
intern

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: ___________ b. Review Results: ___________
c. Number of Subjects Enrolled During Reporting Period: ___________
d. Total Number of Subjects Enrolled to Date: ___________
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to determine if differences exist between control and luteal phase defect induced cycles in the short-term production of steroids significant during the mid-luteal phase of the menstrual cycle of monkeys. If differences exists, possible new therapy for specific types of infertility may be recommended.

(16) Technical Approach: Luteal cells are obtained 5-8 days post-ovulation by luteectomy. The luteectomy obtained cells are processed, then cultured for 3 hours. The supernatant will be assayed for pregnenolone, progesterone, 170H progesterone and testosterone using RIA procedures. The differences in assay levels of the steroid production from the control and treated cells will be statistically measured using multiple mean tests.

(17) Progress: Culture and production of luteal cells from the control cycle has been completed. Problems having occurred during the treatment phase have been evaluated. The plan is to rectify past problems but the research has been placed in abeyance by LACUC constraints.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/351  (3) Status: Ongoing

(4) Title: A Randomized Comparison of Hydroxyurea Versus 5-FU Infusion and Bolus Cisplatin as an Adjunct to Radiation Therapy in Patients with Stages II-B, III and IV-A Carcinoma of the Cervix and Negative Para-Apical Nodes

GOG 85

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:
George L. Phillips, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: OB-GYN  (10) Associate Investigators

(11) Key Words:
pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing

Publications and Presentations: None
Date: 30 Sep 88 (2) Protocol WU#: 87/352 (3) Status: Completed

Title: A Phase II Trial of Methotrexate in Patients with Advanced or Recurrent Endometrial Carcinoma
GOG 86D

Start Date: (6) Est Compl Date:

Principal Investigator: George L. Phillips, COL, MC

Facility: FAMC

Dept/Svc: OB-GYN

Associate Investigators

Key Words:
pelvic neoplasms

Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: __________  b. Review Results: __________
c. Number of Subjects Enrolled During Reporting Period: __________
d. Total Number of Subjects Enrolled to Date: __________
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the GOG group in the study of malignancies.

Technical Approach: See Protocol

Progress: Completed.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/353  (3) Status: Ongoing

(4) Title: Evaluation of Cisplatin, Etoposide, and Bleomycin Induction Followed by Vincristine, Dactinomycin and Cyclophosphamide Consolidation in Advanced Ovarian Germ Cell Tumors

GOG 90

(5) Start Date:  (6) Est Compl Date: 

(7) Principal Investigator: George L. Phillips, COL, MC  (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators

(11) Key Words: pelvic neoplasms

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: __________ b. Review Results: __________
c. Number of Subjects Enrolled During Reporting Period: __________
d. Total Number of Subjects Enrolled to Date: __________
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing

Publications and Presentations: None
Title: Randomized Clinical Trial for the Treatment of Women with Selected Stage IAi & IAii & IBii Ovarian Cancer (Phase III) GOG 95

Start Date: 
Est Compl Date: 
Principal Investigator: George L. Phillips, COL, MC
Facility: FAMC
Dept/Svc: MED/Hema/Oncol
Associate Investigators: Torrence Wilson, COL, MC
Key Words: pelvic neoplasms

Study Objective: The objective is to participate in the GOG group in the study of malignancies.

Technical Approach: See Protocol

Progress: Ongoing

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 87/355  Status: Completed

Title: Evaluation of a Shortened Course of Vincristine, Dactinomycin and Cyclophosphamide as Adjuvant Therapy for Immature Teratoma of the Ovary, Stage I, Grade 2, Completely Resected

GOG 84

Start Date:  
Est Compl Date:  

Principal Investigator: George L. Phillips, COL, MC

Facility: FAMC

Dept/Svc: OB-GYN

Associate Investigators

Key Words: pelvic neoplasms

Accumulative MEDCASE:*  Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the GOG group in the study of malignancies.

Technical Approach: See Protocol

Progress: Completed.

Publications and Presentations: None
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) **Date:** 30 Sep 89  
(2) **Protocol WU#:** 87/356  
(3) **Status:** Ongoing

(4) **Title:** A Phase III Randomized Study of Cyclophosphamide and Cisplatin in Patients with Suboptimal Stage III and Stage IV Epithelial Ovarian Carcinoma Comparing Intensive and Non-Intensive Schedules  
GOG 97

(5) **Start Date:**  
(6) **Est Compl Date:**

(7) **Principal Investigator:** George L. Phillips, COL, MC

(8) **Facility:** FAMC

(9) **Dept/Svc:** OB-GYN

(10) **Associate Investigators**

(11) **Key Words:** pelvic neoplasms

(12) **Accumulative MEDCASE:**  
(13) **Est Accum OMA Cost:**  
*Refer to Unit Summary Sheet of this Report.

(14) a. **Date, Latest IRC Review:**  
b. **Review Results:**  
c. **Number of Subjects Enrolled During Reporting Period:** 0  
d. **Total Number of Subjects Enrolled to Date:** 3  
e. **Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.**

(15) **Study Objective:** The objective is to participate in the GOG group in the study of malignancies.

(16) **Technical Approach:** See Protocol

(17) **Progress:** One dead of disease, one partial response, one alive with no evidence of disease.

**Publications and Presentations:** None
Date: 30 Sep 88  Protocol WU#: 87/357  Status: Ongoing

Title: Echinocycin in Advanced Pelvic Malignancies
GOG 26W

Start Date:  Est Compl Date:

Principal Investigator:  Facility: FAMC
George L. Phillips, COL, MC

Dept/Svc: OB-GYN  Associate Investigators

Key Words:
pelvic neoplasms

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 0
d. Total Number of Subjects Enrolled to Date: 1
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

Study Objective: The objective is to participate in the GOG group in the study of malignancies.

Technical Approach: See Protocol

Progress: One patient, still receiving therapy, no adverse reactions.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88
(2) Protocol WU#: 87/358
(3) Status: Ongoing

(4) Title: Evaluation of Intraperitoneal Chromic Phosphate After Negative Second-Look Laparotomy in Ovarian Carcinoma

GOG 93

(5) Start Date: 
(6) Est Compl Date: 

(7) Principal Investigator: George L. Phillips, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: OB-GYN

(10) Associate Investigators

(11) Key Words: pelvic neoplasms

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 
    b. Review Results: 
    c. Number of Subjects Enrolled During Reporting Period: 0 
    d. Total Number of Subjects Enrolled to Date: 0 
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing, no patients.
Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 87/359  Status: Ongoing

Title: Adjunctive Radiation Therapy in Intermediate Risk Endometrial Carcinoma
GOG 99

Start Date:  Est Compl Date:

Principal Investigator: George L. Phillips, COL, MC

Facility: FAMC

Dept/Svc: OB-GYN

Associate Investigators

Key Words: pelvic neoplasms

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  Review Results:  Number of Subjects Enrolled During Reporting Period: 0  Total Number of Subjects Enrolled to Date: 0

Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

Study Objective: The objective is to participate in the GOG group in the study of malignancies.

Technical Approach: See Protocol

Progress: Ongoing, no patients.

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 88/350  (3) Status: Ongoing

(4) Title: Radiation Therapy vs No Further Therapy in Selected Patients with Stage IB Invasive Carcinoma of the Cervix

GOG 92

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: George L. Phillips, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: OB-GYN  (10) Associate Investigators

(11) Key Words: pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 0 d. Total Number of Subjects Enrolled to Date: 0 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing, no patients.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 88/351  Status: Ongoing

Title: A Phase II Study of the Treatment of Stage III and IV Disease of Advanced Endometrial Carcinoma and All Stages of Papillary Serious Carcinoma and Clear Cell Carcinoma of the Endometrium with Total Abdominal Radiation Therapy

GOG 94

Start Date:  Est Compl Date:

Principal Investigator: George L. Phillips, COL, MC

Facility: FAMC

Dept/Svc: OB-GYN  Associate Investigators

Key Words:
pelvic neoplasms

Accumulative MEDCASE:*  Est Accum OMA Cost:*  Refer to Unit Summary Sheet of this Report.

a. Date, Latest TRC Review:  b. Review Results:  c. Number of Subjects Enrolled During Reporting Period: 0  d. Total Number of Subjects Enrolled to Date: 0  e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

Study Objective: The objective is to participate in the GOG group in the study of malignancies.

Technical Approach: See Protocol

Progress: Ongoing, no patients.

Publications and Presentations: None
Date: 30 Sep 88  
Protocol WU#: 88/352  
Status: Ongoing  

Title: A Phase II Trial of N-Methylformamide in Patients with Advanced Pelvic Malignancies  
GOG 26V  

Principal Investigator: George L. Phillips, COL, MC  
Facility: FAMC  

Dept/Svc: OB-GYN  
Associate Investigators  

Key Words: pelvic neoplasms  

Study Objective: The objective is to participate in the GOG group in the study of malignancies.  

Technical Approach: See Protocol  
Progress: Ongoing, no patients.  
Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/353  (3) Status: Ongoing

(4) Title: A Phase II Trial of Vinblastine (NSC#049842) in Patients with Advanced Pelvic Malignancies

   GOG 26Y

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: George L. Phillips, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: OB-GYN  (10) Associate Investigators

(11) Key Words:

   pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  

   *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing, no patients.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 88/354  Status: Com

Title:  A Phase II Trial of Cisplatin and 5-FU in Patients with Advanced Cancer of the Cervix

GOG 76G

Start Date:  Est Compl Date:

Principal Investigator:  George L. Phillips, COL, MC

Facility:  FAMC

Dept/Svc: OB-GYN

Associate Investigators

Key Words: pelvic neoplasms

Accumulative MEDCASE:*  Est Accum OMA Cost:*

Date, Latest IRC Review:  Review Results:

Number of Subjects Enrolled During Reporting Period: 0

Total Number of Subjects Enrolled to Date: 0

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

Study Objective: The objective is to participate in the GOG group in the study of malignancies.

Technical Approach: See Protocol

Progress: Completed, one patient still receiving therapy, no adverse effects.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 88/355  Status: Ongoing

Title: Intraperitoneal (SWOG8501) Intraperitoneal Cis-Platinum and Cyclophosphamide IV vs Intravenous Cis-Platinum and Cyclophosphamide IV in Patients with Optimal Stage III Ovarian Cancer

Start Date:  
Est Compl Date:  
Principal Investigator: George L. Phillips, COL, MC

Facility: FAMC

Dept/Svc: OB-GYN

Associate Investigators

Key Words: pelvic neoplasms

Accumulative MEDCASE:*  Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

Study Objective: The objective is to participate in the GOG group in the study of malignancies.

Technical Approach: See Protocol

Progress: Ongoing, no patients.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/356  (3) Status: Ongoing

(4) Title: A Phase II Trial of Mitomycin-C (NSC #26980) in Patients with Advanced Squamous Cell Carcinoma of the Cervix
   GOG 76J

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: George L. Phillips, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: OB-GYN

(10) Associate Investigators

(11) Key Words: pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
   *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:___
    c. Number of Subjects Enrolled During Reporting Period: 0
    d. Total Number of Subjects Enrolled to Date: 0
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

(15) Study Objective: The objective is to participate in the GOG 76J in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing, no patients.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/357  (3) Status: Ongoing

(4) Title: Phase Two Study of the Intraperitoneal Administration of Cisplatin (NSC#119875) and 5-Fluorouracil (NSC#19893) in Residual Ovarian Carcinoma  
GOG 102B

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: George L. Phillips, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: OB-GYN  (10) Associate Investigators

(11) Key Words: pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing, no patients. 
Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 88/359  Status: Ongoing


Start Date:  
Est Compl Date:  

Principal Investigator: George L. Phillips, COL, MC  
Facility: FAMC

Dept/Svc: OB-GYN  
Associate Investigators: Francis J. Major, COL, MC

Key Words:  

Accumulative MEDCASE:*  
Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the GOG group in the study of malignancies.

Technical Approach: See Protocol

Progress: Newly approved study.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/361  (3) Status: Completed

(4) Title: GOG Protocol 26Z - A Phase II Trial of Leuprolide Acetate in Advanced Ovarian Carcinoma

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
George L. Phillips, COL, MC

(9) Dept/Svc: OB-GYN  (10) Associate Investigators
(11) Key Words:
Francis J. Major, COL, MC

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: __________  b. Review Results: __________
c. Number of Subjects Enrolled During Reporting Period: __________
d. Total Number of Subjects Enrolled to Date: __________
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Due to rapid patient accrual this study has been completed.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 78/40X-001 (3) Status: Ongoing

(4) Title: Use of Laboratory Animals (Cats) to Teach Medical Skills

(5) Start Date: 
(6) Est Compl Date: 

(7) Principal Investigator: 
C. Gilbert Frank, LTC, MC

(8) Facility: FAMC

(9) Dept of Pediatrics

(10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* 
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 
   b. Review Results: 
   c. Number of Subjects Enrolled During Reporting Period: 
   d. Total Number of Subjects Enrolled to Date: 
   e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective:

(16) Technical Approach:

(17) Progress: Laboratory exercise in FY 88 was successful in teaching intubation/chest tube placement skills to Pediatric House officer. This remains an excellent model for teaching skills.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 82/403 (3) Status: Ongoing

(4) Title: Rare Tumor Protocol for Childhood Solid Tumor Malignancies, Ancillary
POG 7799

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC
Askold D. Mosijczuk, COL, MC

(9) Dept of Pediatrics (10) Associate Investigators
(11) Key Words: (12) Accumulative MEDCASE:
POG protocol neoplasms

Thomas Carter, COL, MC
Jeffrey Clark, COL, MC
Randal Henderson, MAJ, MC
Vishnu Reddy, LTC, MC
Michael Edwards, CPT, MC

*Refer to Unit Summary Sheet of this Report.

(13) Est Accum OMA Cost:*

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date: 2
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: Two patients have been registered at FAMC, one pt with superficial melanoma of the eye is continuing to do well, in complete remission. The other patient, a newborn with metastatic undifferentiated sarcoma of the face has died. The study remains open for new patient entry.

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 82/407  (3) Status: Terminated
(4) Title: National Wilms' Tumor Study-3 Phase III POG 8000

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
Askold Mosijczuk, COL, MC

(9) Dept/Svc: PED/Hema/Oncol (10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for 
studies conducted under an FDA-awarded IND. May be continued on a 
separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the POG group 
in the study of pediatric malignancies.

(16) Technical Approach: See Protocol

(17) Progress: No patients have been entered at Fitzsimons. The study 
is closed for new patient entry.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 82/414  (3) Status: Ongoing
(4) Title: NWTS Long Term Follow-Up Study: A Non-therapeutic Study

POG 8158

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
Askold Mosijczuk, COL, MC

(9) Dept/Svc: Pediatrics  (10) Associate Investigators

(11) Key Words:
drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the POG group in the study of pediatric malignancies.

(16) Technical Approach: See Protocol

(17) Progress: No patients have been entered at Fitzsimons, the study remains open to new patient registrations.

Publications and Presentations: None
Date: 30 Sep 88
Protocol WU#: 82/420
Status: Ongoing
Title: Intergroup Thabdomyosarcoma Study III
POG 8451

Start Date: 
Est Compl Date:

Principal Investigator:
Askold Mosijczuk, COL, MC

Dept/Svc: Pediatrics
Associate Investigators

Key Words: drug therapy

Accumulative MEDCASE:* 
Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 2
d. Total Number of Subjects Enrolled to Date: 3
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the POG group in the study of pediatric malignancies.

Technical Approach: See Protocol

Progress: Three patients have been entered at FAMC. Two in the current reporting period. The first patient has relapsed with metastatic disease after having completed the prescribed two years of chemotherapy. The patient is still alive. One new patient, who was entered in the past year, achieved a complete remission status of his undifferentiated sarcoma of the pelvis region, but has subsequently died of overwhelming sepsis as a result of severe myelosuppression of the chemotherapy. The other patient who was entered this year with nasopharyngeal rhabdomyosarcoma is currently in complete remission status; however, the patient's parents are refusing further chemotherapy because of toxicity of the drugs. The study remains open to new patient entry.

Publications and Presentations: None
Date: 30 Sep 88  
Protocol WU#: 83/401  
Status: Ongoing

Title: Prevalence of Endometriosis Externa in Adolescent Women Complaining of Severe Dysmenorrhea

Start Date: 1983  
Est Compl Date:

Principal Investigator:  
David W. Wells, COL, MC

Facility: FAMC

Dept of Pediatrics  
Associate Investigators

Key Words:  
endometriosis  
dysmenorrhea

Accumulative MEDCASE:*  
Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  
Review Results:

Number of Subjects Enrolled During Reporting Period:

Total Number of Subjects Enrolled to Date: 622

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

Study Objective: An epidemiologic survey of young women will document the prevalence of symptomatic endometriosis externa in a middle class primary care population of adolescent women complaining of dysmenorrhea. This prevalent figure will tell the health care provider how alert he has to be to this condition.

Technical Approach: This retrospective stage of epidemiologic survey is designed to isolate by questionnaire those young women who might have endometriosis and subject them to laparoscopy.

Progress: No work has been accomplished since FY 85. COL Wells will be the new principal investigator. He will revise the protocol and update the consent form.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 83/402  (3) Status: Ongoing

(4) Title: B₂ Microglobulin as a Measure of Renal Tubular Function in the Neonate

(5) Start Date: 1983  (6) Est Compl Date: 1988

(7) Principal Investigator:
Beverly Anderson, MAJ, MC

(8) Facility: FAMC
St. Louis Children's Hospital
Ronald Portman, MD, U. Texas at Houston
Gerald B. Merenstein, MD, Univ. of Colo. Health Sciences Center

(9) Dept of Pediatrics

(10) Associate Investigators

(11) Key Words:
kidney tubules
natriuretic peptides

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:
    b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date: 38
    e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The purpose of the study is to examine renal handling of low molecular weight proteins in the neonate at various gestational and postpartum ages who manifest evidence of normal or abnormal intrauterine environments as well as extraterine insults. Recent data has shown that these insults can cause previously undiagnosed renal damage.

(16) Technical Approach: We will study the effects of these insults on the neonatal kidney from the standpoint of GFR as well as tubular function. These will both be evaluated in light of the rapid and profound changes in fluid and electrolytes in the first days of life. The protocol continues to be low risk as blood sampling is minimal. The protocol will clearly benefit the patient as renal damage from the aforementioned insults cannot be diagnosed in any other fashion with current technology.

(17) Progress: The laboratory evaluations continue to follow the expected trends, i.e., a change in the Atrial Natriuretic Factor value in newborn infants between days 1 and 3 of life, and the level of B₂ microglobulin expected during this period of time. No new information has come to light since the last approval. No adverse reactions have been reported since the last protocol approval.
Presentations:


(3) Portman, R.J.: B2 Microglobulin as a Measure of Tubular Damage From Meconim Staining of the Amniotic Fluid. Presented: The USFS 1984 - Finalist for the Ogden Bruton Award.


Publications:

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 85/401 (3) Status: Terminated

(4) Title: Evaluation of Adrenocorticotropic Hormone (ACTH) in the Prevention of Cancer Chemotherapy Induced Nausea and Vomiting in Children

(5) Start Date: 1985 (6) Est Compl Date: 

(7) Principal Investigator: (8) Facility: FAMC
Askold D. Mosijczuk, COL, MC

(9) Dept of Pediatrics (10) Associate Investigators
(11) Key Words:
  drug therapy
  adrenal cortex hormones
  corticotropin

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
  *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 
d. Total Number of Subjects Enrolled to Date: 4 
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Evaluate the effectiveness of ACTH in decreasing nausea and vomiting in children undergoing cancer chemotherapy. To evaluate the toxicity of ACTH and thorazine in this setting.

(16) Technical Approach: This will be a multi-center, double blinded, randomized, crossover study with patients serving as their own control. Patients undergoing at least two courses of identical cancer chemotherapy will be randomized at the beginning of the study to receive either of 2 combinations of antiemetics: (a) ACTH with thorazine or (b) placebo with thorazine. Patients will then receive the other combination prior to their next course of chemotherapy. Extent of nausea, vomiting, side effects and patient preference will be measured and compared between the 2 combinations of antiemetics.

(17) Progress: In FY 87 no new patients have been entered on study. Currently, there have been four patients entered on study, one at FAMC, three at Brooke Army Medical Center. Toxicity has been mild and related to side effects of the thorazine, such as drowsiness and dry mouth. There have been no other toxicities noted. Both treatment arms have been well tolerated. A major problem with this study is the difficulty of recruiting eligible patients to receive the treatment arm with ACTH. Also, our further difficulty is that the ACTH is given IM which necessitates three IM
injections. Because of this the study has been discussed with other coordinators at the other institutions with the possibility of modifying the protocol to include IV ACTH. No formal replies have been received. At this point, I request that the protocol be terminated.

Presentations:


Publications: None
Date: 30 Sep 88  (2) Protocol W#: 85/406  (3) Status: Completed

Title: Live Attenuated Oka/Merck Chickenpox Vaccine in Healthy Children in Day Care Centers

Start Date:  
Est Compl Date: 

Principal Investigator: John K. Podgore, COL, MC

Facility: FAMC

Dept/Svc: Pediatrics  
Associate Investigators

Key Words: varicella vaccine

Myron J. Levin, M.D.
U Co. HSC

Study Objective: In order to determine if the live varicella vaccine administered during the study induces sustained immunity comparable to naturally acquired varicella infection. Follow-up blood specimens for antibody determination are requested at approximately 12-16 months and 24-28 months post vaccination.

Technical Approach: See Protocol

Progress: Follow-up was done on 18 subjects. Determination of immunity is pending lab analysis. Full report and results will be submitted when data is analyzed.

Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 86/401 (3) Status: Terminated

(4) Title: Initial Induction Failures in Childhood Acute Lymphoblastic Leukemia, A Group-Wide Pilot Study POG 8461

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC
Askold D. Mosijczuk, COL, MC

(9) Dept of Pediatrics (10) Associate Investigators

(11) Key Words:
   drug therapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date:
    e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: No patients have been entered at FAMC. The study is closed to new patient entry.

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 86/403  (3) Status: Ongoing

(4) Title: Prophylactic Intravenous Immunoglobulin for Infections in High Risk Neonates

(5) Start Date: March 86  (6) Est Compl Date: '989

(7) Principal Investigator: C. Gilbert Frank, LTC, MC

(8) Facility: FAMC

(9) Dept of Pediatrics

(10) Associate Investigators

(11) Key Words:
high risk neonates
prophylactic IVIG

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:  c. Number of Subjects Enrolled During Reporting Period: 4  d. Total Number of Subjects Enrolled to Date: 14  e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate in a double blind manner the effectiveness compared to an albumin placebo of IVIG preventing infectious disease and/or reducing morbidity and mortality in the high risk neonate.

(16) Technical Approach: 2,000g, 34 wks gestation are eligible for the study. Routine evaluations and therapy will be given as necessary to all infants. IgG antibody titers will be drawn pre and post infusion as well as at 1, 2, and 8 weeks. The incidence of infection as well as mortality and morbidity will be evaluated.

(17) Progress: Study is ongoing with entry of patients into study not only at Fitzsimons but in other participating institutions. This is a double-blind placebo controlled multicenter study administered out of Walter Reed. Results not yet available. There continues to be scattered reports of efficacy of human immunoglobulin in prevention of neonatal infection. No adverse reactions or withdrawals.

Date: 30 Sep 88

Protocol WU#: 86/404

Status: Terminated

Title: Intensive Chemotherapy (MOPP-ABVD) plus Low-Dose Total Nodal Radiation Therapy in the Treatment of Stages IIB, III2A, IIIB, IV Hodgkins Disease in Pediatric Patients, A Groupwide Pilot Study

POG 8426

Start Date: [Blank]

Est Compl Date: [Blank]

Principal Investigator: Askold D. Mosijczuk, COL, MC

Facility: FAMC

Dept of Pediatrics

Associate Investigators

Key Words:

drug therapy

Accumulative MEDCASE:*

Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review: [Blank]

Review Results: [Blank]

c. Number of Subjects Enrolled During Reporting Period: [Blank]

d. Total Number of Subjects Enrolled to Date: [Blank]

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

Technical Approach: See protocol

Progress: No patients have been entered at FAMC. The study is closed for new patient entry.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 86/406 (3) Status: Ongoing

(4) Title: Infant Leukemia Protocol, A Group-Wide Pilot Study
POG 8493

(5) Start Date:
(6) Est Compl Date:

(7) Principal Investigator:
Askold Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept of Pediatrics

(10) Associate Investigators

(11) Key Words:
drug therapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:_____
   c. Number of Subjects Enrolled During Reporting Period: _________
   d. Total Number of Subjects Enrolled to Date: _________
   e. Note any adverse drug reactions reported to the FDA or sponsor for
      studying under an FDA-awarded IND. May be continued on a separate sheet,
      and designated as "(l);j".

(15) Study Objective: To participate in the POG protocol in the study of
pediatric malignancies.

(16) Technical Approach: See Protocol

(17) Progress: One pt. was treated according to this protocol at FAMC after
transferring from Brooke Army Medical Center. The child did well until ap-
proximately nine months after diagnosis when she developed progressive
leukemia and subsequently died 10 months from diagnosis. Toxicity was mild
to moderate myelosuppression with no other unusual toxicities. No new
patients have been entered in the past year. The study remains open to new
patient entry.

Publications and Presentations: None
(1) Date: 30 Sep 88  (2) Protocol WU#: 86/407  (3) Status: Terminated

(4) Title: Treatment of Children with Newly Diagnosed Acute Non-Lymphoblastic Leukemia Using High-Dose Cytosine Arabinoside and Etoposide + Azacytidine for Intensification of Early Therapy, POG Pilot Study

POG 8498

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC

Askold Mosijczuk, COL, MC

(9) Dept of Pediatrics  (10) Associate Investigators

(11) Key Words:  drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See Protocol

(17) Progress: No patients have been entered at FAMC. The study is closed to new patient entry.

Publications and Presentations: None
FAMC A.P.R. (RCS' MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 86/408 (3) Status: Ongoing

(4) Title: Laboratory Classification in Acute Lymphoid Leukemia of Childhood (ALinC 14C) Phase III
   POG 8600

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC
   Askold Mosijczuk, COL, MC

(9) Dept of Pediatrics (10) Associate Investigators

(11) Key Words:
   drug therapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
   c. Number of Subjects Enrolled During Reporting Period: 4
   d. Total Number of Subjects Enrolled to Date: 7
   e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See Protocol

(17) Progress: During the past fiscal year, four new patients (CB, CO'N, MP, RE) have been entered on study. Three additional patients at FAMC are on this study, having been entered more than one year ago. One of those patients was entered at Walter Reed and transferred here. Since this is a laboratory classification study, there is no toxicity. The study is ongoing and is open to new pt. entry. One of the patients (MP) entered on study during this past year has a unique ALL phenotype. The patient has markers on T-cell ALL as well as being Philadelphia chromosome positive. This is a new finding in the protocol and in the Pediatric Oncology Group. The study is ongoing and is open to new patient entry.

Publications and Presentations: None

253
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

<table>
<thead>
<tr>
<th>(1) Date:</th>
<th>30 Sep 88</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2) Protocol WU#:</td>
<td>86/409</td>
</tr>
<tr>
<td>(3) Status:</td>
<td>Ongoing</td>
</tr>
<tr>
<td>(4) Title:</td>
<td>ALinC #14 Pharmacology: A Pediatric Oncology Group Non-Therapeutic Study POG 8601</td>
</tr>
<tr>
<td>(5) Start Date:</td>
<td></td>
</tr>
<tr>
<td>(6) Est Compl Date:</td>
<td></td>
</tr>
<tr>
<td>(7) Principal Investigator:</td>
<td>Askold Mosijczuk, COL, MC</td>
</tr>
<tr>
<td>(8) Facility:</td>
<td>FAMC</td>
</tr>
<tr>
<td>(9) Dept of Pediatrics</td>
<td></td>
</tr>
<tr>
<td>(10) Associate Investigators</td>
<td></td>
</tr>
<tr>
<td>(11) Key Words:</td>
<td>drug therapy</td>
</tr>
<tr>
<td>(12) Accumulative MEDCASE:*</td>
<td></td>
</tr>
<tr>
<td>(13) Est Accum OMA Cost:*</td>
<td>Refer to Unit Summary Sheet of this Report.</td>
</tr>
<tr>
<td>(14) a. Date, Latest IRC Review:</td>
<td></td>
</tr>
<tr>
<td>b. Review Results:</td>
<td></td>
</tr>
<tr>
<td>c. Number of Subjects Enrolled During Reporting Period:</td>
<td>4</td>
</tr>
<tr>
<td>d. Total Number of Subjects Enrolled to Date:</td>
<td>6</td>
</tr>
<tr>
<td>e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as &quot;(14)e&quot;.</td>
<td></td>
</tr>
</tbody>
</table>

| (15) Study Objective: | To participate in the POG protocol in the study of pediatric malignancies. |
| (16) Technical Approach: | See Protocol |
| (17) Progress: | The study is ongoing and is open to new patient entry. Six patients at FAMC are currently on this study. Four having been entered in the past fiscal year. This is a pharmacology study designed to measure Methotrexate and red cell folic acid metabolite levels. All six patients remain on study. |

Publications and Presentation.: None
Date: 30 Sep 88  Protocol WU#: 867410  Status: Ongoing

Title: ALinC #14: Evaluation of Treatment Regimens in Acute Lymphoid Leukemia of Childhood (ALinC#14) - A Pediatric Oncology Group Phase III Study

POG 8602

Start Date:  Est Compl Date:

Principal Investigator: Askold Mosijczuk, COL, MC

Dept of Pediatrics

Key Words: drug therapy

Accumulative MEDCASE:*  Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  b. Review Results:  c. Number of Subjects Enrolled During Reporting Period: 3  d. Total Number of Subjects Enrolled to Date: 5  e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

Technical Approach: See Protocol

Progress: There are currently five patients on this study. Three of whom (CB, CO'N, and RE) who were entered in the past fiscal year. One of the five patients on study were entered at Walter Reed and transferred to FAMC. This patient has subsequently transferred to Roswell Park Memorial Institute in Buffalo, New York. A previous patient diagnosed at FAMC has subsequently been transferred to Travis Air Force Base and continues on protocol with information being related periodically to principal investigator at Fitzsimons. Significant toxicity in two of the five patients has included severe myelosuppression, septicemia in one patient, secondary to high-dose Methotrexate and high-dose Ara-C chemotherapy as per protocol. Otherwise, patients are tolerating therapy well and all remain in complete remission status on treatment. The study remains open for new patient entry.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 86/411  Status: Terminated

Title: Diagnosis and Therapy of Glomerular Hyperfiltration in Pediatric Patients with Type I Diabetes Mellitus

Start Date: 1988  Est Compl Date: 1988

Principal Investigator: Robert H. Slover, LTC, MC

Facility: FAMC

Dept/Svc: Pediatrics

Associate Investigators
Ronald J. Portman, MAJ, MC
Kerry R. Johnson, CPT, MC
Charlotte Stahl, RD

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*  Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: 20 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: Principal Investigator did not fill in.

Technical Approach: Principal Investigator did not fill in.

Progress: We enrolled 20 patients, and were unable to gain statistically significant data. We found the study impossible to perform with adequate precision without a CRC and committed personnel. Patient compliance was low and dropout rate was high. It has become apparent that we will be unable to bring enough patients accurately through the entire study to provide meaningful information.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 86/412 (3) Status: Terminated

(4) Title: Adolescent Oral Contraceptive Study: A Comparison of a Triphasic Formulation (Triphasil) with a Fixed-Combination Pill (Ortho-Novum 1/35)

(5) Start Date: 1986 (6) Est Compl Date: 1988

(7) Principal Investigator: Charles S. Horn, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: PED/Adol. Med. (10) Associate Investigators

David W. Wells, COL, MC
CPT Schaffrinna

(11) Key Words: oral contraceptives comparison

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 60 d. Total Number of Subjects Enrolled to Date: 60 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Compare the clinical usefulness of a triphasic oral contraceptive with a standard, fixed-combination, low-dose pill in an adolescent patient population.

(16) Technical Approach: Patients that agree to enter the study will be randomized by the pharmacy into one of two groups: a) Triphasil and b) Ortho-novum 1/35. An induction questionnaire and physical will be obtained. Subsequent at 1, 3 and 6 month intervals the patients will be contacted and further information obtained. If the patient decides to discontinue pill use a discontinuation form will be filled out.

(17) Progress: Compliance was one of the greatest difficulties encountered. Even so, I was able to partially complete over 30 subjects. This information was sent to Dr. Horn for his evaluation. Unfortunately, the study had to be terminated after an error in the pharmacy was uncovered. Apparently, a substitute during illness gave out pills not in keeping with the randomization protocol. This invalidated a number of subjects.

Publications and Presentations: None

25
Date: 30 Sep 88  (2) Protocol WU#: 87/400  (3) Status: Terminated

Title: Pilot Protocol for Marrow Relapse on Continuation Therapy in Childhood Acute Lymphoblastic Leukemia

POG 8594

Start Date:  Est Compl Date:

Principal Investigator:  Facility: FAMC
Askold D. Mosijczuk, COL, MC

Dept/Svc: PED/Hema/Oncol  Associate Investigators

Key Words: drug therapy

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the POG group in the study of pediatric malignancies.

Technical Approach: See Protocol

Progress: No patients have been entered at Fitzsimons. The study is closed to new patient entry.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/401  (3) Status: Ongoing

(4) Title: Combined Therapy and Restaging in the Treatment of Stages I, IIA, and IIIA Hodgkins Disease in Pediatric Patients, A Pediatric Oncology Group Phase III Study
POG 8625/26

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
Askold D. Mosijczuk, COL, MC

(9) Dept/Svc: PED/Hema/Oncoi  (10) Associate Investigators

(11) Key Words:  drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IPC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 1 
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the POG group in the study of pediatric malignancies.

(16) Technical Approach: See Protocol

(17) Progress: One patient was entered at FAMC in the last fiscal year. The patient achieved complete remission status and is currently doing well, receiving radiation therapy as per protocol. No toxicities have been encountered. The study remains open to new patient entry.

Publications and Presentations: None

259
Title: Randomized Phase II Study of Carboplatin (CBCDA) vs. CHIP in Treatment of Children with Progressive or Recurrent Brain Tumor

POG 8638

Facility: FAMC

Principal Investigator: Askold D. Mosijczuk, COL, MC

Dept/Svc: PED/Hema/Oncol

Associate Investigators

Key Words: drug therapy

Study Objective: The objective is to participate in the POC group in the study of pediatric malignancies.

Technical Approach: See Protocol

Progress: One patient, a twelve-year-old girl with recurrent pontine glioma was entered on this study in November of 1986. The patient is currently off chemotherapy, doing well with stable disease. Toxicity has been limited to moderate myelosuppression. The study is open to new patient entry.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/404  (3) Status: Ongoing

(4) Title: A Study of Childhood Soft Tissue Sarcomas (STS) Other than Rhabdomyosarcoma and Its Variants, A Pediatric Oncology Group Phase III Study

POG 8653/54

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
Askold D. Mosijczuk, COL, MC

(9) Dept/Svc: PED/Hema/Oncol  (10) Associate Investigators

(11) Key Words:
  drug therapy

(12) Accumulative MEDCASE:*

(13) Est Accum OMA Cost:*
  *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 
    b. Review Results: 
    c. Number of Subjects Enrolled During Reporting Period: 
    d. Total Number of Subjects Enrolled to Date: 
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the POG group in the study of pediatric malignancies.

(16) Technical Approach: See Protocol

(17) Progress: No patients have been entered at Fitzsimons. The study remains open to new patient entry.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/405  (3) Status: Ongoing

(4) Title: Front Loading Chemotherapy in Children with Increased Medulloblastoma

POG 8695

(5) Start Date:  (6) Est Compl Date: 

(7) Principal Investigator:
Askold D. Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: PED/Hema/Oncol  (10) Associate Investigators

(11) Key Words:
drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: ________ b. Review Results: ________
c. Number of Subjects Enrolled During Reporting Period: ________
d. Total Number of Subjects Enrolled to Date: ________
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the POG group in the study of pediatric malignancies.

(16) Technical Approach: See Protocol

(17) Progress: One patient was entered at FAMC in April of 1987. The patient suffered severe grade IV myelosuppression secondary to the high-dose Cyclophosphamide as per protocol but recovered. However, during subsequently radiation therapy, the patient developed severe bone marrow hypoplasia lasting for two months but eventually recovered and refused further radiation therapy. He is currently off study, and is alive and is followed at the VA Hospital. The patient achieved at least stable disease status. Nationally, 17 patients have been entered on protocol. Ten patients are evaluable for response. Of these, the following post chemotherapy responses have been documented prior to radiation therapy: CR 2 patients, PR 4 patients, SD (stable disease) 2 patients, progressive disease 2 patients. Most important toxicity has been severe myelosuppression due to the high dose Cyclophosphamide which is expected. Although there have been 2-3 week delays in radiation therapy because of the myelosuppression, most patients have been able to complete chemotherapy and radiation as intended. The study remains open to new patient entry.

Publications and Presentations: Dr. Mosijczuk presented an update on the status of the study at the semi-annual Pediatric Oncology Group Meeting in St. Louis, Missouri in October of 1987.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/406  (3) Status: Ongoing

(4) Title: Effects of Oral Contraceptive Agents on Coagulation Parameters in the Adolescent Patient

(5) Start Date:  (6) Est Compl Date: 

(7) Principal Investigator: 
Patrice T. Gaspard, MAJ, MC
Vishnu Reddy, LTC, MC
Judy Barber, DAC
Patricia Rush, DAC

(8) Facility: FAMC

(9) Dept/Svc: PED/Adolescent Med.  (10) Associate Investigators

(11) Key Words:
oral contraceptive agents
thromboembolic disorders
clotting factors

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:      b. Review Results:      
c. Number of Subjects Enrolled During Reporting Period:  11      
d. Total Number of Subjects Enrolled to Date:  29      
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To assess if the newer oral contraceptive agents used today have effects on the levels of clotting factors in adolescent patients (specifically Factor VIII, PT, PTT, fibrinogen, Antithrombin III, and protein C).

(16) Technical Approach: Patients have the above studies measured at baseline, then 3 months, 6 months and one year after being on oral contraceptives.

(17) Progress: Twenty-nine subjects enrolled; eleven withdrawals, specimens on ice frozen and batched to run by Coagulation Laboratory. No results yet.
Publications and Presentations: None

263
Study Objective: Determine prevalence, type and sex distribution of headaches in adolescents.

Technical Approach: Patients will be given the opportunity to fill out a headache questionnaire when they arrive at the adolescent medicine clinic. Questions were designed to evaluate any headache complaint according to type i.e., migrainous, muscle contraction (tension) or other. The data will then be evaluated to arrive at some demographic information.

Progress: As recommended by the IRC a control trial of the questionnaire was started shortly after approval of the study. After 50 patients enrolled the questionnaire and results were analyzed and questions clarified where necessary or deleted. Current questionnaire began in July and results thus far are good. Of note is the presence of light headedness/dizziness in patients with tension headache. This has to my knowledge not been reported before. I am awaiting higher numbers before this finding will be as significant. FY 87 - finding a large number of patients are not aware that we can aid them with headaches. No adverse reactions.

Publications and Presentations: None
Date: 30 Sep 88 (2) Protocol W0#: 87/408 (3) Status: Ongoing

(4) Title: Efficacy of Prophylactic Anti-Migraine Therapy in the Adolescent Therapy Patient - A Double Blinded Study

(5) Start Date: 

(6) Est Compl Date: 

(7) Principal Investigator: Sharon Freeman, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: PED/Adolescent Med. 

(10) Associate Investigators

MAJ Miller, MD

LTC Dorsett, MD

Michael G. Schaffrinna, CPT, MC

(11) Key Words: migraine headaches verapamil

(12) Accumulative MEDCASE: *

*Refer to Unit Summary Sheet of this Report.

(13) Est Accum OMA Cost: *

(14) a. Date, Latest IRC Review: 

b. Review Results: 

c. Number of Subjects Enrolled During Reporting Period: 

d. Total Number of Subjects Enrolled to Date: 

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Determine efficacy of prophylactic verapamil in a double blinded study in adolescent migraine sufferers. At the same time this study would establish a per kilogram dose for younger adolescents.

(16) Technical Approach: Patients will be evaluated at entry for the diagnosis of migraine headaches with a frequency per history of at least two events per month. Presence of organic disease will be evaluated via physical and laboratory evaluation. If no contraindications to verapamil exist then enrollment will occur. Over the next two months no medications will be given. The patient will see two different neurologists who will again evaluate them and fill out an interval history sheet. If both concur with the diagnosis, the patient will be randomly assigned by the pediatric pharmacy to receive either verapamil or placebo for two months. The patient will be seen every month for evaluation of therapy. At the end of two months, they will have a 7 day washout period. Then they will take the counterpart placebo or verapamil depending on which they were initially assigned. They will again take the drug for two months at which time the study will be completed.

(17) Progress: After notification of HSC approval, the problem of packaging placebo and active ingredient arose. I was able to locate a manufacturer of opaque capsules. Study is now able to proceed.

Publications and Presentations: None
Date: 30 Sep 88

Protocol WU#: 88/400

Status: Ongoing

Title: T Cell#3 Protocol - A Pediatric Oncology Group Phase Study

POG 8704

Start Date: Dec 1987

Est Compl Date: 1990

Principal Investigator:
Askold D. Mosijczuk, COL, MC

Facility: FAMC

Dept/Svc: Pediatrics

Associate Investigators
B. Vishnu Reddy, LTC, MC
Randal Henderson, MAJ, MC
John M. Bodlien, CPT, MS

Key Words:
T cell ALL

Accumulative MEDCASE:* (Refer to Unit Summary Sheet of this Report.)

Est Accum OMA Cost:*

Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

Technical Approach: See protocol

Progress: The one patient entered at FAMC (MP) is an eight-year-old girl who presented with an extremely high white count at diagnosis (852,000) and was found to have T-cell ALL. The patient responded well to initial leukopheresis and chemotherapy according to protocol. She is currently in complete remission, continuing treatment on study. Toxicity has been the expected severe myelosuppression; however, the patient has had no life threatening toxicities or any episodes of septicemia. The study remains open for new patient entry.

Publications and Presentations: None

266
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/401  (3) Status: Ongoing

(4) Title: Stage D NBL #3: Treatment of Stage D Neuroblastoma in Children > 365 Days at Diagnosis

POG 8741/42

(5) Start Date: Dec 1987  (6) Est Compl Date: 1990

(7) Principal Investigator:

Askold D. Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators

B. Vishnu Reddy, LTC, MC
Randal Henderson, MAJ, MC
John M. Bodlien, CPT, MS
Jeffrey R. Clark, COL, MC

(11) Key Words:
treatment of stage D neuroblastoma

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:______  b. Review Results:______
c. Number of Subjects Enrolled During Reporting Period:______
d. Total Number of Subjects Enrolled to Date:______
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: No patients have been entered at FAMC on this study. The study remains open for patient entry.

Publications and Presentations: None

267
Date: 30 Sep 88  
Protocol WU#: 88/402  
Status: Ongoing

Title: The Effectiveness of Phase II Agents in Untreated Metastatic Osteosarcoma (MOS) or Unresectable Primary Osteosarcoma vs Previously Treated Recurrent Osteosarcoma

Principal Investigator: Askold D. Mosijczuk, COL, MC

Facility: FAMC

Dept/Svc: Pediatrics

Associate Investigators
B. Vishnu Reddy, LTC, MC  
David Hahn, LTC, MC  
John M. Bodlien, CPT, MS  
Jeffrey R. Clark, COL, MC

Key Words: phase II agents in untreated or recurrent osteosarcoma

Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

Technical Approach: See protocol

Progress: No patients have been entered at FAMC on this study. The study remains open for patient entry.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/403  (3) Status: Ongoing

(4) Title: Evaluation of Response and Toxicity of Ifosfamide and VP-16-213 in Children with Resistant Malignant Tumors

POG 8763

(5) Start Date: Dec 1987  (6) Est Compl Date: 1990

(7) Principal Investigator: Askold D. Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics  (10) Associate Investigators

John M. Bodlien, CPT, MS

(11) Key Words: ifosfamide VP-16

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: 1 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". ONE PATIENT WAS STARTED ON TREATMENT ACCORDING TO PROTOCOL ON A COMPASSIONATE BASIS FROM THE NCI. HE IS NOT OFFICIALLY ENTERED ON PROTOCOL.

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: No patients have officially been entered at FAMC on this study. One patient is being treated according to protocol on a compassionate basis on a one time basis.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88         (2) Protocol WU#: 88/404         (3) Status: Ongoing

(4) Title: Ceftriaxone vs Amoxicillin/Clavulanate for Initial Empirical Therapy of O:cult Bacteremia in Children

(5) Start Date:             (6) Est Compl Date:

(7) Principal Investigator:   (8) Facility: FAMC
    Frederic W. Bruhn, COL,MC

(9) Dept/Svc: Pediatrics     (10) Associate Investigators
    John K. Podgore, COL, MC

(11) Key Words:

(12) Accumulative MEDCASE:*
     *Refer to Unit Summary Sheet of this Report.

(13) Est Accum OMA Cost:

(14) a. Date, Latest IRC Review: ____________
    b. Review Results: ___________
    c. Number of Subjects Enrolled During Reporting Period: ___________
    d. Total Number of Subjects Enrolled to Date: 1
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine if one of the antibiotic regimens used for the empirical therapy of occult bacteremia will be more effective in preventing serious complications.

(16) Technical Approach:


Publications and Presentations:

270
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/405  (3) Status: Ongoing

(4) Title: Macromolecular Absorption in the Post-Asphyxiated Small Intestine of the Adult Rat

(5) Start Date:  
(6) Est Compl Date:  

(7) Principal Investigator:  Kevin J. Kelly, MAJ, MC  
(8) Facility: FAMC

(9) Dept/Svc: Pediatrics  (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: This protocol will attempt to demonstrate the mechanism of movement of whole protein macromolecules through small intestinal absorptive cells which have been subjected to an asphyxiial injury.

(16) Technical Approach:

(17) Progress: This protocol will not come up for continuing review until January 1989. Principal investigator will submit report next FY.

Publications and Presentations:

271
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 88/406  (3) Status: Ongoing

(4) Title: Efficacy of Methylphenidate in Previously Undiagnosed Adolescents with Attention Deficit Disorders

(5) Start Date: [ ]  (6) Est Compl Date: [ ]

(7) Principal Investigator: Joan R. Griffith MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators
     Bradford Miller, MAJ, MC
     Linda O. Ikle, Ph.D.

(11) Key Words: [ ]

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
     *Refer to Unit Summar: Sheet of this Report.

(14) a. Date, Latest IRC Review: [ ]  b. Review Results: [ ]
     c. Number of Subjects Enrolled During Reporting Period: [ ]
     d. Total Number of Subjects Enrolled to Date: [ ]
     e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objectives of this study is to demonstrate the efficacy of methylphenidate in adolescents with learning problems in school accompanied by attention deficit disorders but previously undiagnosed or untreated in childhood.

(16) Technical Approach:

(17) Progress: This protocol will not come up for continuing review until August 1989. Principal investigator will submit report next FY.

Publications and Presentations:

272
Title: Comparison of Growth Response of Growth Hormone Deficient Children to Two Commercially Available Preparations of Growth Hormone

Start Date: 30 Sep 88
Est Compl Date: 

Principal Investigator: Robert H. Slover, LTC, MC

Associate Investigators:

Key Words:

Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: In a randomized double-blind crossover study, growth response of growth hormone deficient children to two commercially available growth hormone preparations in equal doses will be compared to determine if there is any significant difference in growth response between the two. Growth hormone antibodies will be measured to determine if there is any significant difference in antigenicity.

Technical Approach:

Progress: This protocol will not come up for continuing review until March 1989. Principal investigator will submit report next FY.
Date: 30 Sep 88  (2) Protocol WU#: 88/408  (3) Status: Ongoing

Title: The Effect of Human/Animal Interaction on Stress Levels During Outpatient Pediatric Oncology Visits

Start Date:  (6) Est Compl Date:

Principal Investigator:  (8) Facility: FAMC
Mary Woolverton, MSW
James J. Elliott, CPT, VC

Dept/Svc: Pediatrics  (10) Associate Investigators

Key Words:

Key Words:

Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  Review Results:  Number of Subjects Enrolled During Reporting Period:  Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: a. Does the presence and interaction with animals during outpatient treatment visits have any measurable effect on the patient's stress level as measured by blood pressure and fingertip temperature; b. Does the presence and interaction with animals during outpatient treatment visits have any measurable effect on the patient's anxiety level (as measured by behavioral questionnaires) or discomfort (as measured by the visual analog pain scale).

Technical Approach:

Progress: This protocol will not come up for continuing review until May 1989. Principal investigator will submit report next FY.

Publications and Presentations:
DENTAL ACTIVITIES
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 87/550 (3) Status: Terminated

(4) Title: Effect of Salivary Function on Oropharyngeal Bacterial Colonization

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: Dan Prucha, COL, DDS
    Cheri A. Crane, DDS

(8) Facility: FAMC

(9) Dept/Svc: Dental Activities  (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date:
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The primary objective is to determine the relationship between oropharyngeal Gram-negative bacterial colonization and salivary dysfunction in medically compromised, elderly, and control patients.

(16) Technical Approach: The data collection instrument consists of four major parts: (1) an interview with medical questionnaire; (2) a brief oral health assessment; (3) a parotid salivary collection; and (4) two bacterial throat cultures. The populations to be evaluated include patients from: VAMC geriatric evaluation unit; outpatients of VAMC geriatric clinic; VAMC NHCU and FAMC healthy outpatients.

(17) Progress: This protocol was under evaluation for funding. Funding was not approved for this study, terminate study.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 80/602  Status: Ongoing

Title: I.V. Administration of 131-I-6-B Iodomethylnorcholesterol (NP-59) for Adrenal Evaluation and Imaging

Start Date: 1980  Est Compl Date: Indefinite

Principal Investigator: Peter W. Blue, COL, MC

Facility: FAMC

Dept of Radiology/Nuc.Med.

Key Words:
adosterone
adrenal glands

Accumulative MEDCASE:*  Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: Sep 87  b. Review Results: Ongoing
  c. Number of Subjects Enrolled During Reporting Period: None
  d. Total Number of Subjects Enrolled to Date: approx. 30
  e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: Clinical evaluation of NP-59 as a diagnostic agent for the detection of adrenal cortical disorders and as a potential scanning agent for detecting structural abnormalities of the adrenal medulla.

Technical Approach: Each patient will be studied while taking Lugol's or SSKI to protect thyroid. Some patients will have adrenal function suppressed with Dexamethasone. Following a 2 millicurie dose of NP-59, each patient will be scanned at day 3 and possibly day 5 and 7.

Progress: No studies were performed this period.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 84/601  (3) Status: Completed

(4) Title: An Evaluation of Computed Tomography of the Chest in Changing the Stage or Treatment of Patients with Hodgkin's Disease

(5) Start Date: 1984  (6) Est Compl Date: 1988

(7) Principal Investigator: Kenneth D. Hopper, MAJ, MC  (8) Facility: FAMC WRAMC

(9) Dept of Radiology  (10) Associate Investigators

(11) Key Words:
    - tomography
    - hodgkin's disease

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: 
    c. Number of Subjects Enrolled During Reporting Period: 19 
    d. Total Number of Subjects Enrolled to date: 107 
    e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate the routine use of chest CT/C in the initial staging and evaluation of patients with newly diagnosed Hodgkin's Disease.

(16) Technical Approach: All patients newly diagnosed with Hodgkin's Disease both at FAMC and at WRAMC are requested to enter the study. If they agree, a chest CT will be obtained, even if there is a normal chest x-ray. The chest x-ray is evaluated using form A by one investigator (ML) without knowledge of the CT. The chest CT is evaluated by one investigator (KH) with the use of the chest x-ray. The results are entered on Form B. The two forms are compared and compared to the patients clinical data on Form C.

(17) Progress: Completed.

279
Presentations:


Publications:


(2) Abstract on presentation #3 above to be published December 1987.

Date: 30 Sep 88  (2) Protocol WU#: 88/600  (3) Status: Ongoing

Title: a. The Usefulness of MRI and Transrectal Ultrasound in the Staging of Prostatic Cancer: Comparison to 1mm Whole Gland Mounts. b. Artifacts and Variants of the Normal Prostate Seen by MRI and Transrectal Ultrasound: Comparison to 1mm Whole Gland Mounts

Start Date: (6) Est Compl Date:

Principal Investigator: Kenneth D. Hopper, MAJ, MC  
Daniel Horne, LTC, MC  
David Thickman, MD  
Gary Miller, MD  
Gail Weingast, MD  
Michael Manco-Johnson, MD

Facility: FAMC

Associate Investigators: Michael Raife, LTC, MC  
Edward Pienkos, LTC, MC  
Steve Parker, MAJ, MC  
Merlyn Gibson, MAJ, MC  
Jerry Sims, LTC, MC

Dept of Radiology  (9) Key Words: Edward Pienkos, LTC, MC  
Steve Parker, MAJ, MC  
Merlyn Gibson, MAJ, MC  
Jerry Sims, LTC, MC

Accumulative MEDCASE:* (12) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

Study Objective: Within the past two years, the usefulness of transrectal ultrasound and MRI in the diagnosis and staging of prostatic cancer has been well demonstrated. There are numerous artifacts and variants within the prostate as seen with these two modalities, however, which are poorly understood. In addition, no study evaluating the efficacy of transrectal ultrasound and MRI in prostate cancer has compared the radiographic findings with histological mounts of the entire gland. We intend to correlate the results of the MRI and transrectal ultrasound to 1mm whole gland mounts in order to better understand the aforementioned artifacts/variants as well as tumor extension.

Technical Approach:

Progress: This protocol will not come up for continuing review until March 1989. Principal investigator will submit report next FY.

Publications and Presentations: None
Date: 30 Sep 88  
Protocol WU#: 88/601  
Status: Ongoing

Title: Body Fat Determination by Dual Photon Absorptiometry

Start Date: 1988  
Est Compl Date: Indefinite

Principal Investigator: Peter W. Blue, COL, MC

Facility: FAMC

Dept of Radiology/Nuc.Med.

Associate Investigators
Harry N. Tyler, Jr.

Key Words:
absorptiometry  
body fat

Accumulative MEDCASE:*  
Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: approx.  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To evaluate body fat composition by absorptiometry and other current modalities.

Technical Approach: Each patient will be studied by four methods and the methods compared.

Progress: Study not yet started due to lack of funding.

Publications and Presentations: None
DEPARTMENT OF PRIMARY AND COMMUNITY MEDICINE
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 74/651  (3) Status: Completed

(4) Title: Establishment of and Training in Methods for Special Studies of Abnormal Hemoglobins and Red Cell Metabolism

(5) Start Date: 1974  (6) Est Compl Date: Indefinite

(7) Principal Investigator: Nicholas C. Bethlenfalvay, MD

(8) Facility: FAMC

(9) Dept of Primary Care

(10) Associate Investigators

Joseph Lima, DAC
Ian Stewart, DAC
Elwyn Chadwick, SSG, USA

(11) Key Words: hemoglobin, abnormal

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: ______  b. Review Results: ______
    c. Number of Subjects Enrolled During Reporting Period: ______
    d. Total Number of Subjects Enrolled to Date: ______
    e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To establish and conduct training in methods for special studies of abnormal hemoglobins.

(16) Technical Approach: To acquaint and to train existing personnel in the performance of various procedures as they pertain to biochemical study of hemoglobins and red cell enzymes involved in hemoglobin function.

(17) Progress: There have been no patients referred from the Pediatric and Adult Hematology services.
Presentations: None 

Publications:


FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: 80/650 (3) Status: Ongoing

(4) Title: Studies of Hemoglobin and Red Cell Metabolism in the Opossum Didelphis virginana

(5) Start Date: 1980 (6) Est Compl Date: Indefinite

(7) Principal Investigator: Nicholas C. Bethlenfalvay, MD

(9) Dept of Primary Care (10) Associate Investigators

(11) Key Words: opossums erythrocytes purine metabolism glucose metabolism

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to investigate/define the energy metabolism in red cells.

(16) Technical Approach: Red cells provided with metabolizable substrates and radiolabelled purine ribo and deoxyribonucleosides are extracted and the metabolic trail of the provided material is quantitatively defined by HPLC/radiochromatography.

(17) Progress: It was found, that unlike in human but similar to rabbit, Hypoxanthine and formate is readily incorporated into adenine nucleotides including ATP. As a novel finding, half-millimolar levels of deoxy ATP were found to be present in opossum RBC, which also contain low adenosine deaminase activity.
Publications:


(10) Bethlenfalvay NC, Lima JE, Chadwick E: Studies on the energy metabolism of opossum Didelphis virginiana Erythrocytes-IV. Half-Millimolar levels of deoxy adenosine triphosphate in red cells are found associated with low adenosine deaminase acitvity. (Submitted for publication, Life Sciences, September 1988).
Date: 30 Sep 88
Protocol WU#: 87/650
Status: Ongoing

Title: Clonal Fidelity of Erythroid Lineage in Dyserythropoiesis: An Inquiry Into Ultrastructure

Start Date: July 1987
Est Compl Date: Indefinite

Principal Investigator:
N.C. Bethlenfalvay, DAC, MD
V.V. Reddy, LTC, MC

Dept/Svc: Primary Care

Associate Investigators
C.F. Ferris, CPT, MS
D.B. Mercill, DAC

Key Words:
dyserythropoiesis
ultrastructure
x-ray microanalysis

Accumulative MEDCASE:* (Est Accum OMA Cost:*)
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:
Review Results:
Number of Subjects Enrolled During Reporting Period:
Total Number of Subjects Enrolled to Date:
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To investigate the aspects of ultrastructural components of erythroid precursors to include elemental composition of these components for determination of their role on erythroid maturation, morphology, the process of erythroid denucleation, and functional differentiation in various dyserythropoietic states.

Technical Approach: Burst forming erythroid colonies will be grown in semi-solid tissue-culture media. Bursts will be isolated, fixed, embedded and evaluated by electron microscopy and concurrent x-ray microanalysis of metallic cellular inclusions.

Progress: Difficulties were experienced in obtaining bursts of sufficient size for study. Funding freeze precluded obtaining material needed for an alternate growth medium. Study will resume after lifting of funding freeze.

Publications and Presentations: None
DEPARTMENT OF NURSING
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#: 86/700A  (3) Status: Ongoing

(4) Title: Introduction to Suturing Techniques Using Outbred Adult Rats

(5) Start Date:  (6) Est Compl Date: Indefinite

(7) Principal Investigator:  (8) Facility: FAMC
Sandrah W. Johnson, COL, AN
Chief, Dept of Nursing

(9) Dept of Nursing  (10) Associate Investigators
(11) Key Words: Suture Techniques Training
LTC Lawrence A. Hamer, AN
SGT Carol West, USA

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period: 17
    d. Total Number of Subjects Enrolled to Date: 84
    e. Note any adverse drug reactions reported to the FDA or sponsor for
       studying under an FDA-awarded IND. May be continued on a separate sheet,
       and designated as "(14)e".

(15) Study Objective: To instruct selected Department of Nursing personnel
    to properly suture traumatic lacerations, to establish and maintain a
    sterile field during the suturing procedure, to cleanse traumatic lacer-
    ations, to instruct the patient to manage the wound and facilitate healing,
    and to correctly remove suture when healing is complete.

(16) Technical Approach: Following didactic instruction by Ambulatory Nurs-
    ing Service personnel and demonstration/return demonstration of suturing
    techniques by Animal Research Laboratory staff, students are detailed to
    perform at least 1 successful suturing episode under direct supervision of
    an Emergency Medical Service staff physician to validate learning and
    clinical competence. Once certified, suturing activities become a part of
    the staff members' scopes of nursing practice. Skills are revalidated an-
    nually to ensured continued competence.

(17) Progress: To date, certified personnel have successfully performed
    numerous suturing episodes without incident. Therefore, the program ap-
    pears to be meeting its primary objectives.

Publications and Presentations: None
(1) Date: 30 Sep 88 (2) Protocol WU#: 88/700 (3) Status: Ongoing

(4) Title: A Study of the Clinical Nurse Specialist in the AMEDD

(5) Start Date: 1988 (6) Est Compl Date: 1989

(7) Principal Investigator: A.J. Frelin, COL, AN

(8) Facility: FAMC

(9) Dept/Svc: Nursing

(10) Associate Investigators
    Nancy Staggers, MAJ, AN
    Ass. Prof., School of Nursing
    Univ. of California

(11) Key Words:
    role development
    role

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cst:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date:
    e. Note any adverse drug reactions reported to the FDA or sponsor for
       studies conducted under an FDA-awarded IND. May be continued on a
       separate sheet, and designated as "(14)e".

(15) Study Objective: The purpose of this descriptive study is to ex-
    plore the role of the clinical nurse specialist (CNS) as implemented by
    the ANC from the perspective of the CNSs now in practice as well as the
    Nurse Managers where the roles are or could be implemented. (a) to
describe the role of the CNS in HSC from the perspective of the practic-
ing CNSs; (b) to describe the role of the CNS in HSC as perceived by ANC
officers who rate/senior rate them and by Chiefs of Nursing Departments;
(c) to compare the perceptions of these groups regarding role
implementation; (d) to describe a normative profile of the ANC officer
practicing in the CNS role and (e) to assess potential for the future
implementation of this specialty in the ANC.

(16) Technical Approach: Each group will be surveyed using a written
    mailed survey instrument constructed for this purpose. Data analysis
    will be directed to describing the role and the normative characteris-
tics of those practicing in the role.

(17) Progress: Surveys have been distributed to practicing CNSs and
    their raters/senior raters. Collection is estimated to be completed by
    30 Sep 88 with analysis to follow.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

<table>
<thead>
<tr>
<th>1. Date:</th>
<th>30 Sep 88</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Protocol WU#:</td>
<td>83/902</td>
</tr>
<tr>
<td>3. Status:</td>
<td>Ongoing</td>
</tr>
<tr>
<td>4. Title:</td>
<td>Training Study, Emergency Medical Procedures</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Start Date:</td>
<td>1982</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Est Compl Date:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Principal Investigator:</td>
<td>Martin Artman, MAJ, MC</td>
</tr>
<tr>
<td>8. Facility:</td>
<td>FAMC</td>
</tr>
<tr>
<td></td>
<td>Ft. Carson Veterinary Activity and Ft. Carson MEDDAC Emergency Medical Service AV 691-7226/7111</td>
</tr>
<tr>
<td>10. Associate Investigators</td>
<td>Michael Sugg, MAJ, MC</td>
</tr>
<tr>
<td>11. Key Words:</td>
<td>emergency medical services</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12. Accumulative MEDCASE:*</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>*Refer to Unit Summary Sheet of this Report.</td>
<td></td>
</tr>
</tbody>
</table>

| 14. a. Date, Latest IRC Review: |          |
| b. Review Results:              |          |
| c. Number of Subjects Enrolled During Reporting Period: | 75 |
| d. Total Number of Subjects Enrolled to Date:              | 75 |
| e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". |

| 15. Study Objective: | This project is a refresher/teaching course in Emergency Medicine operative procedures. It is conducted on a monthly basis for EMS physicians and PA's. |
| 16. Technical Approach: | Under general anesthesia animals are subjected to common emergency medicine operative procedures including venous cutdown, peritoneal lavage, chest tube insertion, and thorocotomy with aortic cross clamp with cardiac laceration repair. At the end of the exercise, the animals are disposed of by lethal injection. |
| 17. Progress: | Held 7 training exercises since September 1987. No animals were available until Feb 1988 due to reductions in animal acquisition. Have had animal lab monthly since Feb 1988 except July 1988. Have enrolled 75 attendees. All attendees report increased procedural skill levels after participation. COL Mark Larsen will replace MAJ Artman as the Principal Investigator. The Associate Investigator will remain the same. |

Publications and Presentations: None

293
| (1) Date: | 30 Sep 88 | (2) Protocol WU#: | 87/900 | (3) Status: Ongoing |
| (4) Title: | Serological Assessment of Lyme Disease Among Soldiers Training at Fort McCoy, Sparta, Wisconsin |
| (5) Start Date: | | (6) Est Compl Date: | 1988 |
| (7) Principal Investigator: | Michael W. Hastriter, MAJ, MC | (8) Facility: | FAMC Fort Leonard Wood, MO 65473-5700 Preventive Medicine Service A-581-9471 |
| (9) Dept/Svc: | US Army MEDDAC | (10) Associate Investigators | Kim Mello, DAC, Fort McCoy, Sparta, WI Paul H. Duray, MD, Yale Univ. Leo A. Andron, LTC, MS, FAMC Sandra L. Tessier, DAC, FAMC |
| (11) Key Words: | lyme disease | (12) Accumulative MEDCASE:* | | (13) Est Accum OMA Cost:* |
| | ixodes dammini | *Refer to Unit Summary Sheet of this Report. |

| (14) | a. Date, Latest IRC Review: | b. Review Results: | c. Number of Subjects Enrolled During Reporting Period: | d. Total Number of Subjects Enrolled to Date: | e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". N/A |
| (15) Study Objective: | To determine the number of cases of Lyme Disease contracted at Fort McCoy among a small population of soldiers at high risk which are those soldiers bitten by a tick. |
| (16) Technical Approach: | Soldiers training at Fort McCoy who receive tick bites are initially bled and a second follow-up blood samples is obtained after 6 weeks. Serum samples will be tested for Lyme Disease antibodies by the ELISA technique. |
| (17) Progress: | 459 of the total 988 serum samples have been tested by ELISA and 250 of the 459 have been tested by FIAX. The 250 sera were comprised of sera from 156 service members (SM) (94 paired and 62 unpaired samples). Twenty-three of the 94 paired sera were from SM that had B. burdorferi positive I. dammini removed at the time the initial serum samples were obtained. Five of the 23 were positive by FIAX (4/5 positive on both initial and follow-up, 1/5 sero converted with less than four-fold increase in titer). Western Blot tests ran on all positive FIAX tests gave banding consistent with known positive controls. The remaining 529 samples will be screened by ELISA and positives confirmed with FIAX and Western Blot. The 529 samples include all Fort Leonard Wood personnel. |

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 86  (2) Protocol WU#: 87/901  (3) Status: Terminated

(4) Title: Effect of Patient's Position at the Time of Subarachnoid Puncture on the Incidence of Post-Spinal Puncture Headache

(5) Start Date: __________________________  (6) Est Compl Date: __________________________

(7) Principal Investigator: Alexander S. Rubin, CPT, MC  (8) Facility: FAMC
  Fort Leonard Wood, MO

(9) Dept/Svc: Anesthesia Svc  (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: __________ b. Review Results: __________
    c. Number of Subjects Enrolled During Reporting Period: __________
    d. Total Number of Subjects Enrolled to Date: __________
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective:

(16) Technical Approach:

(17) Progress: Protocol was approved pending revisions according to IRC stipulations. No follow-up by Principal Investigator. Administratively terminated.

Publications and Presentations:

295
Date: 30 Sep 88  Protocol WU#: 88/900  Status: Ongoing

Title: IOLAB Investigational Plan for the Clinical Study of Intraocular Lenses

Start Date:  
Est Compl Date:  

Principal Investigator:  
Luis E. Colon, MAJ, MC  
Fort Leonard Wood, MO 65473-5700

Dept/Svc: Ophthalmology Svc  
Associate Investigators:

Key Words:
IOL (posterior chamber)

Accumulative MEDCASE:*  
Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 8  
d. Total Number of Subjects Enrolled to Date: 62  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". N/A

Study Objective: To establish the safety and effectiveness of intraocular lens implantation of the cataract patient.

Technical Approach: Extracapsular cataract extraction with PC IOL secondary intraocular lens (IOL) implants.

Progress: No adverse effects noted to date.

Publications and Presentations: None
Date: 30 Sep 88  Protocol WU#: 88/901  Status: Ongoing

Title: Coburn Intraocular Lens Study AT GLWACH

Start Date:  

Est Compl Date:  

Principal Investigator:  
Luis E. Colon, MAJ, MC  
Fort Leonard Wood, MO 65473-5700  

Dept/Svc: Ophthalmology Svc  

Associate Investigators:  

Key Words:  
IOL (anterior chamber)  

Accumulative MEDCASE:*  

Est Accum OMA Cost:* 
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 13  
d. Total Number of Subjects Enrolled to Date: 13  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". N/A

Study Objective: To establish the safety and effectiveness of intraocular lens implantation of the cataract patient.

Technical Approach: Secondary intraocular lens implant.

Progress: No adverse effects noted to date.

Publications and Presentations: None
COMPASSIONATE, EMERGENCY USE PROTOCOLS
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

<table>
<thead>
<tr>
<th>(1) Date: 30 Sep 88</th>
<th>(2) Protocol WU#:</th>
<th>(3) Status:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(4) Title:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compassionate Use of POG 8495 &quot;A Phase I Study of Hyperfractionation in Brain Stem Glioma in Children&quot;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(5) Start Date:</th>
<th>(6) Est Compl Date:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(7) Principal Investigator:</th>
</tr>
</thead>
<tbody>
<tr>
<td>COL Askold Mosijczuk</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(9) Dept of Pediatrics</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(10) Associate Investigators</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(11) Key Words:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(12) Accumulative MEDCASE:*</th>
<th>(13) Est Accum OMA Cost:*</th>
</tr>
</thead>
<tbody>
<tr>
<td>*Refer to Unit Summary Sheet of this Report.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(14) a. Date, Latest IRC Review:</th>
<th>b. Review Results:</th>
</tr>
</thead>
<tbody>
<tr>
<td>c. Number of Subjects Enrolled During Reporting Period:</td>
<td></td>
</tr>
<tr>
<td>d. Total Number of Subjects Enrolled to Date:</td>
<td></td>
</tr>
<tr>
<td>e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as &quot;(14)e&quot;.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(15) Study Objective:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(16) Technical Approach:</th>
</tr>
</thead>
</table>

| (17) Progress: COL Mosijczuk reported that the patient is responding clinically and neurologically. This is the third patient enrolled in this study on a compassionate basis. COL Mosijczuk has considered presenting the protocol to the IRC for full review; however, Pediatric Oncology Group is planning to close the study to new patients. |

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#:  (3) Status: Completed

(4) Title: Compassionate Use of "Ciprofoxacin Therapy"
          Protocol U87-007

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility:  FAMC
   LTC James Bales

(9) Dept of Infectious Disease  (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
     *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
     c. Number of Subjects Enrolled During Reporting Period:
     d. Total Number of Subjects Enrolled to Date:
     e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective:

(16) Technical Approach:

(17) Progress: Ciprofoxacin therapy for highly resistant pseudomonas aeruginosa infection under compassionate protocol U87-007 (Miles). Patient is reported improving.

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88  (2) Protocol WU#:  (3) Status: Completed

(4) Title:  
SWOG 8710

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility:  FAMC

  MAJ Michael Stone

(9) Dept of  Hema/Oncol Svc  (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for  
studying under an FDA-awarded IND. May be continued on a separate  
sheet, and designated as "(14)e".

(15) Study Objective:

(16) Technical Approach:

(17) Progress:  Received permission to enroll a bladder cancer patient on a  
compassionate basis.

Publications and Presentations:

301
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 88 (2) Protocol WU#: (3) Status: 

(4) Title: Experimental Drug "Ofloxacin"

(5) Start Date: (6) Est Compl Date: 

(7) Principal Investigator: COL Michael E. Perry (8) Facility: FAMC

(9) Dept of Pulmonary Disease (10) Associate Investigators 

(11) Key Words: 

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: 

(16) Technical Approach: 

(17) Progress: Received approval for continuation of compassionate use of experimental drug. COL Perry has provided reports to the IRC regarding continued use of the drug. Sufficient precautions have been taken to protect the subject from adverse effects of the medication. 

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

<table>
<thead>
<tr>
<th>(1) Date: 30 Sep 38</th>
<th>(2) Protocol WU#:</th>
<th>(3) Status:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(4) Title:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compassionate Use of NCI Protocol I-88-14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(5) Start Date:</td>
<td>(6) Est Compl Date:</td>
<td></td>
</tr>
<tr>
<td>(7) Principal Investigator:</td>
<td>(8) Facility: FAMC</td>
<td></td>
</tr>
<tr>
<td>MAJ David S. Brantley</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(9) Dept of</td>
<td>(10) Associate Investigators</td>
<td></td>
</tr>
<tr>
<td>Hema/Oncol Svc</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(11) Key Words:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(12) Accumulative MEDCASE:*</td>
<td>(13) Est Accum OMA Cost:*</td>
<td></td>
</tr>
<tr>
<td>*Refer to Unit Summary Sheet of this Report.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(14) a. Date, Latest IRC Review:</td>
<td>b. Review Results:</td>
<td></td>
</tr>
<tr>
<td>c. Number of Subjects Enrolled During Reporting Period:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>d. Total Number of Subjects Enrolled to Date:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as &quot;(14)e&quot;.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(15) Study Objective:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(16) Technical Approach:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(17) Progress: Received permission to treat refractory adult acute myelogenous leukemia patient.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

<table>
<thead>
<tr>
<th>(1) Date: 30 Sep 88</th>
<th>(2) Protocol WU#:</th>
<th>(3) Status:</th>
</tr>
</thead>
</table>

| (4) Title: Compassionate Implant (Storz Ophthalmic Inc. Co.) |

<table>
<thead>
<tr>
<th>(5) Start Date:</th>
<th>(6) Est Compl Date:</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(7) Principal Investigator:</th>
<th>(8) Facility: FAMC</th>
</tr>
</thead>
<tbody>
<tr>
<td>COL Floyd M. Cornell</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(9) Dept of Ophthalmology Svc</th>
<th>(10) Associate Investigators</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(11) Key Words:</th>
</tr>
</thead>
</table>

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

<table>
<thead>
<tr>
<th>(15) Study Objective:</th>
</tr>
</thead>
</table>

| (16) Technical Approach: |

(17) Progress: Received permission to implant an intraocular lens in a pediatric patient on a compassionate, emergency basis. (Protocol approved at Aug 88 meeting)

Publications and Presentations:
(1) Date: 30 Sep 88  (2) Protocol WU#:  (3) Status:  

(4) Title:  
Compassionate Enrollment in POG 8696/97

(5) Start Date:  (6) Est Compl Date:  

(7) Principal Investigator:  (8) Facility:  FAMC  
COL Askold Mosijczuk

(9) Dept of  Pediatrics  (10) Associate Investigators

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective:

(16) Technical Approach:

(17) Progress:  Subject accrual in POG 8696/97 is near completion.

Publications and Presentations:
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

| (1) Date: | 30 Sep 88 | (2) Protocol WU#: |  |
| (3) Status: |  |
| (4) Title: | Compassionate IND #124001487 Carboplatin |
| (5) Start Date: |  |
| (6) Est Compl Date: |  |
| (7) Principal Investigator: | COL George Phillips |
| (8) Facility: | FAMC |
| (9) Dept of | OB/GYN |
| (10) Associate Investigators |  |
| (11) Key Words: |  |
| (12) Accumulative MEDCASE:* |  |
| (13) Est Accum OMA Cost:* |  |
| *Refer to Unit Summary Sheet of this Report. |
| (14) a. Date, Latest IRC Review: |  |
| b. Review Results: |  |
| c. Number of Subjects Enrolled During Reporting Period: |  |
| d. Total Number of Subjects Enrolled to Date: |  |
| e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". |
| (15) Study Objective: |  |
| (16) Technical Approach: |  |
| (17) Progress: | COL Phillips indicated compassionate IND #124001487 Carboplatin was an ongoing compassionate use protocol for a patient originally approved in January 1987. |

**Publications and Presentations:**
<table>
<thead>
<tr>
<th>NAME</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adnot, J.</td>
<td>43</td>
</tr>
<tr>
<td>Andersen, P.A.</td>
<td>69,100</td>
</tr>
<tr>
<td>Anderson, B.</td>
<td>243,249</td>
</tr>
<tr>
<td>Andron, L.A.</td>
<td>84,85,110,180,294</td>
</tr>
<tr>
<td>Arena, J.</td>
<td>181,185,189,192</td>
</tr>
<tr>
<td>Aronson, C.E.</td>
<td>142</td>
</tr>
<tr>
<td>Artman, M.</td>
<td>293</td>
</tr>
<tr>
<td>Asp, A.</td>
<td>80,86,104</td>
</tr>
<tr>
<td>Atchley, S.H.</td>
<td>129</td>
</tr>
<tr>
<td>Bales, J.D.</td>
<td>114,300</td>
</tr>
<tr>
<td>Barber, J.</td>
<td>263</td>
</tr>
<tr>
<td>Barbour, A.G.</td>
<td>179</td>
</tr>
<tr>
<td>Barrett, J.R.</td>
<td>115</td>
</tr>
<tr>
<td>Barrs, D.M.</td>
<td>168</td>
</tr>
<tr>
<td>Beougher, K.</td>
<td>245</td>
</tr>
<tr>
<td>Bethlenfalvay, N.C.</td>
<td>284,286,288</td>
</tr>
<tr>
<td>Bezier, J.L.</td>
<td>140</td>
</tr>
<tr>
<td>Bizousky, D.</td>
<td>159</td>
</tr>
<tr>
<td>Blaedel, M.E.</td>
<td>264</td>
</tr>
<tr>
<td>Blue, P.</td>
<td>70,82,278,282</td>
</tr>
<tr>
<td>Bodien, J.M.</td>
<td>266,267,268,269</td>
</tr>
<tr>
<td>Bornemann, M.</td>
<td>35,71,86</td>
</tr>
<tr>
<td>Brantley, S.</td>
<td>116,303</td>
</tr>
<tr>
<td>Bray, V.</td>
<td>125</td>
</tr>
<tr>
<td>Brewster, E.</td>
<td>159</td>
</tr>
<tr>
<td>Brown, J.S.</td>
<td>75</td>
</tr>
<tr>
<td>Brugman, J.L.</td>
<td>165,192</td>
</tr>
<tr>
<td>Bruhn, F.W.</td>
<td>270</td>
</tr>
<tr>
<td>Burris, R.W.</td>
<td>84</td>
</tr>
<tr>
<td>Byers, N.T.</td>
<td>138,157,162</td>
</tr>
<tr>
<td>Calkins, R.</td>
<td>192</td>
</tr>
<tr>
<td>Campbell, R.L.</td>
<td>121</td>
</tr>
<tr>
<td>Carter, T.</td>
<td>238</td>
</tr>
<tr>
<td>Casey, K.F.</td>
<td>144,168</td>
</tr>
<tr>
<td>Chadwick, E.</td>
<td>284,286</td>
</tr>
<tr>
<td>Clark, J.</td>
<td>104,148,155,238,267,268</td>
</tr>
<tr>
<td>Clark, R.A.F.</td>
<td>42</td>
</tr>
<tr>
<td>Clayton, W.</td>
<td>85</td>
</tr>
<tr>
<td>Coatney, M.W.</td>
<td>138</td>
</tr>
<tr>
<td>Cobb, P.W.</td>
<td>130</td>
</tr>
<tr>
<td>Cohn, E.A.</td>
<td>162</td>
</tr>
<tr>
<td>Colon, L.E.</td>
<td>139,296,297</td>
</tr>
<tr>
<td>Colpini, A.W.</td>
<td>163,164,297</td>
</tr>
<tr>
<td>Conran, R.M.</td>
<td>180</td>
</tr>
<tr>
<td>Corby, D.G.</td>
<td>216</td>
</tr>
<tr>
<td>Cornell, F.M.</td>
<td>138,157,304</td>
</tr>
<tr>
<td>Coulter, S.</td>
<td>128</td>
</tr>
<tr>
<td>Crane, C.A.</td>
<td>276</td>
</tr>
<tr>
<td>Crosby, B.L.</td>
<td>68,75</td>
</tr>
</tbody>
</table>

308
<table>
<thead>
<tr>
<th>NAME</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Davis, R.C.</td>
<td>136</td>
</tr>
<tr>
<td>Dolen, W.</td>
<td>77,83</td>
</tr>
<tr>
<td>Donatucci, C.</td>
<td>146,149,150</td>
</tr>
<tr>
<td>Dorosy, M.E.</td>
<td>129</td>
</tr>
<tr>
<td>Dorsett</td>
<td>265</td>
</tr>
<tr>
<td>Duray, P.H.</td>
<td>294</td>
</tr>
<tr>
<td>Dwyer, K.</td>
<td>178</td>
</tr>
<tr>
<td>Dyer, P.D.</td>
<td>127</td>
</tr>
<tr>
<td>Eckel, R.</td>
<td>105</td>
</tr>
<tr>
<td>Edwards, M.</td>
<td>238,245</td>
</tr>
<tr>
<td>Elliott, J.J.</td>
<td>274</td>
</tr>
<tr>
<td>Enzenauer, R.W.</td>
<td>138,153,157</td>
</tr>
<tr>
<td>Ernst, J.L.</td>
<td>188</td>
</tr>
<tr>
<td>Fall, S.</td>
<td>188,191,158</td>
</tr>
<tr>
<td>Ferris, C.F.</td>
<td>42,44,50,74,80,128,216,288</td>
</tr>
<tr>
<td>Fitzpatrick, J.E.</td>
<td>74,128</td>
</tr>
<tr>
<td>Fortenberry, E.J.</td>
<td>98</td>
</tr>
<tr>
<td>Foucault, J.</td>
<td>97</td>
</tr>
<tr>
<td>Frank, C.G.</td>
<td>237,249</td>
</tr>
<tr>
<td>Freeman, S.</td>
<td>265</td>
</tr>
<tr>
<td>Frelin, A.J.</td>
<td>291</td>
</tr>
<tr>
<td>Friel, T.G.</td>
<td>161</td>
</tr>
<tr>
<td>Fullerton, J.</td>
<td>159</td>
</tr>
<tr>
<td>Garrow, D.C.</td>
<td>215</td>
</tr>
<tr>
<td>Gaspar, P.T.</td>
<td>263</td>
</tr>
<tr>
<td>Gates, R.H.</td>
<td>84,109,114</td>
</tr>
<tr>
<td>Gentry, R.</td>
<td>43</td>
</tr>
<tr>
<td>Georgitis, W.J.</td>
<td>35,70,71,80,86,104,105,115,132</td>
</tr>
<tr>
<td>Getter, M.D.</td>
<td>152</td>
</tr>
<tr>
<td>Ghaed, N.</td>
<td>82</td>
</tr>
<tr>
<td>Gibson, M.</td>
<td>281</td>
</tr>
<tr>
<td>Ginter, J.</td>
<td>192</td>
</tr>
<tr>
<td>Granger, E.</td>
<td>93,94,95,96</td>
</tr>
<tr>
<td>Grape, R.G.</td>
<td>85</td>
</tr>
<tr>
<td>Griffith, J.R.</td>
<td>272</td>
</tr>
<tr>
<td>Grimwood, R.E.</td>
<td>42,44,50</td>
</tr>
<tr>
<td>Haburchak, D.R.</td>
<td>86</td>
</tr>
<tr>
<td>Hahn, D.B.</td>
<td>154,192,268</td>
</tr>
<tr>
<td>Hamer, L.A.</td>
<td>290</td>
</tr>
<tr>
<td>Hannon, R.N.</td>
<td>84,85,109</td>
</tr>
<tr>
<td>Harrison, S.M.</td>
<td>84,85,86,109,114,121</td>
</tr>
<tr>
<td>Hasbargen, J.A.</td>
<td>78,105,125</td>
</tr>
<tr>
<td>Hastriter, M.W.</td>
<td>294</td>
</tr>
<tr>
<td>Henderson, R.</td>
<td>238,266,267</td>
</tr>
<tr>
<td>Henry, A.R.</td>
<td>79</td>
</tr>
<tr>
<td>Hockenbury, R.T.</td>
<td>166</td>
</tr>
<tr>
<td>Hofeldt, F.D.</td>
<td>29,34,41</td>
</tr>
<tr>
<td>Hollis, H.W.</td>
<td>155</td>
</tr>
</tbody>
</table>
NAME | PAGE
---|---
Hopper, K. | 279, 281
Horn, C.S. | 257
Horne, D. | 146, 149, 150, 281
Huff, J.C. | 42, 44, 50, 78
Hull, R.W. | 108, 129
Ikle, L.O. | 272
Jackson, G.L. | 97
Johns, J. | 143, 159, 166
Johnson, K.R. | 256
Johnson, S.W. | 290
Jones, L.E. | 80
Jordon, L.W. | 129
Kelly, K.J. | 271
Kidd, G.S. | 29, 34, 35, 37, 39, 40, 41, 47, 67, 70, 71, 80, 82, 86, 98, 101, 104, 105, 107, 109, 115, 132
Kindig, N.B. | 32
Lanier, D. | 130
Larsen, L.V. | 134
Ledoux, R.A. | 68, 77, 83
Lee, L. | 128
Lemar, H.J. | 123
Lepore, M.L. | 160
LeSueur, C. | 64
Levin, M. | 247
Lima, J.E. | 284, 286
Lockard, J. | 125, 126
Lundblad, E. | 196, 215, 216
Maco-Johnson, M. | 281
Manier, S.M. | 70
Marx, W.H. | 148, 170
Maulding, W.M. | 138, 157
McCullen, A.H. | 216
Mellette, J.R. | 43, 128
Mello, K. | 294
Mercill, D.B. | 74, 128, 288
Merenich, J. | 82, 86, 104, 105, 107, 109, 115
Merenstein, G.B. | 243
Miles, F.W. | 121
Miller, B. | 272
Miller, E. | 216, 265
Miller, G. | 281
Morse, P.L. | 177, 180
<table>
<thead>
<tr>
<th>NAME</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myers, C.</td>
<td>163, 164</td>
</tr>
<tr>
<td>Negron, F.</td>
<td>82</td>
</tr>
<tr>
<td>Nelson, H.S.</td>
<td>49</td>
</tr>
<tr>
<td>Noble, S.</td>
<td>80</td>
</tr>
<tr>
<td>Nordstrom, D.</td>
<td>69, 131</td>
</tr>
<tr>
<td>O'Barr, T.P.</td>
<td>29, 34, 44, 47, 74, 107, 108, 109, 172</td>
</tr>
<tr>
<td>Odom, J.A.</td>
<td>165</td>
</tr>
<tr>
<td>Olson, G.C.</td>
<td>45, 120</td>
</tr>
<tr>
<td>Ow, C.L.</td>
<td>113</td>
</tr>
<tr>
<td>Ozaki, J.K.</td>
<td>147, 156, 163, 164, 181, 183, 186, 189</td>
</tr>
<tr>
<td>Paine, D.D.</td>
<td>180</td>
</tr>
<tr>
<td>Parker, S.</td>
<td>28'</td>
</tr>
<tr>
<td>Perloff, J.J.</td>
<td>101, 119</td>
</tr>
<tr>
<td>Pernelli, D.P.</td>
<td>138, 157, 162</td>
</tr>
<tr>
<td>Perry, M.E.</td>
<td>32, 82, 90, 97, 302</td>
</tr>
<tr>
<td>Pfander, N.</td>
<td>132</td>
</tr>
<tr>
<td>Plenkos, E.J.</td>
<td>281</td>
</tr>
<tr>
<td>Podgore, J.K.</td>
<td>175, 191, 247, 270</td>
</tr>
<tr>
<td>Pope, J.</td>
<td>157</td>
</tr>
<tr>
<td>Porogy, M.</td>
<td>126</td>
</tr>
<tr>
<td>Portman, R.J.</td>
<td>243, 256</td>
</tr>
<tr>
<td>Prewitt, K.C.</td>
<td>105</td>
</tr>
<tr>
<td>Prucha, D.</td>
<td>276</td>
</tr>
<tr>
<td>Pruitt, A.</td>
<td>161, 163, 164, 165, 169</td>
</tr>
<tr>
<td>Quinones, D.</td>
<td>146, 149, 150</td>
</tr>
<tr>
<td>Ralfe, M.J.</td>
<td>146, 149, 150, 281</td>
</tr>
<tr>
<td>Ramirez, C.</td>
<td>141, 180</td>
</tr>
<tr>
<td>Reddy, V.</td>
<td>238, 263, 266, 267, 268, 288</td>
</tr>
<tr>
<td>Rich, J.D.</td>
<td>145</td>
</tr>
<tr>
<td>Riess, O.K.</td>
<td>154</td>
</tr>
<tr>
<td>Rodinelli, R.</td>
<td>181, 183, 186</td>
</tr>
<tr>
<td>Rothschild, B.</td>
<td>181</td>
</tr>
<tr>
<td>Roy, C.R.</td>
<td>146, 149, 150</td>
</tr>
<tr>
<td>Rubin, A.S.</td>
<td>295</td>
</tr>
<tr>
<td>Rush, P.</td>
<td>263</td>
</tr>
<tr>
<td>Shackelford, A.</td>
<td>29</td>
</tr>
<tr>
<td>Schaffrinna, M.G.</td>
<td>257, 264, 265</td>
</tr>
<tr>
<td>Shanefield, M.</td>
<td>64</td>
</tr>
<tr>
<td>Sherman, R.A.</td>
<td>156, 169, 181, 183, 186, 188, 189, 192</td>
</tr>
<tr>
<td>Shull, M.</td>
<td>245</td>
</tr>
<tr>
<td>Simcic, K.</td>
<td>115, 132</td>
</tr>
<tr>
<td>NAME</td>
<td>PAGE</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Sims, J.</td>
<td>148, 281</td>
</tr>
<tr>
<td>Singleton, J.D.</td>
<td>100, 131</td>
</tr>
<tr>
<td>Sjoberg, R.J.</td>
<td>34, 47, 107, 109, 115</td>
</tr>
<tr>
<td>Slover, R.</td>
<td>256, 273</td>
</tr>
<tr>
<td>Smith, D.R.</td>
<td>158</td>
</tr>
<tr>
<td>Staggers, N.</td>
<td>291</td>
</tr>
<tr>
<td>Stahl, C.</td>
<td>256</td>
</tr>
<tr>
<td>Suggs</td>
<td>293</td>
</tr>
<tr>
<td>Stewart, I.B.</td>
<td>284</td>
</tr>
<tr>
<td>Stewart, R.S.</td>
<td>175</td>
</tr>
<tr>
<td>Stock, J.</td>
<td>157</td>
</tr>
<tr>
<td>Stone, M.</td>
<td>301</td>
</tr>
<tr>
<td>Swanson, E.</td>
<td>80</td>
</tr>
<tr>
<td>Szefer, S. J.</td>
<td></td>
</tr>
<tr>
<td>Tessier, S.</td>
<td>179, 180, 294</td>
</tr>
<tr>
<td>Thickman, D.</td>
<td>281</td>
</tr>
<tr>
<td>Thrasher, J.B.</td>
<td>149, 150, 170</td>
</tr>
<tr>
<td>Truxal, A.R.</td>
<td>52</td>
</tr>
<tr>
<td>Tyler, H.N.</td>
<td>281</td>
</tr>
<tr>
<td>Urry, L.</td>
<td>128</td>
</tr>
<tr>
<td>VanDeren, J.M.</td>
<td>136</td>
</tr>
<tr>
<td>Vaughan, R.</td>
<td>45, 49, 79, 127, 134</td>
</tr>
<tr>
<td>Walden, T.</td>
<td>70, 71, 80</td>
</tr>
<tr>
<td>Walton, W.</td>
<td>157</td>
</tr>
<tr>
<td>Ward, F.</td>
<td>127</td>
</tr>
<tr>
<td>Wartofsky, L.</td>
<td>52</td>
</tr>
<tr>
<td>Weaver, M. J.</td>
<td>113, 123, 133</td>
</tr>
<tr>
<td>Weber, R.W.</td>
<td>45, 68, 75, 79, 120, 127, 134</td>
</tr>
<tr>
<td>Weingast, G.</td>
<td>281</td>
</tr>
<tr>
<td>Wells, D.W.</td>
<td>242, 257</td>
</tr>
<tr>
<td>West, S.G.</td>
<td>64, 69, 100, 131</td>
</tr>
<tr>
<td>Weston, W.</td>
<td>128</td>
</tr>
<tr>
<td>Whitaker, M.</td>
<td>157</td>
</tr>
<tr>
<td>Wilkerson, R.</td>
<td>166</td>
</tr>
<tr>
<td>Williams, W.</td>
<td>119</td>
</tr>
<tr>
<td>Wilson, J.</td>
<td>147</td>
</tr>
<tr>
<td>Winter, W.G.</td>
<td>154</td>
</tr>
<tr>
<td>Woolverton, M.</td>
<td>274</td>
</tr>
<tr>
<td>Young, T.</td>
<td>181, 183, 186, 189</td>
</tr>
<tr>
<td>KEY WORDS</td>
<td>Page</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>absorptiometry</td>
<td>282</td>
</tr>
<tr>
<td>achilles tendon reupture</td>
<td>166</td>
</tr>
<tr>
<td>acquired immune deficiency syndrome</td>
<td>86</td>
</tr>
<tr>
<td>acrylic resins</td>
<td>147</td>
</tr>
<tr>
<td>acute renal failure</td>
<td>126</td>
</tr>
<tr>
<td>adolescents</td>
<td>264</td>
</tr>
<tr>
<td>adosterone</td>
<td>278</td>
</tr>
<tr>
<td>adrenal cortex hormones</td>
<td>245</td>
</tr>
<tr>
<td>adrenal glands</td>
<td>86, 278</td>
</tr>
<tr>
<td>insufficiency</td>
<td>109</td>
</tr>
<tr>
<td>alcohol</td>
<td>105</td>
</tr>
<tr>
<td>allergens</td>
<td>68</td>
</tr>
<tr>
<td>extracts</td>
<td>83</td>
</tr>
<tr>
<td>angina pectoris</td>
<td>136</td>
</tr>
<tr>
<td>angiotensin</td>
<td>80</td>
</tr>
<tr>
<td>anthropometry</td>
<td>90</td>
</tr>
<tr>
<td>articular cartilage regeneration</td>
<td>163</td>
</tr>
<tr>
<td>antihistamine</td>
<td>120</td>
</tr>
<tr>
<td>apolipoproteins</td>
<td>105</td>
</tr>
<tr>
<td>basal cell CA</td>
<td>42, 43, 50</td>
</tr>
<tr>
<td>biomechanics</td>
<td>161</td>
</tr>
<tr>
<td>bladder augmentation and substitution</td>
<td>149</td>
</tr>
<tr>
<td>blood glucose</td>
<td>29</td>
</tr>
<tr>
<td>body fat</td>
<td>282</td>
</tr>
<tr>
<td>bone cement</td>
<td>147</td>
</tr>
<tr>
<td>density</td>
<td>37</td>
</tr>
<tr>
<td>borrelia</td>
<td>179</td>
</tr>
<tr>
<td>breathing patterns</td>
<td>32</td>
</tr>
<tr>
<td>bypass loagulopathy</td>
<td>108</td>
</tr>
<tr>
<td>calcium</td>
<td>82, 98</td>
</tr>
<tr>
<td>calcitomin deficiency</td>
<td>37</td>
</tr>
<tr>
<td>carbohydrate</td>
<td>34</td>
</tr>
<tr>
<td>carduction velocity</td>
<td>159</td>
</tr>
<tr>
<td>chemotherapy</td>
<td>87</td>
</tr>
<tr>
<td>clotting factors</td>
<td>263</td>
</tr>
<tr>
<td>colonic neoplasms</td>
<td>148</td>
</tr>
<tr>
<td>comparison</td>
<td>257</td>
</tr>
<tr>
<td>cognitive, moral &amp; faith development</td>
<td>121</td>
</tr>
<tr>
<td>continuous passive motion</td>
<td>163</td>
</tr>
<tr>
<td>corpus lufeum</td>
<td>216</td>
</tr>
<tr>
<td>corticotropin</td>
<td>245</td>
</tr>
<tr>
<td>cyclosporin</td>
<td>52</td>
</tr>
<tr>
<td>d-deimer</td>
<td>129</td>
</tr>
<tr>
<td>d-penicillamine</td>
<td>131</td>
</tr>
<tr>
<td>KEY WORDS</td>
<td>Page</td>
</tr>
<tr>
<td>-------------------------------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>desferrioxamine</td>
<td>78</td>
</tr>
<tr>
<td>diabetes mellitus</td>
<td>107</td>
</tr>
<tr>
<td>diabetes type II</td>
<td>132</td>
</tr>
<tr>
<td>dialysis</td>
<td>78</td>
</tr>
<tr>
<td>drug induced lupus</td>
<td>100</td>
</tr>
<tr>
<td>dyserythropoiesis</td>
<td>288</td>
</tr>
<tr>
<td>dysmenorrhea</td>
<td>242</td>
</tr>
<tr>
<td>emergency medical services</td>
<td>293</td>
</tr>
<tr>
<td>endometriosis</td>
<td>242</td>
</tr>
<tr>
<td>environmental recording</td>
<td>181,192</td>
</tr>
<tr>
<td>enzyme-linked immunosorbent assay</td>
<td>77,180</td>
</tr>
<tr>
<td>erythrocytes</td>
<td>286</td>
</tr>
<tr>
<td>estrogen</td>
<td>74,108</td>
</tr>
<tr>
<td>eye disease</td>
<td>52</td>
</tr>
<tr>
<td>fibrin monomer</td>
<td>129</td>
</tr>
<tr>
<td>fluorouracil</td>
<td>148</td>
</tr>
<tr>
<td>food hypersensitivity</td>
<td>45</td>
</tr>
<tr>
<td>foot pads</td>
<td>154</td>
</tr>
<tr>
<td>gastroduodenal ulcer</td>
<td>170</td>
</tr>
<tr>
<td>gliburite</td>
<td>132</td>
</tr>
<tr>
<td>glipizide</td>
<td>132</td>
</tr>
<tr>
<td>glucose counter regulation</td>
<td>107</td>
</tr>
<tr>
<td>glucose metabolism</td>
<td>286</td>
</tr>
<tr>
<td>gonadal dysgenesis</td>
<td>39,140</td>
</tr>
<tr>
<td>gonadotropins</td>
<td>39</td>
</tr>
<tr>
<td>gram-negative shock</td>
<td>114</td>
</tr>
<tr>
<td>gram-negative sepsis</td>
<td>114</td>
</tr>
<tr>
<td>gynecomastia</td>
<td>41</td>
</tr>
<tr>
<td>ha-la, monoclonal antibody</td>
<td>114</td>
</tr>
<tr>
<td>headaches</td>
<td>192,264</td>
</tr>
<tr>
<td>hemoglobin, abnormal</td>
<td>284</td>
</tr>
<tr>
<td>heparin</td>
<td>148</td>
</tr>
<tr>
<td>high risk neonates</td>
<td>249</td>
</tr>
<tr>
<td>hip fracture</td>
<td>101</td>
</tr>
<tr>
<td>histones</td>
<td>100</td>
</tr>
<tr>
<td>HIV virus</td>
<td>84</td>
</tr>
<tr>
<td>HLA antigens</td>
<td>64</td>
</tr>
<tr>
<td>hodgkins disease</td>
<td>279</td>
</tr>
<tr>
<td>human immunodeficiency virus</td>
<td>85</td>
</tr>
<tr>
<td>humanistic qualities</td>
<td>113</td>
</tr>
<tr>
<td>hypersensitivity</td>
<td>68</td>
</tr>
<tr>
<td>hyperparathyroidism</td>
<td>104</td>
</tr>
<tr>
<td>hypertension</td>
<td>125</td>
</tr>
<tr>
<td>hyperthyroidism</td>
<td>34,49</td>
</tr>
<tr>
<td>KEY WORDS</td>
<td>Page</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>hypoglycemia</td>
<td>107</td>
</tr>
<tr>
<td>hypothyroidism</td>
<td>39,40,47,49</td>
</tr>
<tr>
<td>ifosfamide</td>
<td>269</td>
</tr>
<tr>
<td>immunoelectrophoresis</td>
<td>77</td>
</tr>
<tr>
<td>immunologic diseases</td>
<td>175</td>
</tr>
<tr>
<td>immunotherapy</td>
<td>75</td>
</tr>
<tr>
<td>impaired adrenal antagonists</td>
<td>29</td>
</tr>
<tr>
<td>insulin coma</td>
<td>29</td>
</tr>
<tr>
<td>intern</td>
<td>216</td>
</tr>
<tr>
<td>intramedullary nails</td>
<td>161</td>
</tr>
<tr>
<td>intraocular lens</td>
<td>138-142,157</td>
</tr>
<tr>
<td>intraoperative monitoring</td>
<td>168</td>
</tr>
<tr>
<td>lol (posterior chamber)</td>
<td>296,297</td>
</tr>
<tr>
<td>ixodes dammini</td>
<td>294</td>
</tr>
<tr>
<td>keratin</td>
<td>44</td>
</tr>
<tr>
<td>kidney tubules</td>
<td>243</td>
</tr>
<tr>
<td>lipase</td>
<td>105</td>
</tr>
<tr>
<td>lipid analysis</td>
<td>154</td>
</tr>
<tr>
<td>lipoproteins</td>
<td>105</td>
</tr>
<tr>
<td>low back pain</td>
<td>181,189</td>
</tr>
<tr>
<td>lupus erythematosus</td>
<td>64</td>
</tr>
<tr>
<td>lyme disease</td>
<td>179,294</td>
</tr>
<tr>
<td>malignant melanoma</td>
<td>74</td>
</tr>
<tr>
<td>mechanisms</td>
<td>183</td>
</tr>
<tr>
<td>mediators</td>
<td>45</td>
</tr>
<tr>
<td>medical residents</td>
<td>113</td>
</tr>
<tr>
<td>MMPI</td>
<td>189</td>
</tr>
<tr>
<td>methotrexate</td>
<td>131</td>
</tr>
<tr>
<td>methylprednisolone</td>
<td>49</td>
</tr>
<tr>
<td>microbiological techniques</td>
<td>177</td>
</tr>
<tr>
<td>microbiology</td>
<td>177</td>
</tr>
<tr>
<td>microsurgery</td>
<td>150</td>
</tr>
<tr>
<td>microvascular surgery &amp; training</td>
<td>143,144</td>
</tr>
<tr>
<td>migraine</td>
<td>45</td>
</tr>
<tr>
<td>headaches</td>
<td>265</td>
</tr>
<tr>
<td>muscle tension</td>
<td>192</td>
</tr>
<tr>
<td>nasal compression</td>
<td>159</td>
</tr>
<tr>
<td>nasal obstruction</td>
<td>160</td>
</tr>
<tr>
<td>nasal surgery</td>
<td>160</td>
</tr>
<tr>
<td>natriuretic peptides</td>
<td>243</td>
</tr>
<tr>
<td>neoplasms</td>
<td>238</td>
</tr>
<tr>
<td>nerve graft</td>
<td>168</td>
</tr>
<tr>
<td>neuropsychological tests</td>
<td>85</td>
</tr>
<tr>
<td>nifedipine</td>
<td>67,125,136</td>
</tr>
<tr>
<td>nifedipine GITS</td>
<td>163</td>
</tr>
<tr>
<td>non-steroidal anti-inflammatory agent</td>
<td>152,163</td>
</tr>
<tr>
<td>nosocomial pneumonia</td>
<td>170</td>
</tr>
<tr>
<td>nude mice</td>
<td>50</td>
</tr>
<tr>
<td>KEY WORDS</td>
<td>Page</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>opossum</td>
<td>286</td>
</tr>
<tr>
<td>oral contraceptives</td>
<td>257, 263</td>
</tr>
<tr>
<td>oral hypoglycemic agents</td>
<td>132</td>
</tr>
<tr>
<td>orthopedic disorders</td>
<td>156</td>
</tr>
<tr>
<td>osteoporosis</td>
<td>37, 101</td>
</tr>
<tr>
<td>oximetry</td>
<td>97</td>
</tr>
<tr>
<td>pain</td>
<td>156</td>
</tr>
<tr>
<td>pelvic neoplasms</td>
<td>197–214, 217–232, 233–235</td>
</tr>
<tr>
<td>percutaneous repair of achilles</td>
<td></td>
</tr>
<tr>
<td>tendon ruptures</td>
<td>166</td>
</tr>
<tr>
<td>phantom body pain</td>
<td>188</td>
</tr>
<tr>
<td>phantom limb pain</td>
<td>183, 186</td>
</tr>
<tr>
<td>phase II agents in untreated or recurrent osteosarcoma</td>
<td>268</td>
</tr>
<tr>
<td>phenindamine</td>
<td>120</td>
</tr>
<tr>
<td>physical exam</td>
<td>123</td>
</tr>
<tr>
<td>pituitary</td>
<td>35, 39</td>
</tr>
<tr>
<td>platelet function test</td>
<td>172</td>
</tr>
<tr>
<td>pms</td>
<td></td>
</tr>
<tr>
<td>pneumocystis carinii</td>
<td>180</td>
</tr>
<tr>
<td>POG protocols</td>
<td>238</td>
</tr>
<tr>
<td>pollen</td>
<td>68</td>
</tr>
<tr>
<td>postoperative hypocalcemia</td>
<td>104</td>
</tr>
<tr>
<td>prednisone</td>
<td>52</td>
</tr>
<tr>
<td>procainamide</td>
<td>100</td>
</tr>
<tr>
<td>progesterone</td>
<td>74</td>
</tr>
<tr>
<td>prolactinemic states</td>
<td>80</td>
</tr>
<tr>
<td>prophylactic IVIG</td>
<td>249</td>
</tr>
<tr>
<td>prostaglandins</td>
<td></td>
</tr>
<tr>
<td>synthetics</td>
<td>107</td>
</tr>
<tr>
<td>psycho-social-spiritual</td>
<td>121</td>
</tr>
<tr>
<td>pulmonary gas exchange</td>
<td>90</td>
</tr>
<tr>
<td>purine metabolism</td>
<td>286</td>
</tr>
<tr>
<td>reactive arthritis</td>
<td>69</td>
</tr>
<tr>
<td>receptors</td>
<td>74</td>
</tr>
<tr>
<td>reiter's disease</td>
<td>69</td>
</tr>
<tr>
<td>renal trauma</td>
<td>149</td>
</tr>
<tr>
<td>renovascular surgery</td>
<td>149</td>
</tr>
<tr>
<td>retinoids</td>
<td>43</td>
</tr>
<tr>
<td>role development</td>
<td>291</td>
</tr>
<tr>
<td>rheumatoid arthritis</td>
<td>131</td>
</tr>
<tr>
<td>rhinomanometry</td>
<td>160</td>
</tr>
<tr>
<td>screening</td>
<td>123</td>
</tr>
<tr>
<td>silent ischemia</td>
<td>136</td>
</tr>
<tr>
<td>skin test</td>
<td>75, 83</td>
</tr>
<tr>
<td>sleep apnea syndromes</td>
<td>97</td>
</tr>
<tr>
<td>spinal cord injury</td>
<td>188</td>
</tr>
<tr>
<td>spirochete</td>
<td>179</td>
</tr>
<tr>
<td>steady-state DLCO</td>
<td>32</td>
</tr>
<tr>
<td>KEY WORDS</td>
<td>Page</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>steroids</td>
<td>71</td>
</tr>
<tr>
<td>surface EMG</td>
<td>181,189</td>
</tr>
<tr>
<td>suture techniques training</td>
<td>290</td>
</tr>
<tr>
<td>systemic</td>
<td>64</td>
</tr>
<tr>
<td>t cell ALL</td>
<td>266</td>
</tr>
<tr>
<td>tendon healing</td>
<td>152</td>
</tr>
<tr>
<td>theophylline</td>
<td>49,67,98</td>
</tr>
<tr>
<td>therapy</td>
<td>215</td>
</tr>
<tr>
<td>thermography</td>
<td>156,188,189</td>
</tr>
<tr>
<td>thromboembolic disorders</td>
<td>263</td>
</tr>
<tr>
<td>thyroid function tests</td>
<td>35</td>
</tr>
<tr>
<td>hormones</td>
<td>35,37</td>
</tr>
<tr>
<td>thyrotropin</td>
<td>35</td>
</tr>
<tr>
<td>thyroxine</td>
<td>126</td>
</tr>
<tr>
<td>tibia fractures</td>
<td>161</td>
</tr>
<tr>
<td>tomography</td>
<td>279</td>
</tr>
<tr>
<td>transplantation</td>
<td>50</td>
</tr>
<tr>
<td>traumatic facial palsy</td>
<td>168</td>
</tr>
<tr>
<td>treatment of stage D neuroblastoma</td>
<td>267</td>
</tr>
<tr>
<td>treatments</td>
<td>186</td>
</tr>
<tr>
<td>ultrastructure</td>
<td>288</td>
</tr>
<tr>
<td>unstable coronary artery disease</td>
<td>129</td>
</tr>
<tr>
<td>varicella vaccine</td>
<td>247</td>
</tr>
<tr>
<td>vasectomy</td>
<td>150</td>
</tr>
<tr>
<td>vasovasostomy</td>
<td>150</td>
</tr>
<tr>
<td>verapamil</td>
<td>265</td>
</tr>
<tr>
<td>vitamin d</td>
<td>98</td>
</tr>
<tr>
<td>vitamin d rifampin</td>
<td>82</td>
</tr>
<tr>
<td>deficiency</td>
<td>82</td>
</tr>
<tr>
<td>vp-16</td>
<td>269</td>
</tr>
<tr>
<td>water electrolyte balance</td>
<td>47</td>
</tr>
<tr>
<td>imbalance</td>
<td>47</td>
</tr>
<tr>
<td>x-ray microanalysis</td>
<td>288</td>
</tr>
</tbody>
</table>
## DISTRIBUTION LIST

<table>
<thead>
<tr>
<th>Copies</th>
<th>Recipient</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Commander</td>
</tr>
<tr>
<td></td>
<td>US Army Medical Research Command</td>
</tr>
<tr>
<td></td>
<td>Fort Detrick, ATTN: SGRD-AJ</td>
</tr>
<tr>
<td></td>
<td>Frederick, MD 21701</td>
</tr>
<tr>
<td>2</td>
<td>Commander</td>
</tr>
<tr>
<td></td>
<td>US Army Medical Research Command</td>
</tr>
<tr>
<td></td>
<td>Fort Detrick, ATTN: SGRD-HR</td>
</tr>
<tr>
<td></td>
<td>Frederick, MD 21701</td>
</tr>
<tr>
<td>12</td>
<td>Defense Documentation Center</td>
</tr>
<tr>
<td></td>
<td>ATTN: DDC-TCA, Cameron Station</td>
</tr>
<tr>
<td></td>
<td>Alexandria, VA 22314</td>
</tr>
<tr>
<td>2</td>
<td>Commander</td>
</tr>
<tr>
<td></td>
<td>HQ, US Army Health Services Command</td>
</tr>
<tr>
<td></td>
<td>ATTN: HSHN-I</td>
</tr>
<tr>
<td></td>
<td>Fort Sam Houston, TX 78234-6060</td>
</tr>
<tr>
<td>1</td>
<td>Superintendent</td>
</tr>
<tr>
<td></td>
<td>Academy of Health Sciences, US Army</td>
</tr>
<tr>
<td></td>
<td>ATTN: AHS-COM</td>
</tr>
<tr>
<td></td>
<td>Fort Sam Houston, TX 78234-6000</td>
</tr>
<tr>
<td>1</td>
<td>Each US Army Medical Center</td>
</tr>
</tbody>
</table>